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ABSTRACT    
Over the past two decades, research groups in both academia and private industry 
have developed key technologies, including viral delivery vectors and engineered 
transposon-based or zinc finger protein-based nucleases, towards achieving the long-
sought goal of therapeutic genome editing in humans. To date, Zinc Finger Nucleases 
(ZFNs) have been the most promising reagents for potential therapeutic applications in 
humans, but the recently characterized Transcription Activator Like Effector (TALE) 
proteins may soon change this status quo. Although it remains to be seen whether 
nucleases based on these proteins (TALENs) will be as broadly applicable and effective 
as ZFNs, based on initial reports, TALENs look very promising. Currently, the primary 
advantage of TALENs is that the DNA binding code for TALENs appears to be simple 
and robust, making their synthesis relatively simple. 
In this dissertation, I summarize advances made in the field of genome editing 
over the past decade and compare and contrast the currently available tools, focusing on 
ZFNs and TALENs. Specifically, I describe our efforts to make ZFN technology more 
accessible by designing and implementing models to help researchers choose target sites 
that are most amenable to targeting using ZFNs. Also, to help explore the potential of 
TALENs as tools for genome editing, I describe the development of a simple protocol to 
aid in constructing TALENs. As ZFNs become easier to use, and TALENs become more 
robust, the use of genome editing techniques as therapeutics appears poised to become 
reality in the near future. 
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CHAPTER 1. GENERAL INTRODUCTION 
This dissertation describes a combined experimental and computational effort to 
genetically engineer and functionally characterize Zinc Finger Nucleases (ZFNs) and 
Transcription Activator-Like Effector Nucleases (TALENs), with the goal of developing 
improved tools for genomic modification. 
 
BACKGROUND 
In the years since Paul Berg first described a method (ligation) to join two pieces 
of DNA in 1972, scientists have been incrementally developing tools to modify genomes 
efficiently and precisely [1]. Although significant progress has been made in the ensuing 
four decades, the goal of using genome editing techniques as therapeutic tools in humans 
remains elusive. Because most of the progress has improved the “efficiency”, but not the 
“precision” of recombination, the problem that remains unsolved. The first experiments 
in genome engineering were conducted using homologous recombination (HR), which is 
a highly precise but extremely inefficient mechanism[2]. The next stage of development 
in genome engineering technology involved methods that were significantly more 
efficient (such as retroviruses, and transposons), but, also, less precise.  
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       Credit: Thomas Splettstoesser 
 
Figure 1.1. Cartoon representation of Zif268 (blue and red) in complex with DNA (orange), a 
zinc finger protein comprised of 3 modules. The zinc ion is represented as green spheres.  
 
The field of genome engineering switched into high gear in 2001, when Bibikova 
and Carroll used zinc finger nucleases (ZFNs) [3, 4], first described by Chandrashekaran 
in 1996 [5], to induce a double-stranded breaks (DSB) into DNA in Drosophila, and 
observed a 1000-fold increase levels of HR. The concept that introduction of DSBs 
increases the efficiency of HR was first demonstrated by Maria Jasin in 1996, using I-
SceI endonuclease [6]. Unlike the I-SceI endonuclease, a ZFN is composed of a 
“designable” ZFP fused to a non-sequence specific FokI endonuclease. The DNA binding 
specificity is provided by the ZFP, while the FokI nuclease provides the functionality. In 
theory, if one could design a ZFP that displays sufficient DNA binding specificity for a 
desired target site, in the context of an entire genome, genome editing would no longer be 
a pie in the sky. Unfortunately, designing and building highly specific ZFPs was not as 
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trivial as originally thought. Based on the crystal structure published by Pavleteich and 
Pabo in 1991 [7] (and improved by Fairall and Finch in 1993[8]), and a series of 
biochemical experiments performed by Berg, Miller, Klug, Roeder, Brown, Neuhaus, 
Wright and their colleagues [9-13], the hope was that the specificity of a ZFP was 
determined by the 4 residues that directly contact the bound DNA molecule. If the code 
for ZFP-DNA interaction were that simple, one could string together several ZFPs (each 
of which would specify 3 bps of DNA) and synthesize a zinc finger array (ZFA) with the 
desired sequence specificity. See Figure 1.1 and 1.2 
 
 
Figure 1.2. Schematic for modular assembly 
 
This approach, commonly called “modular assembly” dominated the first wave of 
ZFN engineering; it was elegant and simple, but the failure rate of these enzymes was 
unacceptably high [14]. The most plausible explanation for the high failure rates was that 
the “recognition code” describing the ZFN–DNA interaction wasn’t as simple as initially 
thought. Simply stringing together ZFPs that have been designed to bind a given 3-bp 
target site isn’t sufficient as the behavior of a single ZFP is different from a ZFP that is 
part of a ZFA. The conundrum is that when the 1-to-1 ZF-DNA binding code breaks 
down, the design problem becomes exponentially more difficult. The set reagents 
required to build ZFPs to a 9-bp DNA target site increases from 64 to 262144 as we 
would have to design a protein to every 9-bp target site rather than every 3-bp target site.  
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The current state-of-the-art methods for ZFN engineering take into account that 
the DNA sequence recognized by a ZFP depends on the entire protein sequence, rather 
than a code simply defined by individual ZF modules that are pasted together. In other 
words, the current methods take into account the fact that the context of an individual ZF 
module (its neighboring modules, as well as its position in a linear array of several 
modules), can dramatically impact its DNA recognition properties. These newer methods, 
e.g., Sangamo, OPEN, Greismann, and Isalan (reviewed by Davis and Stokoe [15]) 
involve making large libraries of potential ZFNs, followed by several rounds of selection 
to identify candidate ZFNs with high relative affinity for the desired target DNA 
sequence. These methods have improved the success rates of ZFNs, but are much more 
technically demanding than their predecessor, modular assembly [16]. 
 
 
Credit: Davis and Stokoe [15] 
 
Figure 1.3. Summary of selection methods used to design ZFPs. A. Greismann method. B. 
Oligomerized pool Engineering (OPEN). C. Isalan, Klug method. 
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In 2009, two groups, Boch and Bogdanove, reported that a surprisingly simple 
code governs the DNA recognition properties of a family of bacterial DNA binding 
proteins called Transcription Activator-Like Effectors (TALEs) [17, 18]. This report 
kicked the field into overdrive. Although it is still too early to rigorously evaluate the 
utility of TALEs (and judge their advantages vs. ZFNs), the frenzy created by this 
discovery is undeniable, and based on results from initial published reports, they do not 
suffer from several drawbacks of ZFPs. Most importantly, TALENs do seem to be truly 
modular, with a 1–to-1 correspondence between a repeat variable di-residue (RVD) in the 
TALE protein sequence and a single nucleotide in the DNA sequence (in which NI 
specifies A, NN specifies G, NG specifies T, and HD specifies C) [19] 
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Credit: Bogdanove et al. [19] 
Figure 1.4. Structure of a TALE. 
 
Benefiting from the lessons learned by the zinc finger community, TALE 
engineering has progressed in leaps and bounds over the past 2 years (~ 20 high-profile 
papers describing examples of TALEN-mediated genome editing since the seminal 2009 
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papers were published). Furthermore, the construction of TALEs is significantly easier 
than ZFPs. In the next section I’ve summarized the currently available methods. 
 
METHODS FOR ASSEMBLING TALENs. 
1. Modularly assembled designer TAL effector nucleases for targeted gene knockout 
and gene replacement in eukaryotes [20]. 
This assembly method described by Li et al., creates 8 sets of RVD containing 
domains (total of 32) via PCR. Each of these 8 sets are designed to have different 
overhangs when digested using type IIS restriction enzyme BsmBI, such that, they 
would ligate in a fixed order - 1 through 8. A potential drawback of this assembly 
method is that the lengths of the constructs have to be multiples of 8. However, an 
easy work around is to create a compatible end on the final unit via PCR. The TAL 
constructs are then cloned into a repeat-deficient pAvrXa7-FN scaffold which has 
288-aa on the N-Term and 196-aa on the C-term. 
 
2. Efficient design and assembly of custom TALEN and other TAL effector-based 
constructs for DNA targeting [21] 
This method described by Cermak et  al. uses the golden gate strategy, which 
involves a series of digestions using type IIs restriction enzymes to generate unique 
overhangs such that a single ligation step would yield the final construct. The 
advantage of the method is that it is fast. A TAL construct can be generated as little 
as 5 days. The disadvantage to this method is that it is complicated and there is a 
significant startup cost associated – about 60 different constructs. The TALE 
constructs are then cloned into vectors previously described in [22] that provide the 
N term (287 AA) and C term (230 AA) of the TAL.  
 
3. Assembly of custom TALE-type DNA binding domains by modular cloning.[23] 
This method described my Morbitzer et al., also utilizes the golden gate technology. 
The main difference, as described in the manuscript, is that this method can be used 
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to make constructs of fixed length - 10, 17 and 20. This method also uses only 1 type 
IIS restriction enzyme – BsaI. Similar to Cermak et al., users need to acquire at least 
52 constructs before they proceed to build TALEs.  The TAL constructs are then 
cloned into an avrBs3 scaffold. 
 
4. Targeted gene disruption in somatic zebrafish cells using engineered TALENs. [24] 
This method described by Sander et al. is perhaps the simplest of the lot, and also the 
most time consuming. This essentially involves a series of digestions and ligations 
(see figure 1.5).  
 
Figure 1.5. Schematic of the TAL units used in the assembly described in Sander et al. 
(Figure from [24]). 
 
The assembly method is based on the framework published by Miller et al. To 
summarize: Miller et al.[25] showed that TAL scaffolds that include 135AA (153-
288 from the endogenous TAL13 TALE) on the N-term and 63 AA (715 – 777 from 
the endogenous TAL13 TALE) on the C-term resulted in the most effective 
nucleases. Although, the assembly method isn’t as fast as the rest of the methods 
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summarized here, it has the advantage of using the framework that has been used 
most successfully. Evidence of genome editing using TALEN designed using this 
framework have been shown to work in a variety of organisms including zebrafish, 
C. elegans, rat, human somatic cells, and human pluripotent stem cells. The 
assembly strategy is summarized in the following figure. 
 
Figure 1.6. TAL assembly process described in Sander et al. (figure from [24]). 
 
Another confounding factor in TALEN engineering is the lack of constraints 
while choosing target sites. Sander et al. describe an addendum to the ZiFiT software 
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from the Dobbs, Joung and Voytas labs to aid in the identification of target sites. 
http://zifit.partners.org/ZiFiTBeta/ 
 
5. Efficient construction of sequence-specific TAL effectors for modulating mammalian 
transcription. [25] 
This assembly method described by Zhang et al., differs for the rest of the methods 
in that the unique overhangs are introduced via PCR. Rather than starting off with a 
set of modules that can be cyclically digested and ligated, in this method 12 separate 
PCR reactions are performed on each of the four RVD modules. These PCR products 
are then digested and ligated to form 4mers. These 4mers are then PCR amplified 
and digested. These fragments are then ligated to assemble a TAL array of length 12. 
This method should be expandable to generate longer TAL, but, as published, 12mer 
are the only option. Another potential problem is the errors that could be introduced 
during PCR. The 12mers built using this method is cloned into a TAL scaffold that 
has the first 48-aa deleted from the N-term and the C-term is also truncated to a 
length of 68-aa. 
 
6. Assembly of designer TAL effectors by Golden Gate Cloning. [26] 
This assembly method, also based on the golden gate technology, is very similar to 
the method described by Feng Zhang et al., sans the PCR amplification. This method 
is potentially superior to Zhang et al, because it can be used to synthesize TALEs 
that bind 17mers rather than 12mers. A potential drawback is that this method can be 
used to build only 17mers. Furthermore, the upfront cost is considerable as there are 
17 * 4 modules + backbones. The 17mer constructs are then cloned into an avrBs3 
scaffold. 
 
7. Transcriptional Activators of Human Genes with Programmable DNA-Specificity. 
[27]  
This method described by Geissler et al., is also based on the golden gate strategy 
and involves the construction of 6mer (or less) subunits that are than ligated together 
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to form a full length TALEs. As this method assembles subunits as 6mers so, only 
6*4 units, 5 termination units, and 6 assembly vectors are required. Though this 
assembly method is not as fast as Cermak et al., it has the advantage of being simple 
and easy to practice. The constructs assembled using this method is then cloned into 
a Hax3 scaffold.  
 
Of these methods, Cermak et al., [21] is probably the fastest among the flexible 
(any length TALs) frameworks. And, the Miller et al.[25] framework has the most 
number of published gene editing successes. Ultimately, it will not matter which 
assembly method is better because the field will benefit either way. The sooner we solve 
the problem of acquiring high quality reagents, the sooner we can start dealing with other 
inherent problems that accompany any biological system. 
OVERALL GOAL AND RESEARCH AIMS 
The overall goal of this dissertation is to develop improved tools for genomic 
modification. Specifically, my research is focused on three complementary aims: 1) to 
develop and implement computational tools and resources to facilitate the design and 
evaluation reagents made using the two dominant technologies for genome engineering at 
present, Zinc Finger Nucleases (ZFNs) and Transcription Activator-Like Effector 
Nucleases (TALENs); 2) to apply these tools in the design of novel ZFN and TALEN 
reagents to target specific DNA sequences; and 3) to experimentally evaluate the 
functional activities of the designed ZFNs and TALENs, both in vitro and in vivo, in 
several model genetic organisms.  An important aspect of this study, which has only very 
recently become possible, is a comparison of the relative advantages and disadvantages 
of ZFN vs. TALEN technologies for genome editing applications. 
ZFNs have been studied for over 20 years, and, hence, have an inherent advantage 
because we have a much deeper understanding of their three-dimensional structures, 
mode of DNA binding, and requirements for activity. TALENs, on the other hand, are so 
new that we do not yet have a complete three-dimensional structure and can only 
speculate about their mode of DNA binding. TALENs seem to function at least as well as 
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ZFNs, however, and offer one significant advantage over ZFNs: they are very easy to 
design and synthesize. The major drawback of the TALEN technology is that relatively 
few TALEN enzymes have been functionally tested, and the activities of novel 
engineered TALENs may be unpredictable. It remains to be seen which one of these 
technologies will dominate the field of genome engineering in the future.  
 
DISSERTATION ORGANIZATION 
The dissertation has five chapters and four appendices. Chapter 1 is a general 
introduction that focuses on comparison of the various methodologies for engineering 
ZFNs and TALENs as tools for genomic modification, Chapter 2 is a paper published in 
BMC Bioinformatics in 2010, on which I am co-first author. This manuscript describes 
the development of a Naïve Bayes classifier to help researchers identify and rank 
potential ZFN target sites that are most amenable to targeting using ZFNs generated using 
the most successful publically available protocol – OPEN from the Joung Lab. Chapter 3 
is a paper published in BMC Genomics in 2011, on which I am first and corresponding 
author. This paper presents all potential target sites within the context of the entire 
genomes of several model organisms. To further assist researchers with picking target 
sites we also score each target sites using the Naïve Bayes classifier described in Chapter 
2 and a “uniqueness” score. Chapter 4 is a paper published in the Nature Biotechnology 
in 2011, describing the construction of TALE nucleases using the framework described in 
Miller et al [25]. My contribution to this work included construction of the TALE 
nucleases that were tested in Zebrafish. Chapter 5 is a co-first-authored paper currently 
under review for publication in Nature Protocols, describing, in detail, the protocol used 
to assemble TALENs used in Sander et al. [24]. In this paper we also describe the 
modification of the ZiFiT software [28] to include the capability to identify TALEN 
target sites. Chapter 6 includes general conclusions, a summary of the major 
contributions of this dissertation research, and suggested future directions. Appendix A is 
a paper published in Nature Methods in 2011, in which we describe a new method to 
construct designer zinc finger proteins called context dependent assembly (CoDA). Prior 
to the description of this method the two prevalent methods were modular assembly, 
which does not take context into account and as a result was easy to practice, but also had 
an unacceptably high failure rate; and selection based methods that had a higher success 
rate, but were significantly more difficult to practice. CoDA is a hybrid. In a nutshell, 
CoDA involves the assembly of 2 finger modules that were identified in three finger 
selections. My contributions to this paper include the identification of all CoDA target 
sites in several model organisms and the calculation of varies statistics to evaluate the 
effectiveness of CoDA. After the publication of the paper I performed some selections to 
improve the targeting range of CoDA. This data is summarized in Table 1.1.
 
Table 1.1. Published (Purple) and new unpublished (Blue) CoDA Zinc Finger Units
  
Appendix B is a paper published in 
issue) presenting ZiFiT 2.0. ZiFiT is a web server that identifies target sites for zinc 
finger proteins designed using the publically available methods 
OPEN, and CoDA. ZiFiT is dynamically linked to ZiFDB, which is a repository for 
previously designed ZFPs and NCBI BLAST to aid in identification of unique sites. 
Recently, ZiFiT was updated to include scores generated using ZiFOpT (the classifier 
described in chapter 2) and also identify TALEN target sites (described in Chapter 5). 
Appendix C includes Supplemental Data for papers in Chapters 
Appendix D is my Curriculum vitae.
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Nucleic Acids Research in 2010 (web server 
– modular assembly, 
4, 5, and appendix A
 
 
 
 
. 
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ABSTRACT  
Background:  
Precise and efficient methods for gene targeting are critical for detailed functional 
analysis of genomes and regulatory networks and for potentially improving the efficacy 
and safety of gene therapies. Oligomerized Pool ENgineering (OPEN) is a recently 
developed method for engineering C2H2 zinc finger proteins (ZFPs) designed to bind 
specific DNA sequences with high affinity and specificity in vivo. Because generation of 
ZFPs using OPEN requires considerable effort, a computational method for identifying 
the sites in any given gene that are most likely to be successfully targeted by this method 
is desirable. 
Results:  
Analysis of the base composition of experimentally validated ZFP target sites 
identified important constraints on the DNA sequence space that can be effectively 
targeted using OPEN. Using alternate encodings to represent ZFP target sites, we 
implemented Naïve Bayes and Support Vector Machine classifiers capable of 
distinguishing "active" targets, i.e., ZFP binding sites that can be targeted with a high rate 
of success, from those that are "inactive" or poor targets for ZFPs generated using current 
OPEN technologies. When evaluated using leave-one-out cross-validation on a dataset of 
135 experimentally validated ZFP target sites, the best Naïve Bayes classifier, designated 
ZiFOpT achieved 87% overall accuracy and specificity+ of 90%, with an AUC of 0.89. 
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The performance of ZiFOpT on a completely independent (blind) test set of 66 validated 
ZFP target sites was comparable (88% accuracy; 92% specificity+). 
Conclusion:  
ZiFOpT, a machine learning classifier trained to identify DNA sequences 
amenable for targeting by OPEN-generated zinc finger arrays, can guide users to target 
sites that are most likely to function successfully in vivo, substantially reducing the 
experimental effort required.  
BACKGROUND 
Zinc finger (ZF) DNA binding proteins can be used to target functional protein 
domains to specific regions in complex genomes. For example, zinc finger nucleases 
(ZFNs) have tremendous potential for introducing site-specific gene knockouts or gene 
targeting events with high efficiency in various cell types including human [1, 2]. A ZFN 
consists of two zinc finger proteins (ZFPs) each fused to a monomeric FokI nuclease 
domain. When the ZFPs co-locate to adjacent sequences within the genome, the nuclease 
monomers are able to dimerize, generating an active nuclease that cleaves the double-
stranded DNA at the target site. In the presence of exogenous donor DNA, genetic 
material may be exchanged through repair by homologous recombination; alternatively, 
the break may be repaired by non-homologous end joining, which is an error-prone 
mechanism that commonly results in knockout mutations [3, 4]. To date, ZFNs have been 
used to manipulate endogenous genes in several organisms, e.g., tobacco, maize, fruit fly, 
zebrafish, rats, and human [5-14], and are being evaluated in human clinical trials, 
including gene therapies to treat AIDS [15-17]. 
Zinc finger DNA binding domains, especially the C2H2 class of zinc fingers, have 
been exploited for performing targeted genome modification because they can be 
engineered to bind a wide range of desired DNA sequences. Each individual C2H2 zinc 
finger consists of an α-helix (the DNA "recognition helix") and a β-hairpin, stabilized by 
a single zinc ion coordinated through interactions with cysteine and histidine residues. 
Individual ZFs recognize and bind specific triplet DNA sequences through base-specific 
contacts within the major groove of double-stranded DNA [18]. Extended DNA 
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sequences can be targeted by joining together several ZF domains [1, 19]. In the 
traditional "modular assembly" approach to ZF engineering, one ZF domain is identified 
for targeting each nucleotide triplet sequence [20-22].  Three-finger arrays generated 
using modular assembly have been shown to bind specifically to their 9-bp targets in vitro 
[23]. However, several studies have demonstrated that many ZF arrays fail to function 
successfully in vivo [7, 24-26].  These failures have been attributed to insufficient affinity 
of engineered arrays [25], variations in target specificity or affinity due to inter-finger 
context dependencies [24, 27].  
Compared with modular assembly, ZFP design using the recently developed 
Oligomerized Pool ENgineering (OPEN) method has been reported to provide higher in 
vivo success rates, particularly for zinc finger nucleases (ZFNs) [7, 8]. For constructing 
ZFPs that recognize 9-bp targets, the OPEN method involves combinatorial assembly and 
subsequent selection of fingers from three pre-constructed pools, each of which contains 
up to 95 different engineered ZF recognition helix "solutions" for a chosen DNA triplet 
[7, 28]. Currently, pools are available for all 16 GNN triplets and several of the TNN 
triplets for each position in a three-finger array [7]. ZFNs generated by OPEN have been 
used to target genes in tobacco, zebrafish, and human cells with high efficiency [7-9]. 
Because using the OPEN procedure requires investment of time and effort and 
because there are often numerous potential targetable sites in any given gene, it is 
desirable to focus experiments on target sites that are most likely to yield functional 
ZFPs. For example, there are 315,186 OPEN ZFN sites in the protein encoding regions of 
the zebrafish genome (an average of 10.8 sites per transcript). While OPEN often 
generates ZFPs that function well in a bacterial two-hybrid (B2H) reporter system [7, 8], 
it does not have a 100% success rate. Thus, to reduce the experimental effort involved in 
applying the OPEN procedure, we sought to develop a computational approach to 
identify the "best" targets, i.e., those most likely to be successfully targeted by OPEN, 
from among the relatively large number of theoretically "targetable" ZFP sites that may 
exist for any chosen gene or genomic region of interest. 
In this study, we demonstrate that sequence characteristics of ZFP target sites, 
when used as input to Naïve Bayes or Support Vector Machine (SVM) classifiers, can be 
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used to reliably predict whether a specific DNA sequence will (or will not) be 
successfully targeted by OPEN. The performance of these classifiers on two 
experimentally validated datasets of ZF target sites suggests that their use could 
substantially reduce the experimental effort required to generate a functional ZFN using 
the OPEN method. 
RESULTS 
Results from several groups [24, 29, 30] have suggested that ZFP recognition sites 
with a high purine nucleotide content, especially those containing several GNN-triplets, 
more frequently correspond to "active" targets for zinc finger proteins generated using 
modular assembly. To investigate whether such potential biases could be exploited to 
identify optimal sequences for ZFP targeting using OPEN, we analyzed sequence and 
base composition characteristics of sites targeted by this method.  
For this study, we first generated an experimentally-validated dataset, ZFTS135, 
consisting of 135 9-bp target sites for which OPEN did or did not successfully yield 
ZFPs.  ZFTS135 includes 53 ZF target sites from recently published OPEN experiments 
[7, 8] and 82 OPEN ZF target sites which we report here for the first time. Each target 
site in the dataset was assigned a class label of either "active" (79%) or "inactive" (21%).  
“Active” target sites were those yielding at least one ZFP that showed DNA-binding 
activity in a well-validated bacterial two-hybrid (B2H) reporter assay (defined as the 
ability to activate transcription by three-fold or more, a level previously shown to identify 
ZF arrays that possess high affinity and high specificity for their cognate DNA binding 
site [7, 28]). “Inactive” target sites were those that failed to yield a ZFP that showed 
activity in the B2H reporter assay. All 135 functionally validated ZFP target sites and 
their assigned labels are provided in Supplemental Table 1. 
Figure 2.1 presents analyses of the sequence and base composition characteristics 
of ZFP target sites in the ZFTS135 dataset. The average number of times each base 
occurs in active and inactive targets is shown in Figure 2.1 A. On average, active sites 
contain more guanines and fewer thymines than inactive targets. Because OPEN ZF 
finger pools are available exclusively for GNN and TNN triplet sub sites at present, total 
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guanine and thymine counts are inflated, compared to adenine and cytosine counts. To 
account for this, as well as the fact that specific bases, when located in different positions 
within a triplet sub site, may preferentially contact different amino acids, the average base 
occurrences were calculated for each position within the triplets (Figure 2.1 B). This 
analysis identified thymine frequency, at any position within a triplet, as the primary 
difference between active and inactive target sites. Guanine, adenine, and cytosine 
typically appear more frequently in active sites than in inactive sites, compensating for 
the decrease in thymine content.   
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Figure 2.1 | Base composition differs 
A) Total base counts for active and inactive ZFP target sites
experimentally validated 9-bp target sites, see Supplemental Table 1) reveal that variation in the 
average frequency of each base differentiates active versus inactive target sites. The total number of G 
and T residues relative to A and C is inflated because currently available OPEN pools are designed to 
target GNN and TNN triplets.  
within target site triplets (1st, 2nd
three positions. C) An iceLogo 
composition of nucleotides at each position, from 1 
entire dataset. For example, 78% of all sites in ZFTS135 have a G in position 1, whereas 88% of all 
active sites have a G at position 1, resulting in a difference of 10%. Positive difference values indicate 
that, on average, the indicated bases are favored at those positions in act
values indicate that the indicated bases are disfavored. These position
percentage composition also support the conclusion that thymine bases tend to occur in inactive 
targets (i.e., they have large negative propensities).
 
Differences in base composition
also analyzed. As shown in Figure 
sites, with strong negative propensities in the 1
residues showed marginally positive propensities in most positions. 
reagents are currently limited to those that target GNN and TNN triplets 
triplet; M. Maeder & J.K. Joung, unpublished data
significance of the relatively low percentage of adenine and cytosine residues in
4 and 7. 
Taken together, the results of these analyses suggested that base composition biases in 
active versus inactive ZFP target sites could be exploited by 
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predict whether a specific DNA sequence can be targeted successfully using the OPEN 
procedure. Machine learning classifiers that use a string of sequence identities as input have 
been successfully applied to a variety of problems, including protein functional site 
classification [32-35]. Because several different machine learning classifiers we tested gave 
comparable results (data not shown), here we present representative results obtained using 
two types of classifiers:  Naïve Bayes and support vector machines (SVMs). 
We compared classifiers trained using three different target site sequence encodings: 
i) sequence identity: 9 nucleotide identities corresponding directly to the target site sequence; 
ii) base counts: 4 numerical values representing the overall base counts of G,A,C,T in the 
target site; iii) positional base counts: 12 numerical values encoding the position-specific 
base composition of the target site (see Methods for details).  
 
 Table 2.1 | Performance of classifiers in predicting active OPEN target sites. 
Classifier Target site 
encoding 
Correlation 
Coefficient 
Accuracy 
   % 
Specificity+ 
% 
Sensitivity+ 
% 
 ROC 
AUC 
N
a
ïv
e 
 
Ba
ye
s 
Sequence 
Identity 0.61 87 90 94 0.89 
Base Counts 0.57 87 89 94 0.79 
Positional 
Base Counts 0.59 87 88 97 0.84 
SV
M
 
Sequence 
Identity 0.48 84 86 95 0.76 
Base Counts 0.54 85 89 92 0.78 
Positional 
Base Counts 0.63 88 90 95 0.84 
  
Table 2.1 summarizes performance statistics for Naïve Bayes and SVM classifiers 
tested using the three different target site encodings and evaluated using leave-one-out cross-
validation. In these experiments, classifiers were optimized for correlation coefficient, which 
is an indicator of how effectively a classifier identifies both positive (active) and negative 
(inactive) instances. All classifiers achieved correlation coefficients between 0.48 and 0.63, 
with accuracies ≥ 84%. For the practical application of identifying target sites for ZFPs that 
provide the greatest chance of success (for cases in which several potential target sites are 
available), it is appropriate to choose a classifier with a high specificity+ value, i.e., one that 
predicts a smaller number of "active" sites with higher confidence, rather than a high 
correlation coefficient per se.   
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The receiver operating characteristic (ROC) curves in Figure 2.2 illustrate the 
tradeoffs between true positive rate (TPR), i.e., the percentage of active target sites correctly 
predicted as such, and false positive rate (FPR), i.e., the percentage of inactive sites 
incorrectly predicted to be active, for the different target sequence encodings. Using the base 
counts and positional base counts encodings, the Naïve Bayes and SVM classifiers gave 
similar results. Based on the Area Under the Curve (AUC) of the ROC curves, the best 
overall results were obtained using the sequence identity encoding with the Naïve Bayes 
classifier (AUC = 0.89), which slightly outperformed the best SVM classifier (AUC = 0.84). 
We designate the sequence-based Naïve Bayes classifier, ZiFOpT, for Zinc Finger OPEN 
Targeter. 
 
 
Figure 2.2 | Receiver Operating Characteristic (ROC) curves for Naïve Bayes and SVM classifiers.  
 
To ensure that the performance of ZiFOpT on ZFTS135 was not over-estimated due 
to over-fitting, we generated a second completely independent data set of experimentally 
validated ZFP target sites. ZFTS66 consists of 66 9-bp target sites that were chosen by 
experts, unaided by our classifier, as ideal candidates for OPEN selection (see Supplemental 
Table 2). Active ZFPs were found for 58 of the 66 sites tested. Using ZiFOpT, we were able 
to accurately classify 88% of the sites, with 92% specificity+ and 95% sensitivity+ (Table 2, 
bottom row). Thus, ZiFOpT performs reliably when evaluated either by cross-validation or 
on an independent “blind” test set. 
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It is possible to rank the predicted active sites using a confidence score derived from 
the posterior probability returned by ZiFOpT (see Methods). As shown in Table 2, using a 
confidence score cutoff ≥ 6 results in improved accuracy, specificity+ and sensitivity+.  
 
Table 2.2 | Performance of ZiFOpT on an independent test set (ZFTS66)  
 
Confidence 
Score 
Accuracy 
   % 
Specificity+ 
% 
Sensitivity+ 
% 
≥ 6 94 94 100 
< 6 67 75 81 
Optimized 
for CC 88 92 95 
 
 
Due to the large number of potential OPEN target sites for most genomic targets of 
interest, it is desirable to identify a subset of target sites with the greatest chance of success. 
Currently, OPEN pools are available for 26 triplets in position 1, 21 triplets in position 2, and 
23 triplets in position 3 of a 3-finger ZFP. Hence OPEN can, in theory, target 12,558 distinct 
sites. Because 415 of these sites are not targetable due to dam or dcm methylation, 12,143 
distinct 9-bp ZFP target sites are currently targetable. The ZiFOpT classifier, when optimized 
for correlation coefficient, predicts that 8,412 (69%) of these sites will be active target sites. 
For ZF nuclease sites, which consist of two ZF array sites, OPEN can theoretically target a 
total 147,452,449 distinct nuclease sites (assuming a fixed number of nucleotides between 
the arrays). ZiFOpT predicts that only 70,761,744 (48%) of these nuclease sites will have 
two active sites. 
An analysis of recently published OPEN ZFN sites in zebrafish [8] illustrates the 
value of ZiFOpT in reducing the experimental effort required to target a large number of 
genomic transcripts. In the previous study, at least one potential OPEN nuclease site was 
identified within the first three coding exons in ~86% of zebrafish transcripts [8]. As shown 
in Table 3, using a classification threshold that corresponds to a confidence score > 4 for the 
active sites (24% predicted FPR), ZiFOpT predicts that 15,565 (53%) of all zebrafish 
transcripts can be targeted successfully using OPEN. By restricting targets to those identified 
by ZiFOpT at a higher confidence score (> 8), the number of potential target sites for 
experimental testing could be reduced from 114,392 to 10,515, i.e., by ~ 90%. Thus, for 
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functional genomic studies, ZiFOpT is a valuable tool for identifying sites most amenable to 
targeting by ZFNs. Indeed, we have used ZiFOpT to predict activity for all 315,186 OPEN 
ZFN targets previously identified in zebrafish [8]. These results are presented in 
Supplemental Tables 3-27.  
 
   Table 2.3 | Summary of zebrafish OPEN ZFN target sites, classified by ZiFOpT 
 
Confidence 
Score 
(Active Sites) 
False Positive 
Rate1  
(FPR) 
# of zebrafish 
transcripts 
targeted2 
Average # of ZFN target 
sites2 in transcripts 
containing nuclease sites 
# of potential target 
sites2 eliminated by 
using ZiFOpT 
** ** 25,174  (86%) 4.5 0 (0%) 
> 4 24% 15,565 (53%) 2.3 78,934 (69%) 
> 6 14% 12,622 (43%) 2.0 89,580 (78%) 
> 8 7% 6,942 (24%) 1.5 103,877 (90%) 
1estimated from training data  2in coding exons 1-3  **no classification 
 
DISCUSSION 
Detailed analyses of available high resolution structures for DNA-protein complexes 
support the conclusion that there is no simple general code for DNA-protein recognition [36]. 
For certain classes of DNA binding proteins, including the C2H2 zinc finger proteins, it may 
be possible to decipher some of the rules that govern protein-DNA recognition by exploiting 
the increasing availability of data regarding sequence determinants of binding affinity and 
specificity. For example, Stormo’s group has utilized contact propensities and weight 
matrices to predict which target sites a zinc finger motif is most likely to bind [27, 37].  
Recently, Singh and colleagues utilized SVMs to predict whether a specific zinc finger 
protein will bind a specified target site [38].  Methods such as these utilize binding 
information for specific ZFPs interacting with a limited number of DNA target sites. In 
contrast, DNA microarray based experiments provide binding preferences of a transcription 
factor for thousands of potential sites [39-42]. These experiments should provide additional 
data for predicting and assessing transcription factor binding site models, including those for 
zinc finger proteins.  
In the current study, we propose an approach for predicting whether a ZFP can be 
engineered to bind a specific DNA sequence without a priori knowledge of the ZFP amino 
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acid sequence. We analyzed base composition features and position-specific base 
propensities in a dataset of 135 different DNA target sites for which the OPEN selection 
method had been experimentally attempted. Our goal was to use this information to develop 
a rapid and reliable machine learning classifier to identify DNA sequences most amenable to 
site-specific targeting by zinc finger arrays generated using the OPEN design procedure. 
Based on our results, we developed a server-based application, ZiFOpT, which implements a 
sequence identity-based Naïve Bayes classifier, and identifies active OPEN target sites with 
an estimated average accuracy of 87%, specificity+ ≥ 90% and sensitivity+ ≥ 94% when 
evaluated using cross-validation and optimized for correlation coefficient. ZiFOpT 
performance on an independent “blind” test set of 66 experimentally validated ZFP targets 
was comparable, indicating that the performance measures are not likely biased by over-
fitting. 
In our statistical analysis of active versus inactive target sites, we detected biases in 
position-specific base composition of ZF targets (Figure 2.1). Thus, we anticipated that 
classifiers in which we attempted to capture base count biases or position-specific base 
propensities in the sequence encoding might perform as well as those using sequence 
identity, particularly in light of the size of the dataset relative to the size of the feature space 
for the sequence identity representation. For the Naïve Bayes classifier, however, sequence 
identity outperformed positional base counts and gave the best overall performance, in terms 
of the AUC of the ROC curve (0.89). For the SVM classifier, using positional base counts as 
input did provide substantially better performance than sequence identity (84% vs. 76%). 
Because the dataset used to train the SVM classifiers was smaller (to ensure a balanced 
number of positive and negative instances, see Methods), this difference in performance may 
be partly attributable to relatively sparse data for the sequence identity encoding. 
Although the OPEN procedure tests only a small fraction of the total theoretical 
protein sequence space for the zinc finger recognition helix, it generates up to approximately 
1 million ZFP combinations, clustered in what are expected to correspond to regions of 
optimal amino acid sequence space for the DNA target site of interest. Together with the 
results summarized in Figure 2.1, this suggests there are utilizable constraints on the DNA 
sequence space for 9-bp target sites that can be successfully targeted by ZFPs engineered by 
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OPEN. For example, the results in Figures 2.1 B and 2.1 C indicate that increased thymine 
content in target sites, especially at positions 1 and 7, may preclude high affinity or high 
specificity binding. Previous studies have suggested that ZFP recognition sites with relatively 
high purine nucleotide content are more often active targets for engineered zinc finger 
proteins [24, 29]. These earlier conclusions were based on analysis of target sites containing 
predominantly GNN-triplets and for ZFPs generated using modular assembly. The current 
analysis confirms and quantifies the contributions of high purine content as an important 
determinant of success for sequences targeted using OPEN. More specifically, our analyses 
indicate that for three-finger ZFPs, it is advisable to avoid target sites containing many 
thymine bases. 
Based on the results reported here, ZiFOpT will be valuable for guiding investigators 
using OPEN to ZFN target sites with the greatest opportunities for success. The calculations 
shown in Table 3 illustrate the potential reduction in experimental effort that could be 
achieved by using ZiFOpT to identify ZFP target sites for every protein encoded by the 
zebrafish genome. Also, ZiFOpT should be valuable for selecting targets among the 695,819 
total OPEN nuclease targets identified in protein-encoding transcripts of the human genome 
(Ensemble V51.1) [D. Reyon and J. Sander, unpublished], and could assist investigators who 
wish to apply OPEN technology to target specific genes or genomic regions of interest in 
other organisms. ZiFOpT classifies potential target sites for OPEN-generated ZFPs as 
"active" or "inactive" and provides a confidence score for the prediction. ZiFOpT is freely 
available and incorporated in the Zinc Finger Targeter (ZiFiT 3.2) web server 
(http://bindr.gdcb.iastate.edu/ZiFiT)[43]. ZiFiT can scan a given DNA sequence of interest and 
identify every potential DNA site targetable by OPEN. With the integration of ZiFOpT, users 
will be able to evaluate the expected success rate of OPEN for target sites identified by 
ZiFiT. 
CONCLUSION 
In this study, we developed machine learning classifiers that reliably identify DNA 
sites highly amenable to targeting by the OPEN zinc finger protein engineering method. 
Analysis of a dataset of 135 experimentally validated ZFP binding sites identified high 
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thymine content as a significant barrier to effective targeting by OPEN. In addition, 
comparison of results obtained using three different target sequence encodings as input for 
Naïve Bayes and SVM classifiers suggested that positional context plays a significant role in 
ZFP target site recognition. Importantly, however, a simple encoding based on sequence 
identity is sufficient to identify the most promising ZFP target sites, with ~87% accuracy. As 
more ZFP functional data become available and we learn more about the sequence 
composition of fingers in OPEN pools, our predictions should improve. At present, the 
ZiFOpT classifier presented here is expected to reduce the experimental effort required to 
identify an active ZFP-target site pair by ~75%, compared with selection of target sites 
without classification. By restricting experimental targets to "active" OPEN sites predicted 
with highest confidence, experimental success rates should be significantly enhanced. This in 
turn should accelerate the application of zinc finger proteins as tools for precise genetic 
manipulation in basic genomics research as well as in gene therapy.  
METHODS 
Definition of active and inactive ZFP target sites based on B2H assays 
An active target site is a 9-bp DNA sequence for which the OPEN procedure has been 
used successfully to obtain at least one ZFP capable of binding the site with sufficient affinity 
and specificity to provide three-fold activation in a bacterial 2-hybrid (B2H) assay, i.e., to 
induce production of β-galactosidase by at least three-fold above the basal level of induction 
obtained using control constructs that lack the cognate ZFP target site [7, 28, 44]. An inactive 
target site is a 9-bp DNA sequence for which none of the corresponding OPEN-generated 
ZFPs tested were capable of producing a three-fold activation in the B2H assay. 
Datasets of experimentally validated ZFP-target sites  
ZFTS135 (cross-validation dataset): A zinc finger target site dataset generated from 
a group of 135 potential 9-bp zinc finger target sites (ZFTSs) that have been experimentally 
targeted using OPEN. For each ZFTS in the dataset, ZFPs have been selected using OPEN 
[7] and evaluated for DNA-binding activity in vivo using the B2H assay [9, 28, 44]. The 
sequences of all 135 ZFTS, together with their experimentally determined functional activity 
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labels (active or inactive) are provided in Supplemental Table 1. For 83 target sites in 
ZFTS135, functional activity labels, based on B2H assays, are reported here for the first time. 
The remaining 53 target sites, denoted by asterisks (*) were characterized previously [7, 28, 
44]  and experimental activity data were extracted from the Zinc Finger Database, ZiFDB 
(http://bindr.gdcb.iastate.edu:8080/ZiFDB/) [45].  
 
ZFTS66 (independent test set): This dataset is an independent group of 66 potential 
9-bp ZFN target sites (none of which overlap with those in ZFTS135), that have been 
experimentally targeted using OPEN. These sites were chosen by experts in the field, unaided 
by our classifier, in order to generate a “blind” test set for rigorous evaluation of ZiFOpT 
performance. 57 of these sites were determined to be ‘active’ based on B2H assay results, as 
described above. The sequences of all 66 ZFTS, along with classification and confidence 
scores, are provided in Supplemental Table 2. 
Machine learning classifiers 
Naïve Bayes is a probabilistic classifier that assumes the independence of each 
attribute and generates models that are amenable to user interpretation, usually without 
compromising performance [46]. We used the implementation available in the WEKA 
package version 3.5.7 [47].  For each instance, the classifier returns a classification of either 
“active” or “inactive” based on the posterior probability (Bayes' rule). The value of the 
classification threshold ( ) can be selected based on the desired trade-off between sensitivity 
and specificity. We evaluated several classification performance measures (see below), using 
a standard leave-one-out cross validation procedure. 
Support Vector Machines (SVMs) find a hyper plane in high-dimensional space that 
maximizes the distance between the different classes of data in that space. We implemented 
the SVM classifier using the wrapper class available for LIBSVM [48]. We tested several 
different kernel functions. Best results were obtained using the radial basis function (RBF) 
kernel. Optimal cost and gamma parameters were determined using a grid search algorithm. 
Because SVM classifiers are sensitive to the number of positive and negative instances in the 
training set, and because our dataset is unbalanced (106 positive and 29 negative instances), 
we used a variation of the standard leave-one-out cross validation technique.  For each test 
θ
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case, we removed that instance and generated 10 randomized balanced training sets. The 
probability assigned to each test case was an average of the probability estimate generated 
from 10 randomized balanced training sets. 
Target site sequence encoding  
For each classifier, three different input sequence encodings were evaluated. The 
sequence identity input window consists of a target site represented as a 9 nucleotide DNA 
sequence, reading in the 5' to 3' direction on one strand (e.g., GTTGACGGC). The base 
counts input window consists of four single-digit values that represent the number of 
occurrences of each of the four DNA bases (G, A, C, T) within a target site (e.g., 4,1,2,2 for 
the target site in the preceding example). The positional base counts input window consists 
of a string of 12 values (3 sets of 4 digits), ranging from 0 to 3 and representing the number 
of times each base occurs in the first, second, and third positions within a triplet (e.g., 
3,0,0,0;1,1,0,1;0,0,2,1, for the target site in the preceding example, in which G occurs in the 
first position of a triplet 3 times, once in the second and 0 times in the third.).  
Classification performance measures 
We used several standard performance measures: accuracy, correlation coefficient 
(CC), specificity+, and sensitivity+, and the AUC for standard ROC curves as described by 
Baldi et al. [49]. Here True Positives (TP) is the number of validated targets correctly 
predicted to be "active" target sites, i.e., sites that have been targeted successfully by an 
OPEN-generated ZFP to produce >3-fold activation in the B2H assay; False Positives (FP) is 
the number of "inactive" target sites incorrectly predicted to be "active" sites; True Negatives 
(TN) is the number of "inactive" target sites correctly predicted as such; False Negatives 
(FN) is the number of "active" target sites incorrectly predicted to be "inactive" sites. 
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Specificity+ =    Sensitivity+ =  
 
FNTNFPTP
TNTP
+++
+
))()()((
**
FNTNFPTNFPTPFNTP
FNFPTNTP
++++
−
FPTP
TP
+ FNTP
TP
+
31 
 
 
 
False Positive Rate (FPR) =   True Positive Rate (FPR) =  
 
A Receiver Operating Characteristic (ROC) curve displays the tradeoff between the true 
positive rate (hit rate) and the false positive rate (false alarm rate) for different discrimination 
thresholds [49]. The Area Under the Curve (AUC) of the ROC plot is valuable for comparing 
performance of different classifiers because it portrays the tradeoff between the false positive 
rate and the true positive over the range of classification threshold values.  
 
Confidence Score 
 The posterior probability returned by ZiFOpT for classifying each target site 
was used to generate a confidence score. Target sites with posterior probability were 
classified ‘active’ if they had posterior probability ≥ 0.5 and ‘inactive’ otherwise. For the 
‘active’ class, the posterior probability was transformed to a scale from 0 to 9 by 
incrementing the confidence score by 1 as the posterior probability increased by 0.05 above 
0.5. Therefore, a posterior probability of 0.75 corresponds to an ‘active’ classification with a 
confidence score of 5. For the ‘inactive’ class, the confidence score was incremented by 1 as 
the posterior probability decreased by 0.05 below 0.5. Therefore, a posterior probability of 
0.25 corresponds to an ‘inactive’ classification with a confidence of 5. 
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Supplemental Table 2.1.  ZFTS135 dataset of zinc finger target sequences and activity labels.  
DNA sequences of zinc finger target sites (shown reading 5' - 3') and functional activity labels for 135 
experimentally validated ZFP-target site pairs analyzed in this study. "Active" indicates sites for 
which the OPEN method has been used to generate at least one corresponding zinc finger array that 
provides ≥ 3-fold activation of a β-galactosidase reporter gene in a bacterial 2-hybrid (B2H) reporter 
assay. For 82 target sites, B2H assay results are reported here for the first time. Asterisks (*) denote 
the remaining 53 target sites for which B2H activity results were reported previously and were 
extracted from ZiFDB (http://bindr.gdcb.iastate.edu/ZiFDB/). 
 
 
Target 
5' - 3' 
Activity 
Label  
Target 
5' - 3' 
Activity 
Label  
Target 
5' - 3' 
Activity 
Label 
GCATTTTTT Inactive  GAGGGCGGC Active  *GGAGGGGCT Active 
GCCGCAGCT Inactive  GAGGGGGCG Active  GGAGGTGAC Active 
GCTTGAGCT Inactive  *GAGTGAGGA Active  GGAGGTGGA Active 
*GGCGCCTAC Inactive  GAGTGAGTT Active  *GGAGGTGGT Active 
*GGCGGAGAT Inactive  *GAGTTTGCC Active  GGCGCAAAC Active 
*GGCGTTTGC Inactive  GATGAAGAC Active  *GGCGGCGGA Active 
GGGGAATAC Inactive  *GATGAAGCT Active  GGCTGAGGC Active 
GGTGTCTTT Inactive  GATGAGGCG Active  GGCTGGGCT Active 
*GTGGCGGAT Inactive  GATGCCAAC Active  GGCTGGGTG Active 
GTGTTTGAA Inactive  GATGCGGCA Active  *GGGGAAGAG Active 
GTTGATTTT Inactive  GATGTAGCC Active  GGGGAAGAT Active 
GTTTTTGAG Inactive  GATTGAGTT Active  *GGGGACGTC Active 
TAAGTTGTT Inactive  GCAGAAGCT Active  *GGGGAGGAG Active 
TCTGCATTC Inactive  *GCAGCAGAG Active  GGGGTCGAC Active 
*TCTGGCGCT Inactive  *GCAGCAGGA Active  GGGGTGGGT Active 
*TCTGGTTTC Inactive  *GCAGCGGGC Active  GGTGAATTT Active 
TCTGTGTTC Inactive  *GCAGGAGGT Active  GGTGAGGCA Active 
TCTTGGGTA Inactive  GCAGTGTGT Active  GGTGCAGCA Active 
*TGCGGCTGT Inactive  GCCGAAGAT Active  GGTGCTGAC Active 
TGCTGAGAC Inactive  *GCCGCCGGC Active  GGTGGCGCT Active 
TGCTTTGTT Inactive  GCCGCTGGA Active  GGTGGGGTG Active 
TGGGTAGAA Inactive  *GCCGCTGGG Active  GTAGAGGAG Active 
TGGTTTGTA Inactive  *GCCGGCGGC Active  *GTAGATGGA Active 
TGTGTGTTC Inactive  GCCGGTGCA Active  GTAGCCTGT Active 
TTAGGAGGT Inactive  *GCCGGTGGC Active  GTAGCTGGA Active 
TTTGAGGAT Inactive  *GCCGTCGCC Active  GTCGACGCC Active 
TTTGCTGAA Inactive  GCGGCCGCG Active  *GTCGATGCC Active 
TTTGTGGTG Inactive  *GCGGCGGAC Active  *GTCGGGGTA Active 
TTTGTGTGT Inactive  *GCGGCTGGG Active  GTCTGAGGC Active 
*GAAGAAGCT Active  GCGGGGGGC Active  GTCTGGGCT Active 
*GAAGACGCT Active  GCGGGTGTG Active  *GTGGACGCG Active 
*GAAGATGGT Active  GCGGTGGCG Active  *GTGGCTGGT Active 
*GAAGCAGCA Active  GCGTGGGCG Active  *GTGTAGGGG Active 
*GAAGGATTC Active  GCGTTGGCG Active  TAAGCAGAA Active 
*GAAGTGGTC Active  GCTGACTTT Active  TAATTGGAG Active 
GAATTGGCG Active  GCTGAGGCT Active  TCTGCTGGC Active 
*GACGACGGC Active  *GCTGATGCC Active  TCTGGTGAG Active 
GACGCCGGA Active  GCTGCAGAA Active  *TGGGAGTCT Active 
*GACGCTGCT Active  GCTGCCGTC Active  TGGGATGTT Active 
GACTGAGAA Active  *GCTGCTGCC Active  *TGGGGTGCC Active 
GACTGGGCG Active  GCTGCTGGT Active  *TGGGTGGCA Active 
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Target 
5' - 3' 
Activity 
Label  
Target 
5' - 3' 
Activity 
Label  
Target 
5' - 3' 
Activity 
Label 
GACTGGGCT Active  GCTGGAGGG Active  *TTAGAAGTG Active 
*GAGGACGGC Active  GCAGCGGGA Active  *TTATGGGAG Active 
*GAGGACGTG Active  *GGAGGAGGT Active  TTTGTTGGC Active 
*TGGGCTGCT Active  GGAGGCGTG Active  *GGTGCTGCC Active 
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Supplemental Table 2.2. ZFTS66 dataset of 66 experimentally validated zinc finger target site 
sequences, used as an independent (“blind”) test set in this study.  Target 5' - 3'  = DNA sequence of 
zinc finger target site; Activity Label = actual activity, determined experimentally;  Prediction: 
activity predicted by ZiFOpT; Confidence Score = confidence in prediction, ranging from 0 (lowest) 
to 9 (highest); see Methods for additional details. 
  
Target    5' - 3' Activity Label Prediction 
Confidence 
Score 
GGTGGAGCA Active Active 9 
GGTGTCGAA Active Active 9 
GTAGAAGAG Active Active 9 
GTAGCAGTC Active Active 9 
GTAGCTGCG Active Active 9 
GTCGTTGCC Active Active 9 
GTCTGAGTA Active Active 9 
GTGGATGGT Active Active 9 
GTGGCAGGA Active Active 9 
GTGGCCGTG Active Active 9 
TAATTGGGG Active Active 9 
TCTGAGGAC Active Active 9 
TCTGGTGAC Active Inactive 9 
TGGGATGTG Active Active 9 
TGGGCAGTG Active Active 9 
TGGGGGGCA Active Active 9 
TGGGTCGAC Active Inactive 9 
TGTGACGGC Active Active 9 
TGTGGGGGG Active Active 9 
TTAGGGGAC Active Active 9 
TGGGATGGA Active Active 9 
GACGGCAAC Active Active 9 
GTAGAGGGT Active Active 9 
GCCGGAGAC Active Active 9 
GCATGGGCA Active Active 9 
GGTGATGCT Active Active 9 
GCCGAAGAG Active Active 9 
GACGGCTGT Active Active 9 
GCTGCAGGT Active Active 9 
GAGGATGTA Active Active 9 
GCCGAAGTT Active Active 9 
GACGGAGCT Active Active 9 
GCTGATGGC Active Active 9 
GCGGTTGCA Active Active 9 
GACGGAGTC Active Active 9 
GCAGGTGGA Active Active 9 
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Target    5' - 3' Activity Label Prediction 
Confidence 
Score 
GGGGAAGGT Active Active 9 
GCCGCAGTG Active Active 9 
GATGGTGAG Active Active 9 
GGTTGGGAG Active Active 9 
GCAGGCGCA Active Active 9 
GAGGAGGGT Active Active 9 
GGGGAAGGA Active Active 9 
GAGGAGAAC Active Active 9 
GGAGCCGGC Active Active 9 
GCTGAGGGG Active Active 9 
GCAGAAGTA Active Active 9 
GAAGTAGCA Active Active 9 
GCTGAAGCG Active Active 9 
GATGATGGC Active Active 9 
GAGGAAGCT Active Active 9 
GTGGATGCA Active Active 9 
GTGGCAGAA Active Active 9 
TAAGAAGAG Active Active 9 
GACGGAGGA Active Active 9 
GATGAAGAA Active Active 9 
GTAGCGGGT Active Active 9 
GGTTAGGAT Active Active 9 
GCGGCGGCC Active Active 9 
GGTTGAGCG Active Active 9 
GAGGAGGAG Active Active 9 
GAGGCGTGT Active Active 9 
GGAGGTGAG Active Active 9 
GGAGGTGCC Active Active 9 
GAAGAAGAG Active Active 9 
GCGGCCGAA Active Active 9 
GGAGAAGTA Active Active 9 
GCTGAGGGC Active Active 9 
GAGGACTGC Active Active 9 
GGGGCTGCA Active Active 9 
GAGGTAGTG Active Active 9 
GAGGCGGAC Active Active 9 
TGCGATGGA Active Active 9 
GCTGGTGTC Active Active 9 
TGGGCCGAC Active Active 9 
GAGGCAGAA Active Active 9 
GAAGCAGGC Active Active 9 
GAGGATGGG Active Active 9 
GCATGAGCT Active Active 9 
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Target    5' - 3' Activity Label Prediction 
Confidence 
Score 
GCTGGTGGC Active Active 9 
GAGGCCTGT Active Active 9 
GCTGCGGTG Active Active 9 
GGAGGAGAT Active Active 9 
GTGGTGGCT Active Active 9 
GGATGAGCC Active Active 9 
GCTGACTGC Active Active 9 
GCGGGAGGG Active Active 8 
GCGGTAGCT Active Active 8 
GCTGACGGT Active Active 8 
GCTGAGGAA Active Active 8 
GCTGCAGAA Active Active 8 
GCTGGTGAA Active Active 8 
GCTGTCGAA Active Active 8 
GCTGTTGGG Active Active 8 
GGAGACGGT Active Active 8 
GGCGACGGC Active Active 8 
GGCGAGGAA Active Active 8 
GGCGCAGGG Active Active 8 
GGGGCAGTG Active Active 8 
GGGGCGGGT Active Active 8 
GGGGCTGAG Active Active 8 
GGGGGAGGG Active Active 8 
GGTGAAGAG Active Active 8 
GGTGCCGAG Active Active 8 
GACTTTGGT Inactive Active 7 
GAGGCAGCA Active Active 7 
GAGGCCGAG Active Active 7 
GAGGCCGGC Active Active 7 
GAGGGAGGA Active Active 7 
GAGGTGGGT Active Active 7 
GCAGCAGGG Active Active 7 
GCAGGGGCG Active Active 7 
GCAGGTGCT Active Active 7 
GCCGCGGCC Active Active 7 
GCGGCTGCC Active Active 7 
GCGGCTGCG Active Active 7 
GAAGGGTGC Active Active 6 
GAAGGTGTT Active Active 6 
GAAGTCTGC Active Active 6 
GACGAAGGC Active Active 6 
GACGACGAA Active Active 6 
GAGGAGGTC Active Active 6 
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Target    5' - 3' Activity Label Prediction 
Confidence 
Score 
GTCGTGGCC Inactive Active 5 
GTAGGAGAG Inactive Active 5 
GTCGGCGTA Inactive Active 5 
GGTGCTGCG Inactive Active 5 
GAAGGGGCC Active Active 5 
GCAGCCGCA Inactive Active 4 
GGAGTTGTT Inactive Active 4 
GTCTGAGCA Inactive Active 4 
GGGTTTGCA Inactive Active 4 
GGTGATGAA Inactive Active 3 
GTCGCAGTA Inactive Active 3 
GCTTAGGGT Inactive Active 3 
GCGTTTGAG Inactive Active 2 
GTCGCTGTC Inactive Active 1 
TCTGGAGAT Inactive Inactive 1 
TGTGAATGT Inactive Inactive 1 
GGCGGAGCA Inactive Active 1 
GGTTTTGAG Inactive Active 0 
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CHAPTER 3. ZFNGENOME: A COMPREHENSIVE 
RESOURCE FOR LOCATING ZINC FINGER NUCLEASE 
TARGET SITES IN MODEL ORGANISMS 
Deepak Reyon*, Jessica R. Kirkpatrick, Jeffry D. Sander, Feng Zhang, Daniel F. Voytas, J. Keith 
Joung, Drena Dobbs and Clark R. Coffman. ZFNGenome: A comprehensive resource for locating 
zinc finger nuclease target sites in model organisms. BMC Genomics. 2011 Jan. 28.  
 
* Corresponding Author 
ABSTRACT 
Background 
Zinc Finger Nucleases (ZFNs) have tremendous potential as tools to facilitate 
genomic modifications, such as precise gene knockouts or gene replacements by homologous 
recombination. ZFNs can be used to advance both basic research and clinical applications, 
including gene therapy. Recently, the ability to engineer ZFNs that target any desired 
genomic DNA sequence with high fidelity has improved significantly with the introduction 
of rapid, robust, and publicly available techniques for ZFN design such as the Oligomerized 
Pool ENgineering (OPEN) method. The motivation for this study is to make resources for 
genome modifications using OPEN-generated ZFNs more accessible to researchers by 
creating a user-friendly interface that identifies all potential ZFN target sites in the complete 
genomes of seven model organisms. 
Description 
ZFNGenome is a GBrowse-based tool for identifying and visualizing potential target 
sites for OPEN-generated ZFNs. ZFNGenome currently includes a total of more than 11.6 
million potential ZFN target sites, mapped within the fully sequenced genomes of seven 
model organisms. These include: S. cerevisiae, C. reinhardtii, A. thaliana, D. melanogaster, 
D. rerio, C. elegans, and H. sapiens; additional model organisms will be included in future 
updates. ZFNGenome provides researchers with information about each potential ZFN target 
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site, including its chromosomal location, position relative to transcription initiation site(s), 
and frequency of occurrence within the genome. Users can query ZFNGenome using several 
different criteria (e.g., gene ID, transcript ID, or target site sequence). Targets identified using 
ZFNGenome can be visualized at multiple scales within the flexible GBrowse 1.7 
environment and can be imported as annotations into other genome browsers. ZFNGenome is 
dynamically linked to ZiFDB, allowing users access to all available information about zinc 
finger reagents, such as the effectiveness of a given ZFN in creating double-stranded breaks. 
Conclusions 
ZFNGenome provides a user-friendly interface that allows researchers to access 
resources and information regarding genomic target sites for engineered ZFNs in seven 
model organisms. This genome-wide database of potential ZFN target sites should greatly 
facilitate the utilization of ZFNs in both basic and clinical research. 
ZFNGenome is freely available at: http://bindr.gdcb.iastate.edu/ZFNGenome. 
BACKGROUND 
The ability to efficiently modify the genome of an organism with a high degree of 
specificity would advance both research with model organisms and human gene therapy [1-
3]. In recent studies, zinc finger nuclease (ZFN)-mediated genomic modification rates of 3% 
- 100% for specific genes have been reported in zebrafish, Arabidopsis, and rat [4-16]. 
Moreover, ZFNs are being evaluated in human gene therapy clinical trials for treating AIDS 
[11, 17-19]. Thus, ZFNs are emerging as premier tools for site-specific genomic modification 
in both animals and plants. 
Engineered ZFNs consist of two zinc finger arrays (ZFAs), each of which is fused to a 
single subunit of a non-specific endonuclease, such as the nuclease domain from the FokI 
enzyme, which becomes active upon dimerization [20, 21]. Typically, a single ZFA consists 
of 3 or 4 zinc finger domains, each of which is designed to recognize a specific nucleotide 
triplet (GGC, GAT, etc.) [22]. Thus, ZFNs composed of two “3-finger” ZFAs are capable of 
recognizing an 18 base pair target site; an 18 base pair recognition sequence is generally 
unique, even within large genomes such as those of humans and plants. By directing the co-
localization and dimerization of two FokI nuclease monomers, ZFNs generate a functional 
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site-specific endonuclease that creates a double-stranded break (DSB) in DNA at the targeted 
locus [23] (Figure. 3.1 A). 
 
Figure 3.1. ZFNs generate site-specific double-stranded breaks that can be used for homologous 
recombination or mutagenesis. (A) ZFNs are composed of two arrays that recognize 9-12 base pairs 
each. Two arrays with three fingers, F1-F2-F3, that recognize nine base pairs each are shown. Each 
array is fused to one half of a nonspecific FokI endonuclease (green). Upon dimerization, the FokI 
endonuclease is activated and creates a double-stranded break at sites flanked by the DNA binding 
sites recognized by the zinc finger arrays. Scissors and arrows denote the cut sites. (B) In most cells, 
double-stranded breaks (DSBs) are repaired by one of two major pathways. If a donor template is 
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available, homologous recombination can result in engineered nucleotide substitutions at the target 
site (left). Alternatively, DSBs can be repaired by non-homologous end-joining, an error-prone 
mechanism that frequently results in small deletions or insertions at the site of the DSB (right). 
 
In eukaryotes, repair of DSBs in DNA is primarily accomplished via one of two 
pathways, homologous recombination (HR) and non-homologous end-joining (NHEJ) 
(Figure 3.1 B). Depending on the desired modification, either pathway can be exploited in 
ZFN-mediated genomic engineering. Because HR relies on homologous DNA to repair the 
DSB, gene targeting can be achieved by supplying an exogenous “donor” template. This 
results in replication of the “donor” DNA sequence at the target locus, a process that has been 
utilized to introduce small mutations or large insertions [4, 9, 12, 13, 16, 24-27]. In contrast, 
NHEJ is an error-prone repair process and hence is ideal for generating mutations that can 
result in gene knockouts or knock-downs when the ZFN-mediated DSB is introduced into the 
protein coding sequence of a gene [5-9, 11, 28, 29]. 
Oligomerized Pool Engineering (OPEN) is a highly robust and publicly available 
protocol for engineering zinc finger arrays with high specificity and in vivo functionality [9, 
30, 31]. OPEN has been successfully used to generate ZFNs that function efficiently in plants 
[13, 15], zebrafish [6], and human somatic [9] and pluripotent stem cells [16]. OPEN is a 
selection-based method in which a pre-constructed randomized pool of candidate ZFAs is 
screened to identify those with high affinity and specificity for a desired target sequence. 
Significantly higher in vivo success rates have been reported using OPEN-generated ZFNs, 
compared with ZFNs generated using the more traditional modular assembly approach [32-
34]. Resources for generating ZFNs using OPEN have been developed and made publicly 
available by the Zinc Finger Consortium [9, 31, 35]. Currently, OPEN reagents include 
modules that recognize all 16 possible GNN triplets (i.e., DNA triplets beginning with G, 
followed by any nucleotide in the second and third positions), as well as several TNN 
triplets. Thus, all DNA sites that contain only GNN and/or select TNN triplets can potentially 
be targeted using the OPEN protocol [9].  
To facilitate use of OPEN ZFNs for genome modification, we have developed 
ZFNGenome, a resource that displays potential ZFN target sites in a genome browser built on 
the user-friendly GBrowse platform [36]. We analyzed the complete sequenced genomes of 
seven model organisms and identified all sequences that are potentially targetable using 
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currently available OPEN ZFN reagents. ZFN reagents were obtained from Joung and 
colleagues [9] and ZFN target sites were identified using software implemented in the ZiFiT 
web server [37, 38]. ZFNGenome thus allows users to quickly evaluate “pre-identified” ZFN 
target sites for any desired gene or region of interest.  
To our knowledge, ZFNGenome represents the first compendium of potential ZFN 
target sites in sequenced and annotated genomes of model organisms. The current version 
includes ZFN target sites in seven organisms: Saccharomyces cerevisiae (budding yeast), 
Chlamydomonas reinhardtii (green algae), Arabidopsis thaliana (thale cress), Caenorhabditis 
elegans (nematode), Drosophila melanogaster (fruit fly), Danio rerio (zebrafish), and Homo 
sapiens (human). Additional model organisms, including three plant species; Glycine max 
(soybean), Oryza sativa (rice), Zea mays (maize), and three animal species Tribolium 
castaneum (red flour beetle), Mus musculus (mouse), Rattus norvegicus (brown rat) will be 
added in the near future. 
CONSTRUCTION AND CONTENT 
The motivation for implementing ZFNGenome, summarized in Figure 3.2, was to 
create a user-friendly interface between two valuable open-source genomic resources:  i) 
established genome browsers, with associated genomic DNA sequences, annotations and 
other resources available for model organisms; and ii) ZFN design software tools and 
experimental reagents made available by the Zinc Finger Consortium. ZFNGenome 
integrates these resources by allowing users to visualize all potential ZFN target sites in a 
chosen gene or genomic region of a sequenced model organism, with flexible viewing 
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options and annotated genomic features provided in a GBrowse interface.
 
Figure 3.2. An overview of the ZFNGenome architecture. ZFNGenome creates a user-
friendly interface for visualizing all potential ZFN target sites in seven model organisms by 
integrating the genomic information from genome browsers of sequenced and annotated genomes 
with the tools of the Zinc Finger Consortium. This interface allows researchers using these model 
organisms to easily determine whether ZFNs are available for the design and execution of targeted 
genome modifications. 
 
Table 1 lists the organisms for which complete genomic sequence data were analyzed 
in this study, along with the data sources for genomic DNA sequences and annotations. The 
number of potential OPEN target sites identified is shown for each organism. To identify all 
potential OPEN ZFN target sites, annotated complete genome sequence files were scanned 
using the ZiFiT algorithm [38], which was modified to accommodate the sequences of an 
entire chromosome. Only sites for which ZFNs can be engineered using currently available 
OPEN reagents and spacer distances between the two ZFAs of 5, 6 or 7 base pairs were 
included [9]. Because OPEN selections are performed in a Dam+/Dcm+ E. coli strain, 
genomic target sequences that contain potential dam or dcm methylation sites were excluded 
from consideration, as were sites that lacked a GNN sub site. Previous studies have shown 
that most successful OPEN sites contain at least one GNN [31].  
ZFNGenome utilizes GBrowse 1.7 [36] to display identified potential OPEN target 
sites, along with basic genome annotations, such as genes, transcripts, exons, introns, and 5’ 
and 3’ UTRs. ZFNGenome is hosted on an Apache2 web server and uses a MySQL DB 
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linked to a GBrowse front end via open source adaptors available in BioPerl (version 1.6) 
[39]. The ZFN target sites can be exported for use as annotations in other GBrowse-based 
genome browsers such TAIR and Wormbase. As described below, each ZFN target site is 
hyperlinked to ZiFDB [40]. 
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Table 3.1. Model organism genomes analyzed and the number of OPEN ZFN target sites identified. 
 
Organism Source 1 
Total # of OPEN 
target sites2 
Total # of 
transcripts2 
ZFN targetable 
transcripts 2 
Avg. # ZFN 
target sites 
per transcript 
GC 
Content 
#                 % 
Saccharomyces 
cerevisiae 
SGD 31,822 6,685 5,810 87 5.5 38.3 
Chlamydomonas 
reinhardtii 
ChlamyCyc 330,136 15,496 14,423 93 22.9 58.1 
Arabidopsis 
thaliana 
TAIR 171,409 33,200 30,193 91 5.7 35.5 
Caenorhabditis 
elegans 
WormBase 112,725 28,202 23,861 85 4.7 34.2 
Drosophila 
melanogaster 
FlyBase 185,863 21,736 20,259 93 9.2 40.9 
Danio rerio Ensembl 214,809 27,305 25,918 95 8.3 35.9 
Homo sapiens Ensembl 670,597 71,913 66,170 92 10.1 37.1 
 
1
 Data Source URLs:  SGD - http://www.yeastgenome.org/ 
  ChlamyCyc - http://chlamyto.mpimp-golm.mpg.de/chlamycyc/index.jsp 
  TAIR - http://www.arabidopsis.org/ 
  Wormbase - http://www.wormbase.org/ 
  FlyBase - http://flybase.org/ 
  Ensembl Danio rerio - http://uswest.ensembl.org/Danio_rerio/Info/Index 
  Ensembl Homo sapiens- http://uswest.ensembl.org/Homo_sapiens/Info/Index 
2
 “Transcripts” refers to protein encoding transcripts mapped onto chromosomes (i.e., scaffolds are not 
included). 
Note: For Chlamydomonas reinhardtii the average number of ZFN target sites per transcript is very high. This 
likely reflects the increased GC content of this genome. 
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Resources available in ZFNGenome 
Users can choose the model organism of interest from the ZFNGenome homepage, 
http://bindr.gdcb.iastate.edu/ZFNGenome, by choosing an organism from the left hand column 
of the front page or via the “Data Source” dropdown menu from within an organism’s 
ZFNGenome page (Figure. 3.3 A and 3.3 B). Figure 3.3 B is a screenshot of the output 
displayed in response to a search for ZFN target sites in the Saccharomyces cerevisiae 
genome. Several standard GBrowse tracks are displayed by default (genes, transcripts, 
coding regions, etc.). The OPEN Zinc Finger Nuclease Sites track shows that within the 
2.187 kb region illustrated (gene YLR219W) there are 17 potential ZFN sites located within 
the coding region of this gene. Because OPEN reagents are available to recognize all possible 
GNN and some TNN triplets, we have included a track illustrating analysis of the GC content 
of the DNA. Clicking on any genomic feature illustrated below the sequence reveals 
additional information about that feature. For example, clicking on the “OPEN Zinc Finger 
Nuclease Site” (AGCAGCGTCNNNNNNNGAAGGTGTG) opens a page containing more 
information about the site, as illustrated in Figure 3.3 D. The “Note” sections on this page 
provide links to ZiFDB [40], a repository for zinc finger arrays that have been experimentally 
validated, and ZiFiT [37], a tool for identifying potential ZFP and ZFN target sites. A 
hyperlink to NCBI BLAST [41] can be used to check whether the identified ZFN site is 
unique in the genome of interest. By clicking on other features, an investigator can access the 
exact sequence, chromosomal position and sources of reagents needed to experimentally 
target the chosen site.  Users may customize the GBrowse display by choosing which 
feature(s) to display (using the -/+ buttons on the left), and defining the order in which 
features are displayed by dragging and dropping the features within the browser window. The 
ZFN tracks can be exported back into the “home” GBrowse website for a model organism by 
clicking on the “share the track” button (details provided in the Tutorial, Figure 3.3 C). Users 
can also utilize Help, Instruction, and Tutorial functions within the browser windows to 
obtain more information about navigating ZFNGenome. 
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Figure 3.3. Examples of resources available in ZFNGenome. (A) The ZFNGenome Homepage is 
shown. From here, the user can select a model organism from the seven shown in the left hand 
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column. In addition, links to the ZFNGenome Tutorial and Help pages are provided. (B) A screenshot 
of the result of a search of the S. cerevisiae gene YLR219W is displayed. Key areas of the browser 
include the search box and the "Scroll/Zoom" areas at the top. The "Overview" and "Detail" panels 
serve as controls for visualizing the genome. This search shows the single coding region of this gene 
has 17 potential ZFN target sites, color-coding according to their "uniqueness" and "ZiFOpT" scores 
(see text). Additional information on each of the tracks can be obtained by clicking on details of the 
track. For example, clicking on one of the OPEN Zinc Finger Nuclease Sites links the user to details 
about that specific ZFN target. (C) The ZFNGenome Tutorial offers instructions on navigating the 
database. The Tutorial can be accessed from the Homepage or from any GBrowse page within 
ZFNGenome. Help and Instruction links are provided from the GBrowse pages. (D) Clicking on a 
ZFN target site opens a new window that provides links to ZiFDB, which provides additional 
information for each zinc finger array, ZiFiT the zinc finger design software that includes the OPEN 
design method and zinc finger pools, and the BLAST server at National Center for Biotechnology 
Information (NCBI). 
 
To evaluate the reliability of data presented in ZFNGenome, we compared our results 
with other published data. Two types of data are presented in ZFNGenome: annotated 
genomic features and potential ZFN target sites. The sources from which we acquired the 
genomic features are listed in Table 1. These are widely considered to be the “gold standard” 
data sources for the model organisms analyzed because they are carefully annotated and 
repeatedly evaluated by the curators and users of these databases. These source databases are 
also extensively used by investigators utilizing the various model organisms and are therefore 
familiar to users. To identify potential errors that may have been introduced during pre-
processing or data analysis, we performed quality assurance tests as follows: 1) for each 
organism, several 5 kb segments of genomic sequence were randomly selected from each 
chromosome; 2) selected chromosomal DNA sequences were individually re-scanned using 
the ZiFiT web server [37] to identify potential OPEN ZFN sites; 3) sites identified by the 
ZiFiT server were directly compared to the results for the corresponding region obtained 
from the ZFNGenome database; genomic features were checked against the original 
database. To improve the user interface and documentation, we incorporated suggestions 
from at least one expert scientist for each of model organisms included in ZFNGenome. 
DISCUSSION  
Currently available ZFNs can target 85 - 95% of protein coding transcripts in 7 
model organisms.  
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The results presented in Table 1 illustrate both the power and current limitations of 
OPEN ZFN engineering technology and identify gaps where further improvement is needed. 
Most striking is the relatively high level of coverage currently achievable. This ranges from 
85% of protein coding transcripts in Caenorhabditis elegans to 95% of protein coding 
transcripts in Danio rerio. Also noteworthy is the number of potential target sites available 
within any given transcript: in the model organisms examined to date, each transcript 
contains, on average 5 – 23 target sites (Table 1). The current lack of OPEN ZFN reagents for 
targeting TNN, ANN and CNN triplets is a limitation, especially in organisms with AT rich 
genomes. However, even in Arabidopsis (35.5% GC) 91% of the protein coding transcripts 
are potentially targetable. As more ZFN reagents for targeting additional triplets become 
available, the applicability of ZFN technology will continue to increase.  
The first study in which the entire genome of a model organism was analyzed to 
identify potential target sites for ZFNs focused on the zebrafish, Danio rerio [6]. In that 
study, identified ZFN target sites were published in the form of 26 supplemental tables (one 
for each chromosome). Although this information has apparently proven useful for members 
of the zebrafish community, ZFNGenome was developed in an effort to make such large 
datasets searchable and more readily accessible to a broader group of researchers working in 
zebrafish as well as other model organisms. 
In the first implementation of ZFNGenome, we used GBrowse version 1.67 with a 
BerkeleyDB back end to display all potential ZFN target sites found in Arabidopsis [15]. A 
total of 381,497 sites were identified, 171,409 of which were located within coding regions 
(an average of 5.7 sites per protein coding transcript). The current version of ZFNGenome 
(2.0) has been expanded to include S. cerevisiae, C. reinhardtii, C. elegans, D. melanogaster, 
D. rerio, and H. sapiens. In addition, it has been implemented in the newer GBrowse 1.7 with 
a MySQL database, which results in a more dynamic and user-friendly interface. GBrowse 
1.7 is a robust and highly customizable browser available from the Generic Model Organism 
Database project (GMOD) [36]. A noteworthy feature is the ability to share tracks with other 
GBrowse-based resources. To date ~119 implementations of GBrowse are available 
(http://gmod.org/wiki/GMOD_Users). Users accustomed to using popular model organism 
resources, such as TAIR for Arabidopsis [42] or FlyBase for Drosophila [43], can simply 
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export tracks containing ZFN target sites from ZFNGenome and into their browser of choice 
for further analysis. 
Related Resources 
Several existing databases house information on ZFPs and associated binding sites. 
ZiFDB (http://bindr.gdcb.iastate.edu/ZiFDB) contains information about engineered zinc finger 
arrays and individual modules that have been experimentally evaluated for function in vivo 
[40]. ZifBase (http://web.iitd.ac.in/~sundar/zifbase/) is a repository that includes information 
about both naturally occurring and engineered zinc finger proteins [44]. Sequences of ZFP 
binding sites are also collected in TRANSFAC [45] 
(http://www.gene-regulation.com/pub/databases.html) and JASPAR (http://jaspar.genereg.net/) [46]. 
Tools for predicting the DNA target sites for a selected ZFP include ZIFIBI 
(http://bioinfo.hanyang.ac.kr/ZIFIBI/frameset.php), a hidden Markov model based predictor that 
takes into account the interdependence between positions -1, +3 and +6 of a chosen ZFP to 
predict its potential DNA binding site(s) [47]. Also, Persikov et al. [48] have used support 
vector machines (SVMs) to predict and rank potential ZFP binding sites for a selected ZFP. 
Several web-based tools for identifying potential ZFN binding sites within a given 
DNA sequence are currently available. Zinc Finger Tools 
(http://www.scripps.edu/mb/barbas/zfdesign/zfdesignhome.php) can be used to identify target sites 
for zinc finger arrays composed of available modules (16 GNN, 15 ANN, 15 CNN) generated 
by the Barbas laboratory, within any given DNA sequence up to 10 kb in length [49]. ZifBase 
tools (http://web.iitd.ac.in/~sundar/zifbase/) can identify target sites in a given DNA sequence, 
with the option of using target site triplet composition (i.e., the number of GNN, CNN, TNN 
and ANN triplets), as a selection criterion. TagScan 
(http://www.isrec.isb-sib.ch/tagger/tagscan.html) is capable of performing searches for either 
exact or nearly exact matches (≤ 2 mismatches) between a given query sequence, such as a 
ZFP target site, and a large database, such as a genomic sequence database [50].  ZiFiT 
(http://bindr.gdcb.iastate.edu/zifit/) is similar to ZFTools in that it allows users to identifying 
target sites for ZFNs. ZiFiT also can identify sites potentially targetable with ZFPs made 
from zinc finger modules developed and/or characterized by the Barbas lab, Sangamo 
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BioSciences, Inc., and Toolgen (http://www.toolgen.com). In contrast to all of these existing 
web-based tools, which identify potential ZFN target sites within a user-provided DNA 
sequence (typically < 10 kb), ZFNGenome is a comprehensive repository that contains all 
potential ZFN sites targetable using available OPEN reagents in the complete genomic 
sequences of 7 model organisms.  
Planned future development  
ZFNGenome will be updated regularly to incorporate revisions in genomic DNA 
sequences and annotations, and to take into account new potential ZFN target sites that can 
be considered when new reagents, such as additional OPEN pools, become available. The 
genomes of several other established and emerging model organisms currently in the pipeline 
include: maize, rice, soybean, red flower beetle, mouse, and rat. We also intend to implement 
additional features, including capabilities for identifying target sites for ZFNs made by other 
publicly available engineering methods (e.g., modular assembly). Finally, because the 
experimental generation and testing of ZFNs using the OPEN protocol is not a trivial 
undertaking, the utility of a method to discriminate between ZFN target sites that are likely to 
function successfully in vivo and those that are not, cannot be over-emphasized. Our analysis 
indicates that, on average, every transcript in the zebrafish genome contains ~ 8 potential 
ZFN target sites (see Table 1). Thus, software for reliably ranking identified potential target 
sites according to the probability that they will function successfully in vivo is important for 
improving the time and cost-effectiveness of genomic modification experiments utilizing 
ZFNs. The next version of ZFNGenome will include an experimentally validated scoring 
scheme, ZiFOpT (J. Sander and D. Reyon, personal communication) to provide users with a 
ranked list of specific DNA sites that are most amenable to ZFN targeting.  
CONCLUSIONS 
OPEN is a robust, publicly available, experimental platform for the generation of 
engineered ZFNs that function with high specificity in vivo. ZFNGenome was developed to 
enhance and broaden the applicability of ZFNs for genomic modification by providing an 
online resource that contains all potential target sites for OPEN-generated ZFNs in the 
sequenced genomes of several model organisms. ZFNGenome has a user-friendly interface 
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and is seamlessly integrated with other publicly available Zinc Finger Consortium resources, 
such as ZiFiT and ZiFDB. ZFNGenome should be a valuable resource for scientists and 
clinicians who wish to exploit the powerful technologies for genome modification now 
available as a result of recent developments in ZFP design and engineering.   
 
AVAILABILITY AND REQUIREMENTS 
ZFNGenome is freely available over the web at 
http://bindr.gdcb.iastate.edu/ZFNGenome. 
 
LIST OF ABBREVIATIONS USED 
OPEN = Oligomerized Pool ENgineering 
ZF = Zinc Finger 
ZFA = Zinc Finger Array 
ZFP = Zinc Finger Protein 
ZFN = Zinc Finger Nuclease 
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CHAPTER 4. TARGETED GENE DISRUPTION IN SOMATIC 
ZEBRAFISH CELLS USING ENGINEERED TALENS  
Jeffry D Sander, Lindsay Cade, Cyd Khayter, Deepak Reyon, Randall T Peterson, J Keith Joung & 
Jing-Ruey J Yeh. Nature Biotechnology. 2011 Aug 5. 
To the Editor: 
Miller et al. recently described a transcription activator–like effector nuclease 
(TALEN) architecture for efficient genome editing in cultured human cells [1]. We sought to 
determine whether the same framework could be used to efficiently disrupt endogenous 
genes in somatic cells of zebrafish and how the efficiency of TALENs compares with that 
obtained using engineered zinc-finger nucleases (ZFNs). 
TALENs, which comprise an engineered array of transcription activator–like effector 
repeats fused to the nonspecific FokI cleavage domain, introduce targeted double-stranded 
breaks in human cells with high efficiency. Repair of these double-stranded breaks by normal 
DNA repair mechanisms, such as Non-Homologous End-Joining (NHEJ) or homologous 
recombination, enables introduction of alterations at or near the site of the break. A single 34-
amino-acid transcription activator–like effector repeat binds to one bp of DNA, and repeats 
which bind each of the four DNA bases have been described [2, 3]. These modules can be 
assembled into arrays capable of binding extended DNA sequences. TALENs may have 
advantages over engineered ZFNs due to the relative ease with which they can be designed 
and their potential ability to be targeted to a wide range of sequences, with target sites 
reported to be as frequent as 1 in 35 bp of random DNA sequence [4]. 
Previous studies have shown that error-prone repair of ZFN-induced double-stranded 
breaks by NHEJ can result in the efficient introduction of small insertions or deletions 
(indels) at cleavage sites in endogenous zebrafish genes [5-7]. These indels frequently result 
in frameshift knockout mutations that can be passed through the germ line to create mutant 
fish [5-9]. ZFN technology has enabled reverse genetics studies to be performed in zebrafish. 
However, engineering ZFNs can be challenging because of the need to account for context-
dependent effects among individual fingers in an array. In addition, although many zebrafish 
genes can be targeted with ZFNs made by publicly available methods that account for 
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context dependence [6, 10], it can be difficult to target sequences within some genes in 
zebrafish due to the currently limited targeting range of publicly available ZFN engineering 
platforms. Thus, use of TALENs for targeted mutation in zebrafish could provide an 
important additional capability for this model organism. 
To test the ability of TALENs to function in zebrafish, we targeted DNA sequences in 
two endogenous zebrafish genes, gria3a and hey2 (Fig. 4.1). To avoid confounding effects 
that might affect binding and cleavage of DNA sites by TALENs (e.g., chromatin structure or 
DNA methylation), we chose to target sequences that we had efficiently altered previously in 
zebrafish using engineered ZFNs (Supplementary Figs. 1 and 2). Using an iterative assembly 
approach (Supplementary Methods, Supplementary Figs. 3–10, and Supplementary Table 1), 
we constructed four TALEN monomers designed to target partially overlapping sites in 
gria3a and two TALEN monomers designed to target a site in hey2 (Fig. 4.1 and 
Supplementary Fig. 3). These six TALEN monomers all harbor the wild-type FokI cleavage 
domain (Supplementary Figs. 4 and 5) and can be paired in combinations to make three 
TALEN dimers to the gria3a gene and one TALEN dimer to the hey2 gene (Fig. 4.1). We 
injected RNAs encoding the various TALEN pairs into one-cell-stage zebrafish embryos and 
determined the frequency of NHEJ-mediated mutagenesis at the target site by sequence 
analysis of alleles from pooled injected embryos (Supplementary Methods). We found that all 
four pairs of TALENs induced targeted indels with high mutation frequencies ranging from 
11% to 33% (Fig. 4.1). These frequencies are comparable to what we obtained using ZFNs 
targeted to DNA sequences in the same vicinity of the gene (Supplementary Fig. 1); however, 
we note that the TALENs harbor wild-type FokI domains whereas the ZFNs harbor obligate 
heterodimeric FokI domains [11]. Although small indels were typically observed with the 
TALENs, we also observed deletions as large as 303 bp (Fig. 4.1). 
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Figure 4.1: Target sequences, frequencies of mutations and mutations induced by TALENs in 
embryonic zebrafish cells. For each pair of TALENs, the wild-type (WT) target sequence is shown 
at the top with the intended target sites of the TALENs marked in yellow. Deletions are indicated by 
red dashes against a gray background, and insertions by lowercase blue letters against a light blue 
background. The sizes of the insertions (+) or deletions (∆) are indicated to the right of each mutant 
allele. The number of times that each mutant allele was isolated is shown between square brackets. 
Mutation frequencies are calculated as the number of mutant alleles isolated/the total number of 
alleles analyzed. For the hey2 gene, we also identified two larger deletions 142 and 303 bp in length, 
which extend substantially beyond the intended target sites of the TALENs. 
 
 To assess the toxicity of our engineered TALENs, we scored the percentages of dead 
and deformed embryos that resulted from mRNA microinjections (Supplementary Fig. 11). 
Although we cannot directly compare these results with the microinjections of ZFNs due to 
the differences between the FokI endonuclease domains used (EL/KK heterodimeric FokI11 
for ZFNs versus wild-type FokI for the TALENs) and the specific sequences targeted, the 
toxicity we observed with injections of 600 pg of TALEN mRNAs (range of 40–80%) 
appears similar to that observed with 400–500 pg of mRNAs encoding ZFNs targeted to 
sequences in the same vicinity (Supplementary Fig. 12) and to other genes [6]. 
Successful germline transmission of these mutations will be critical for using 
TALENs to perform reverse genetics in zebrafish, although further experiments are needed 
both to demonstrate this and to evaluate the frequency and range of TALEN-induced off-
target effects. Given that the frequencies of mutation and the extent of toxicities we observe 
are similar to what we have seen with ZFNs, we expect that TALEN-induced mutations 
should be efficiently passed through the germ line. Progeny bearing TALEN-induced 
mutations, which unlike founder F0 fish would be uniformly mutated in all cells, will reveal 
whether both mono-allelic and bi-allelic alterations of a gene are possible and provide a more 
straightforward background for analysis of off-target effects. 
In summary, we have shown that the TALEN framework described by Miller et al.[1] 
can be used to efficiently introduce targeted indel mutations in endogenous genes of 
zebrafish somatic cells. Although in this study we chose two genomic loci that have been 
successfully targeted with ZFNs before, all six TALEN monomers we constructed showed 
high mutagenesis activities when tested in various pairwise combinations. This suggests that 
the TALEN framework is also highly robust and effective in zebrafish. As is the case with 
65 
 
 
 
ZFNs, the complete genome-wide spectrum of off-target mutations introduced by TALENs 
remains unknown. However, expression of the TALENs we made in zebrafish did not show 
toxicity substantially different from that observed with expression of ZFNs, suggesting that 
the magnitude of off-target effects may be comparable between the two classes of nuclease. 
In principle, off-target mutations generated by TALENs can be removed by outcrossing the 
founder, provided that the alterations are not tightly linked to the intended mutation. 
Moreover, mutant phenotypes could also be confirmed by generation of a second mutant 
allele using nucleases targeted to a different site. TALENs may offer potential advantages 
over ZFNs for mutagenesis of genes in zebrafish and other model organisms such as 
Caenorhabditis elegans [12], because they can be easily and quickly assembled in a modular 
fashion and can potentially target a greater range of DNA sequences. Thus, we expect that the 
ability to use both ZFNs and TALENs should enable any researcher to rapidly and easily 
create targeted mutations in any zebrafish gene of interest. 
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CHAPTER 5. USER-FRIENDLY PROTOCOL AND 
SOFTWARE FOR RAPID ENGINEERING OF DESIGNER 
TALE NUCLEASES (TALENS) 
Jeffry D. Sander*, Deepak Reyon*, Cyd Khayter, & J. Keith Joung. Nature Protocols (Under 
Review) 
* Co-first authors 
ABSTRACT 
Engineered transcription activator-like effector nucleases (TALENs) are broadly 
useful tools for performing targeted genome editing in a wide variety of organisms and cell 
types including zebrafish, C. elegans, rat, human somatic cells, and human pluripotent stem 
cells.  We recently described a serial, hierarchical ligation strategy for rapidly assembling 
TALENs that requires neither PCR nor specialized multi-fragment ligations and can therefore 
be implemented by any laboratory.  Here we provide a detailed protocol for practicing our 
assembly method together with user-friendly, web-based software that both identifies 
potential target sites in sequences of interest and generates printable graphical guides that 
facilitate assembly of TALENs.  All plasmids required to perform our assembly method are 
publicly available through the Addgene plasmid distribution service 
(http://www.addgene.org/talengineering).  With the platform of reagents, protocols, and 
software we describe, researchers can easily engineer multiple TALENs in two weeks or less 
using standard cloning techniques. 
INTRODUCTION 
Engineered transcription activator-like effector nucleases (TALENs) have recently 
generated much interest as a broadly applicable technology for highly efficient genome 
editing [1]. TALENs, like zinc finger nucleases (ZFNs), are customizable restriction enzymes 
consisting of an engineered DNA-binding domain fused to a non-specific nuclease domain 
[2-6]. Site-specific double-stranded DNA breaks induced by TALENs have been used to 
introduce sequence alterations at investigator-specified endogenous genes in a variety of 
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organisms and cell types (including yeast,[7] plants,[8] C. elegans,[9] zebrafish,[10, 11] 
rats,[12] and human somatic[3, 6, 8] and pluripotent stem cells[13]). 
The DNA-binding domain of a TALEN consists of an array of repeat sequences 
derived from naturally occurring transcription activator-like effectors (TALEs).[14, 15]  
These highly conserved 33-35 amino acids TALE repeat domains each bind to a single DNA 
base with binding specificity determined by the identity of two non-conserved amino acid 
positions.[16, 17]  DNA-binding domains with novel customized specificities can be 
engineered by joining TALE repeats into more extended arrays.  The challenge for 
researchers interested in utilizing TALENs is the need to construct plasmids encoding long 
arrays of TALE repeats that are each highly similar in sequence.   
We recently described a rapid and simple method for assembling DNAs encoding 
extended TALE repeat arrays.[10]  Our method uses a serial, hierarchical ligation strategy in 
which DNA fragments encoding single TALE repeats are joined together using standard 
restriction digest and ligation techniques that can be practiced simply and inexpensively by 
any laboratory.  We have also developed web-based software that aids not only in 
identification of potential target sites within a sequence of interest but also produces a 
customized graphical guide illustrating the series of ligation steps required to construct each 
TALE repeat array.  We recently demonstrated the successful use of our protocol to engineer 
TALENs that induced targeted mutations with high efficiencies in endogenous zebrafish 
genes.[10] 
A variety of other platforms for constructing DNA sequences encoding TALE repeat 
arrays have also been described.[3, 4, 8, 11, 18-21]  Nearly all of these methods rely on the 
use of a specialized multi-fragment ligation strategy referred to by some as Golden Gate 
cloning.  With these approaches, DNA encoding subsets of TALE repeats (ranging in length 
from four- to ten-mers) are initially assembled in parallel using multi-fragment ligation 
reactions and then subsequently joined together to create the final desired plasmid.  Because 
the ordered assembly of DNA fragments in these reactions relies on different sticky end 
overhangs for each TALE repeat at each position in an array, these methods typically require 
a large number of different plasmids or PCR reactions to practice. In addition, many of the 
methods are optimized for construction of arrays with either a fixed number or a fixed 
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multiple of repeats, limiting their flexibility to construct arrays of any desired length.  Among 
all of these methods, only one provides associated software for identifying potential TALEN 
target sites in a sequence of interest.[8]  However, this software only identifies sites and does 
not guide the user through the complex multi-fragment ligation process needed to assemble 
multiple TALENs. 
Another potentially important consideration in choosing a platform for assembly is 
the amino acid sequence and framework of the TALE-based DNA-binding domain.  A 
multitude of different engineered TALE frameworks have been described and utilized in the 
literature.  Two sources of variability exist in these different frameworks:  (1) the TALE 
repeats used differ at certain less well-conserved positions within the domain and (2) 
additional amino-terminal and carboxy-terminal TALE-derived sequences required for DNA-
binding activity of the TALE repeat array vary in both length and amino acid sequence.[2, 3, 
6]  Some have noted that the choice of framework is important and can influence the 
activities of TALENs.  We note that our platform, unlike all other publicly available methods, 
utilizes a framework of TALE repeats and amino-terminal and carboxy-terminal TALE-
derived sequences developed by Rebar and colleagues.[3]  This framework has been used 
successfully to construct TALENs with high activities in C. elegans,[9] zebrafish,[10] 
rats,[12] and human somatic[3] and pluripotent stem cells.[13] 
Here we describe a detailed protocol for identifying potential TALEN targets within a 
sequence of interest and for assembling TALENs to those sites.  Our assembly procedure 
uses standard restriction digest and ligation reactions and therefore does not require 
specialized expertise or performance of multi-fragment ligation reactions.  Our web-based 
software program (freely available without registration) identifies potential TALEN target 
sites in user-defined sequences and generates printable, color-coded graphical guides that 
provide a roadmap for assembly of desired TALENs.  These customized guides also give the 
names of specific plasmids required to assemble each particular TALEN.  All plasmids 
required to practice our protocol are publicly available to academic researchers from non-
profit plasmid distribution service Addgene (http://www.addgene.org/talengineering).   
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OVERVIEW OF THE PROCEDURE 
Our protocol can be conceptually divided into three steps:  (1) identification of 
potential TALEN targets within the sequence of interest; (2) assembly of plasmids encoding 
TALE repeat arrays; and (3) cloning of DNA fragments encoding TALE repeat arrays into a 
TALEN expression vector. 
Identifying TALEN target sites using the ZiFiT Targeter program: 
We have added a new module to our previously described Zinc Finger Targeter 
(ZiFiT) program that enables identification of TALEN target sites in addition to ZFN target 
sites.  To reflect this change, we have re-named our program Zinc Finger & TALE Targeter 
(ZiFiT Targeter).  Because TALENs can be targeted to a broad range of potential sites, ZiFiT 
Targeter restricts its output by default to five highest-ranked potential sites (criteria used to 
rank sites are based on published data describing the length of arrays and the length of spacer 
sequences between the TALEN binding sites as well as avoiding targeting of substantially 
overlapping (and therefore similar) sites; see Supplementary Discussion for chapter 5 in 
Appendix C).  ZiFiT Targeter also provides users with customized graphical guides for 
assembly of each TALEN.   
Assembly of plasmid DNA encoding TALE repeat arrays: 
Plasmid DNAs encoding TALE repeat arrays are rapidly assembled using a serial, 
hierarchical assembly strategy based on simple restriction enzyme digests and standard 
ligations (Figure 5.2).  The details of which particular plasmids to ligate together and in what 
order are provided by the graphical guide generated by ZiFiT Targeter for each TALEN.  This 
procedure generates a plasmid encoding the final desired TALE repeat array flanked by 
unique restriction sites that can be used for cloning into a TALEN expression vector. 
Cloning of DNA encoding TALE repeat arrays into a TALEN expression vector: 
In the final step, a fragment encoding the TALE repeat array is cloned into a TALEN 
expression vector and sequence verified.  Our TALEN expression vectors provide the final 
carboxy-terminal “0.5” TALE repeat domain, additional amino-terminal and carboxy-
terminal TALE-derived sequences required for optimal DNA binding, and the wild-type FokI 
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nuclease domain.  TALENs expressed from these vectors also possess a Triple FLAG epitope 
tag and a nuclear localization signal, both encoded at the amino-terminus.  A TALEN 
encoded on these vectors can be expressed in cells using a CMV promoter that is present on 
the vector.  Alternatively, the TALEN coding sequence can be transcribed into RNA in vitro 
using a T7 promoter also encoded on the expression plasmid.   
MATERIALS 
REAGENTS 
• Plasmids encoding individual TALE repeats (available through Addgene:  
http://www.addgene.org/talengineering) 
• TALEN Expression Vectors (available through Addgene:  
http://www.addgene.org/talengineering) 
• Chemically competent bacterial strain XL-1 Blue (recA1 endA1 gyrA96 thi-1 
hsdR17 supE44 relA1 lac [F´ proAB lacIq lacZDM15 Tn10 (TetR)]; Stratagene 
cat no. 200249) 
• Carbenicillin (Sigma, cat. No C1389) 
• Restriction enzymes from New England Biolabs:  BamHI (cat. no. R0136S), 
BamHI-HF (cat. no. R3136S), BbsI (cat. no. R0539L), BsaI (cat, no. 
R0535L), BsmBI  (cat. no. R0580L), and KpnI-HF (cat. no. R3142L) 
• Bovine Serum Albumin (10 mg/ml; included with enzymes from New 
England Biolabs) 
• NEBuffer2, NEBuffer 3, and NEBuffer 4 (10x restriction enzyme buffers 
included with enzymes from New England Biolabs) 
• Quick Ligation Kit (New England Biolabs, cat. No. M2200L) 
• QIAprep Spin Miniprep Kit (Qiagen, cat. No. 27106) 
• LB medium powder (Difco, cat No. 244620) 
• LB agar medium powder (Difco, cat No 244520) 
• AccuGel 29:1 acrylamide:bis-acrylamide solution (National Diagnostics, cat 
no. EC-852) 
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• 10% ammonium persulfate (Fisher cat. No 7727-54-0) 
• TEMED (Fisher cat. No. BP150-100) 
• 100% ethanol (Pharmco, cat. No. 111ACS200) 
• 70% ethanol  
• Sequencing primer OK163: 5' CGCCAGGGTTTTCCCAGTCACGAC 3' 
• Sequencing primer JDS2978: 5' TTGAGGCGCTGCTGACTG 3' 
• Sequencing primer JDS2980: 5' TTAATTCAATATATTCATGAGGCAC 3' 
• Sequencing primer JDS2778: 5' CTGGCGCAATGCGCTCAC 3' 
• Sequencing primer JDS2979: 5' AAGCAATGGCGACCACCTGTTC 3' 
EQUIPMENT 
• 96-well PCR thermocycler 
• Orbital platform shaker with adjustable speed 
• Sterile bacterial culture tubes 
• 1.5ml Eppendorf Tubes 
• Tabletop Centrifuge  
PROCEDURE 
Identification of potential TALEN target sites using web-based ZiFiT Targeter 
software  
1. Identify any repeat sequences within the target sequence of interest by entering it 
into the RepeatMasker Web Server (http://www.repeatmasker.org/).  Repeat 
sequences should be excluded from any sequence that is to be analyzed for potential 
TALEN target sequences by ZiFiT Targeter. 
2. Visit the ZiFiT Targeter website at http://zifit.partners.org/zifitbeta.  (Note that this 
is a temporary URL for our updated version of ZiFiT Targeter – we will place this 
version on the main ZiFiT website at http://zifit.partners.org if our manuscript is 
published.) 
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3. Click on the ZiFiT option on the top menu and then click on the “Design TALE 
Nucleases” option under the “TALE Assembly” menu. 
4. Paste the nucleotide sequence of interest into the text box labeled ‘Sequence’. The 
sequences may be entered as raw data or in FASTA format. All numbers and 
characters that are not G, A, T, or C will be ignored. The user must indicate the 
nucleotide position at which they wish the break to occur by framing it with brackets 
(e.g.--[A] or [G]).  ZiFiT Targeter will attempt to identify sites that place this 
nucleotide within the spacer sequence between the TALEN target half-sites.   
5. Check the option “Mask redundant sites” to make sure that the sites identified by 
ZiFiT Targeter are different from each other by at least 6 base pairs (3 base pairs in 
each TALEN monomer binding site) 
6. By default, ZiFiT Targeter will only return the five highest-ranked sites it identifies 
using criteria described in Supplementary Discussion in appendix C.  However, a user 
can display all the potential target sites identified by the program by checking the box 
for “Display all”.  With this option checked, ZiFiT Targeter will return all potential 
TALEN target sites that consist of half-sites of lengths 12-22 base pairs (including the 
conserved 5’ T nucleotide) and spacer sequences of lengths 12-23 base pairs. 
7. Click the Submit button. The output reports the top five TALEN target sites below 
the sequence entry box. If the option to “Display all” is selected, all the sites are 
reported on a new page. 
8. To obtain a customized graphical guide for assembling a particular TALEN, click 
on the target site.  The guide will open in a new window and can be saved or printed.   
 
Construction of TAL Arrays  
9. Using the graphical output provided by ZiFiT Targeter as a guide, perform the 
series of ligations indicated in the first row of the figure by using steps 10 - 19 below.  
Note that the numbers above each TALE repeat unit in the graphical guide identify 
the names of the plasmids available from Addgene that are to be used for each 
ligation.  For example, in the graphical output shown in Figure 5.2, one would 
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perform seven ligations of the following pairs of plasmids:  7 and 14, 16 and 22, 30 
and 11, 17 and 24, 26 and 15, 16 and 24, and 30 and 12).  For each pair to be ligated 
the TALE repeat on the left is the amino-terminal repeat and the one on the right is 
the carboxy-terminal repeat.  In each ligation, a DNA vector backbone encoding the 
amino-terminal repeat is ligated to a fragment encoding the carboxy-terminal repeat. 
 
Figure 5.1. Output from ZiFiT Targeter. 
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10. Digest plasmid(s) encoding the amino-terminal TALE repeat(s) with BamHI and 
BsaI using the conditions listed below. Incubate the reaction for 2 hours at 37°C.  
 
 Component      Amount 
 Plasmid encoding amino-terminal TALE repeat(s) 1.5 µg 
 NEB Buffer 2      4 µl 
 Bovine Serum Albumin (10mg/ml)   4 µl  
BbsI  (5 U/µl)      2 µl 
 BamHI  (20 U/µl)     2 µl  
 Add nuclease-free water to a total volume of  40 µl 
 
11. Isolate the vector backbone from the restriction digest of step 10 on a 5% non-
denaturing polyacrylamide gel and purify the DNA according to the protocol found in 
Box 2 of Maeder et al.[22]  Final DNA pellets should be resuspended in 20 µl of 
nuclease-free water. 
12. Digest plasmid(s) encoding the carboxy-terminal TALE repeat(s) with BbsI and 
BamHI using the conditions listed below. Incubate the reaction for 2 hours at 37°C.  
 
 Component      Amount 
 Plasmid encoding carboxy-terminal TALE repeat 1.5 µg 
 10X Buffer (NEBuffer 4)    4 µl 
 Bovine Serum Albumin (10mg/ml)   4 µl  
BsaI  (5 U/µl)      2 µl 
 BamHI  (10 U/µl)     2 µl  
 Add nuclease-free water to a total volume of  40 µl 
 
13. Isolate the DNA fragment encoding the TALE repeat(s) from the restriction digest 
of step 12 on a 5% non-denaturing polyacrylamide gel and purify the DNA using the 
protocol found in Box 2 of Maeder et al.[22]   Final DNA pellets should be 
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resuspended in 20 µl of nuclease-free water.  Note that the size of the DNA fragment 
will be equal to N x ~102 bps where N is the number of TALE repeats encoded on the 
fragment. 
14. Ligate the purified DNA fragment isolated in step 13 into the purified vector 
backbone isolated in step 11 as tabulated below. Also perform a control ligation using 
vector backbone alone (i.e.--without fragment).  Allow the ligation reactions to 
incubate for 15 minutes at room temperature.  
 
 Component      Amount 
 Purified vector backbone (from step 11)  1 µl  
 Purified fragment (from step 13) or water  3 µl 
 Quick Ligase Buffer (NEB)    4.5 µl 
T4 DNA Ligase (400U/ul)    0.5 µl 
 Total       9 µl 
 
15. Transform each ligation from step 14 into 90 µl chemically competent XL1-Blue 
cells. Mix ligations with competent cells and leave on ice for 5 minutes.  Perform heat 
shock at 42°C for 1 minute then return transformations to ice for 1 minute. Add 500 
µl LB and recover with agitation for 45 minutes at 37°C. Plate 200 µl of each 
transformation on an LB agar plate supplemented with 100 µg ml-1 carbenicillin and 
incubate overnight at 37°C for 12 – 16 hours. 
16. If the actual ligation/transformation of step 15 yields at least 10-fold more 
colonies than the control ligation, inoculate two single colonies from the actual 
ligation/transformation plate into 4 ml of LB supplemented with carbenicillin 100 mg 
ml–1 and grow overnight with agitation at 37°C.   
CRITICAL STEP:  To reduce the risk of plasmid deletions, do not allow the cultures 
to grow for more than 12 hours.   
17. Isolate plasmid DNA from overnight cultures using a QIAprep Spin Miniprep Kit 
and following the manufacturer’s instructions. 
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18. To determine whether the plasmids isolated in step 17 have successfully taken up 
the fragment encoding the carboxy-terminal TALE repeat(s), digest the candidate 
plasmids with XbaI and BamHI as detailed below and incubate at 37°C for 1 hour.  
 
  Component      Amount 
 Plasmid      1 µg 
 10X Buffer (NEB Buffer 4)    4 µl 
 Bovine Serum Albumin (10mg/ml)   4 µl  
XbaI  (20 U/µl)     2 µl 
 BamHI-HF  (20 U/µl)     2 µl  
 Add nuclease-free water to a total volume of  40 µl 
 
19. Visualize the products of the restriction digests from step 18 on a 5% non-
denaturing polyacrylamide gel.  Plasmids that have successfully taken up the 
fragment encoding the carboxy-terminal TALE repeat(s) should yield a ([(M + N) x 
102] + 33) bp fragment (where M and N are the numbers of TALE repeats encoded 
by the vector backbone and fragment, respectively, used for the ligation.).   
20. Following completion of the first set of ligations, perform the series of ligations 
indicated in the second row of the graphical guide by using steps 10 - 19 above.  
21. Continue performing ligations in subsequent rows of the graphical guide using 
steps 10 - 19 above until the final assembled array is completed. 
Cloning TAL arrays into the nuclease backbone 
22. Digest the specific TALEN expression vector indicated at the bottom of the 
graphical output (pJDS70, pJDS71, pJDS74 or pJDS78) with BsmBI restriction 
enzyme as detailed below. Incubate the reaction at 55°C for 3 hours. 
 
 Component      Amount 
 TALEN Expression Vector    2µg 
 10x Buffer (NEB Buffer #3)    5 µl 
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 BsmBI  (10U/ul)     5 µl  
 Add nuclease-free water to a total volume of  50 µl 
 
23. Isolate the vector backbone from the restriction digest of step 22 on a 5% non-
denaturing polyacrylamide gel and purify the DNA using the protocol found in Box 2 
of Maeder et al.[22]   Final DNA pellets should be resuspended in 20 µl of nuclease-
free water.   
24. Digest plasmid(s) encoding the final assembled TALE repeat array (from step 21 
above) with BbsI and BsaI as tabulated below. Incubate the reaction for 2 hours at 
37°C.  
 
 Component      Amount 
 Plasmid encoding assembled TALE repeat array 1.5 µg 
 10X Buffer (NEB Buffer 2)    4 µl 
 Bovine Serum Albumin (10mg/ml)   4 µl  
BbsI  (5 U/µl)      2 µl 
 BsaI  (10 U/µl)     2 µl  
 Add nuclease-free water to a total volume of  40 µl 
 
25. Isolate the DNA fragment encoding the TALE repeat array(s) from the restriction 
digest of step 24 on a 5% non-denaturing polyacrylamide gel and purify the DNA 
using the protocol found in Box 2 of Maeder et al.[22]   Final DNA pellets should be 
resuspended in 20 µl of nuclease-free water.  Note that the size of the DNA fragment 
will be equal to N x ~102 bps where N is the number of TALE repeats encoded on the 
fragment. 
26. Ligate the purified DNA fragment isolated in step 25 into the purified TALEN 
expression vector backbone isolated in step 23 as tabulated below. Also perform a 
control ligation using vector backbone alone (i.e.--without fragment).  Allow the 
ligation reactions to incubate for 15 minutes at room temperature.  
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 Component      Amount 
 Purified vector backbone (from step 23)  1 µl  
 Purified fragment (from step 25) or water  3 µl 
 Quick Ligase Buffer (NEB)    4.5 µl 
T4 DNA Ligase (400U/ul)    0.5 µl 
 Total       9 µl 
 
27. Transform each ligation from step 26 into 90 µl chemically competent XL1-Blue 
cells. Mix ligations with competent cells and leave on ice for 5 minutes.  Perform heat 
shock at 42°C for 1 minute then return transformations to ice for 1 minute. Add 500 
µl LB and recover with agitation for 45 minutes at 37°C. Plate 200 µl of each 
transformation on an LB plate supplemented with 100 µg ml-1 carbenicillin and 
incubate overnight at 37°C for 12 – 16 hours. 
28. If the actual ligation/transformation of step 27 yields at least 10-fold more 
colonies than the control ligation, inoculate two single colonies from the actual 
ligation/transformation plate into 4 ml of LB supplemented with carbenicillin 100 mg 
ml–1 and grow overnight with agitation at 37°C.   
CRITICAL STEP:  To reduce the risk of plasmid deletions, do not allow the cultures 
to grow for more than 12 hours.   
29. Isolate plasmid DNA from overnight cultures using a QIAprep Spin Miniprep Kit 
and following the manufacturer’s instructions. 
30. To determine whether the TALEN expression plasmids isolated in step 29 have 
successfully taken up the fragment encoding the TALE repeat array(s), digest the 
candidate plasmids with KpnI and BamHI as detailed below and incubate at 37°C for 
2 hours.   
 
 Component      Amount 
 Plasmid      0.5 µg 
 10X Buffer (NEBuffer 4)    5 µl 
 Bovine Serum Albumin (10 mg/ml)   5 µl  
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KpnI-HF  (20 U/µl)     1 µl 
 BamHI-HF  (20 U/µl)     1 µl  
 Add nuclease-free water to a total volume of  50 µl 
 
31. Visualize the products of the restriction digests from step 30 on a 5% non-
denaturing polyacrylamide gel.  Plasmids that have successfully taken up the 
fragment encoding the TALE repeat array should yield a (650 + [N x ~102]) bp 
fragment (where N is the number of TALE repeats encoded in the array.).   
32. Optional:  TALEN expression plasmids can be sequence-verified by DNA 
sequencing using forward primer JDS2978 and reverse primer JDS2980.  This step is 
not required because no PCR is performed during the assembly process.  However, 
sequencing can be useful to confirm that the correct TALE repeat arrays have been 
ligated together in the extended array.   
 
TALEN expression plasmids encoding 12.5 to 16.5 TALE repeats can be assembled 
in ~9 days. Longer arrays require an additional two days. The process of cloning the 
fragment encoding the assembled TALE repeat array into the TALEN expression vector 
requires 3 days. However, because this final cloning step is started the same day that the 
assembly of the TALE repeat array is completed, the assembly of a TALEN expression 
plasmid containing up to 16.5 TALE repeats can be completed in 11 days.  
ANTICIPATED RESULTS 
We have not encountered any difficulties with assembling various TALEN expression 
plasmids using the approach described above.  A critical factor in ensuring success is to 
check by restriction digest analysis that the ligations work successfully at each step because 
one failed ligation reaction can prevent successful assembly of the final desired array.  In 
addition, we have found that it is critical to sequence the final TALEN expression plasmid to 
verify that the correct TALE units have been used at each step and that the array was cloned 
into the correct TALEN expression vector.   
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CHAPTER 6. GENERAL CONCLUSIONS & FUTURE 
DIRECTIONS 
ZFNs or TALENs – Which platform is better? As Sir Aaron Klug said, “There is only 
one word that matters in biology, and that is specificity.” [1] Ultimately, the more specific 
platform will be the better platform.  
 
 
Figure 6.1. Method to determine off-target sites of ZFNs. IDLV, integrase-deficient lentivirus. (Figure 
from [2]) 
 
The question of which platform provides higher specificity is not easy to answer 
because, to draw definitive conclusions, we would need to sequence and analyze the 
complete genomic DNA for every cell or organism in which several ZFNs or TALENs 
targeted to identical sites had been tested. As this is prohibitively expensive, other more 
creative methods have been devised. Recently, Pattanayak et al. [3] and Gabriel et al. [4] 
published two different approaches (described below) to test the specificity of ZFNs in 
human cells. Both methods detected several off-target effects in K562 cells after introduction 
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of ZFNs designed by Sangamo Biosciences to target the CCR5 locus (i.e., the same ZFNs 
currently being tested in human clinical trials [3]). 
The method described by Pattanayak et al. [3] involved the generation of a library of 
target sites similar to the intended target site. In theory, the library covered all DNA 
sequences that have seven or fewer substitutions in about 10-fold excess. The library was 
incubated with the ZFNs of interest and, subsequently, DNA molecules were cleaved to 
expose a 5’ phosphate required for the ligation of sequencing primers. The library was then 
deep-sequenced and target sites that were preferentially cleaved were identified. Several ZFN 
target sites identified using this in vitro assay was mapped to 37 genomic loci. To check for 
evidence of cleavage at the corresponding sites in vivo, K562 cells were transfected with the 
same ZFNs. Of the 37 sites detected in vitro, 34 could be amplified, and of these 34, 10 
showed evidence of modification via non-homologous end-joining (NHEJ). One of these off-
target sites lies in the promoter region of a malignancy associated gene, BTBD10. An 
interesting observation in this study was the extent to which the amount of off-target 
cleavage was dependent on nuclease concentration. See Figure 6.2. 
 
Figure 6.2   Effects of enzyme concentration on cleavage. Figure from [3] 
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The method described by Gabriel et al. [4] was also straight forward. It involved the 
integration of Integrase-Defective Lentiviral Vectors (IDLV) into the double-stranded breaks 
created by ZFNs. Linear Amplification Mediated (LAM) PCR was performed on ZFN-
treated K562 cells that had been transfected with these vectors, using primers that hybridize 
to the U5 (unique 5) region on the LTR of the integrated IDLV. After filtering for noise 
(because IDLVs can also integrate randomly into DNA), 7 bona fide IDLV insertions at 
potential ZFN off-target sites were identified. Among these, 4 showed evidence of NHEJ-
generated mutations upon deep sequencing. 
Although these numbers may seem alarming at first glance, it should be noted that, 
from the analysis of Pattanayak et al. [3], once the CCR2 off-target site (a previously 
identified off-target site) is eliminated from consideration, the next most frequent off-target 
site is ~100-fold less likely to be cleaved; given the inherently low rate of NHEJ events (< 
1% [5]) in human cells, these off-target cleavage events would indeed be extremely rare.   
The specificity of TALENs haven’t be analyzed is as much detail but preliminary 
studies are promising. The most comprehensive study to date was performed by Li et al [6], 
where they sequenced the genome of yeast expressing TALENs. Of the 5 strains sequenced 
(4 expressing TALENs and 1 expressing a ZFN) none of them showed any signs off-target 
effects. Some point mutations were detected, but these are unlikely to be caused by nuclease 
mediated NHEJ events which tend to be large deletions and insertions. In another study 
Hockemeyer et al. analyzed highly homologous loci for evidence of NHEJ in iPS cells 
transfected with TALENs designed to target the AAVS1 locus. Surprisingly, 2 of the top 20 
off-target sites showed evidence of NHEJ.  
We are starting to gather data about the specificity of TALENs but it is still too early 
to draw any concrete conclusions about how they compare to ZFNs on the bases of 
specificity. 
CONTRIBUTIONS OF THIS DISSERTATION 
In this dissertation I describe: 
1. My contributions to make zinc finger nucleases more accessible as tools for 
genome engineering. Genome modification using ZFNs was first described by 
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Bibikova et al. is 2001 and was poised to revolutionize the field but stumbled 
because acquiring quality reagents didn’t turn out to be as easy as initially 
thought. A schism formed in the field of ZFN design: design several ZFNs using 
an easy inexpensive technology (modular assembly) and find one that works; or 
design few ZFNs using rather cumbersome, expensive technologies (selection 
based) that are more likely to be functional. The debate about the superior 
methodology continues. My contribution to the field is to make these selection 
methods more appealing by helping user find ideal target sites. There that two 
criteria that can be exploited to identify ideal target sites: 1.) Nature of the site 
(i.e., composition of the target site). As described in Chapter 2, we developed a 
Naïve Bayes classifier to capture this information and rank order all potential 
target sites. 2.) Location and uniqueness of the site. Not all ZFN mediated double 
stranded breaks are equal. As described in Chapter 3, to help researchers choose 
ideal sites we found all potential target sites within the genomes of several model 
organisms, scored them using our classifier, found how unique they were, and 
then displayed them within the context of other genomic features using a user-
friendly genome browser. 
2. My contributions to exploring the potential of newly described transcription 
activator like effectors (TALEs) as tools for genome engineering. A simple code 
for TALE-DNA bind was published in 2009 [7, 8] and appear to be ideal tools for 
genome engineering because them seem to be truly modular. As these proteins are 
new the first step is develop methods to build them easily. In Chapter 4, we 
describe a very simple method to build functional (in zebrafish) TALENs. In 
Chapter 5 (under review), we describe the protocol in detail and provide a user 
friendly web interface to help research identify target sites, and, perhaps more 
importantly, guide user through the assembly process. 
3. My other contributions to the field include: 
a. Developing more CoDA reagents (Appendix A) 
b. Upgrading ZiFiT to include CoDA reagents and ZiFOpT scores (Appendix 
B) 
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FUTURE STUDIES 
Although the problem of designing highly sequence-specific ZFNs is far from solved, 
it seems likely that TALENs will dominate the spot-light in the genomic modification theater 
for now. For TALENs to become widely useful tools, however, there are several areas that 
require immediate attention: TALEN cleavage specificity and efficacy, effect of genomic 
context (e.g., chromatin state, epigenetic modifications), toxicity in different cell types, and 
effects on relative rates of homologous recombination (HR) vs. non-homologous end joining 
(NHEJ). In addition, there are many fundamental questions about TALENs that have not yet 
been addressed: What is their mode of DNA binding? What is their 3D structure? Because 
TALENs have only recently been over-expressed and purified, their kinetic and 
thermodynamic properties (on/off rates, binding affinity, etc.) have not yet been 
characterized. 
Specificity: How specific are TALENS? To rigorously examine this, several different 
pairs of nucleases) will have to be tested using assays likes the ones described by Pattanayak 
et al. [3] or Gabriel et al. [4]. Although such direct experiments have not yet been performed 
on a large scale, we can infer a lot about the specificity of TALENs based on the published 
literature. We can safely conclude that TALENs are not extremely promiscuous based on data 
from Li et al [6], Hockemeyer et al [9], and the apparently low levels of toxicity in cells [10]. 
There have been mixed reports about how many mismatches a TALEN can tolerate. Based on 
SELEX data, Miller et al. [11] reported that a TALE monomer that binds a 17-mer could 
potentially tolerate up to 9 bp mismatches [11]. On the other hand, Mussolino et al. [10] 
reported that a single mistake in a 17 bp target was sufficient to abolish binding. It must be 
noted that the target sites that Mussolino et al, compared were the CCR5 site and CCR2 site. 
One crucial difference between the CCR5 site and the CCR2 site is that the CCR2 site does 
not have a 5’ T, which appears to be essential for TALE binding. Currently, the jury is still 
out about the specificity of TALENs. 
Effects of genomic context: We know very little about the effect of chromatin 
structure on TALENs. Most of the TALENs tested to date were designed to target sites that 
had been previously targeted using ZFNs (hence, known to be accessible). Given that some 
of the most important applications of genomic modification tools would be in the context of 
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stem cells which often have different methylation status compared to somatic cells [12], 
understanding the effect of chromatin structure and genomic context on TALEN efficacy will 
be crucial.  
Toxicity: The question of toxicity can be divided into two parts: toxicity due to lack 
of specificity, and inherent toxicity upon over-expression of the enzyme. For most 
applications to date, the inherent toxicity of either ZFNs or TALENs has not been an issue, 
because genome modification is typically performed at the cellular level and the introduced 
enzymes never encounter the immune system. But, it is conceivable that, in a clinical context, 
this will not be the case. It is known that ZFPs are generally non-immunogenic in humans 
[13], but, TALENs, given their origin (a bacterial pathogen), could potentially induce an 
inflammatory immune response and/or cellular toxicity. 
HR vs. NHEJ rates: The relative rate of homologous and non-homologous 
recombination events induced by TALENs is another piece of the puzzle that we very little 
anything. We do know that when a ZFN cleaves DNA, it leaves a 3-bp 5’ overhang. The 
problem is not that straightforward when it comes to TALs, because the spacer region can 
vary from 10 -22 bp. We do not yet know what effect this would have on rates.  
Structural Information:  Since Pavleteich et al. [14] published the first structure of 
Zif268 in 1991, the structures of zinc finger proteins and nucleases have be scrutinized in 
great detail. To date, there is no structure available for a complete TALEN protein (A. 
Bogdanove, personal communication). The best information we have is an NMR structure of 
a 1.5 repeat unit of TALE PthA, combined with a SAXS profile [15].  
 
89 
 
 
 
 
Figure 6.3. NMR structure of 1.5 repeats of the PthA TALE. (Figure from [15]) 
 
Considering the fact that a typical TALE contains ~17.5 repeats, together with a 200-250 
amino acid extensions on both the N- and C-termini, it is difficult to draw too many 
conclusions from this structure of the 1.5 repeats. Nevertheless, these data, combined with the 
published SAXS profile, have been used to make predictions of the overall structure of a 
TALEN and its complex with DNA [13].  
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Figure 6.4. Predicted structure of PthA2 with DNA. (Figure from [13]) 
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Understanding the structure of TALENs and the mechanism by which they bind DNA is 
arguably the most crucial missing piece of the puzzle at the moment. 
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APPENDIX A. SELECTION-FREE ZINC-FINGER-
NUCLEASE ENGINEERING BY CONTEXT-DEPENDENT 
ASSEMBLY (CODA) 
Jeffry D. Sander, Elizabeth J. Dahlborg, Mathew J. Goodwin, Lindsay Cade, Feng Zhang, Daniel 
Cifuentes, Shaun J. Curtin, Jessica S. Blackburn, Stacey Thibodeau-Beganny, Yiping Qi, Christopher 
J. Pierick, Ellen Hoffman, Morgan L. Maeder, Cyd Khayter, Deepak Reyon, Drena Dobbs, David M. 
Langenau, Robert M. Stupar, Antonio J. Giraldez, Daniel F. Voytas, Randall T. Peterson, Jing-Ruey J. 
Yeh, and J. Keith Joung. Nat Methods., 2010 December 12. 
ABSTRACT 
Engineered zinc-finger nucleases (ZFNs) enable targeted genome modification. Here 
we describe Context-Dependent Assembly (CoDA), a platform for engineering ZFNs using 
only standard cloning techniques or custom DNA synthesis. Using CoDA ZFNs, we rapidly 
altered 20 genes in zebrafish, Arabidopsis, and soybean. The simplicity and efficacy of 
CoDA will enable broad adoption of ZFN technology and make possible large-scale projects 
focused on multi-gene pathways or genome-wide alterations. 
MAIN 
Engineered zinc-finger nucleases (ZFNs) can be used to introduce targeted alterations 
into genomes of model organisms, plants and human cells [1, 2]. Repair of ZFN-induced 
double-strand breaks by error-prone nonhomologous end joining leads to efficient 
introduction of insertion or deletion mutations at the site of the double-strand break. 
Alternatively, repair of a double-strand break by homology-directed repair with an 
exogenously introduced donor template can promote efficient introduction of alterations or 
insertions at or near the break site. 
Widespread adoption and large-scale use of ZFN technology have been hindered by 
continued lack of a robust, easy-to-use and publicly available method for engineering zinc-
finger arrays. In one approach, known as modular assembly, preselected zinc-finger modules 
are joined into arrays [3], a procedure simple enough for any researcher to implement. Some 
recent reports have indicated a high failure rate for this method [4, 5], although the 
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consequent need to construct and test large numbers of ZFNs for any given target gene can 
be mitigated by using a more limited subset of modules [6]. We recently described a robust 
selection-based method known as oligomerized pool engineering (OPEN) [7], but the labor 
and expertise required to screen combinatorial libraries have limited its broad adoption [3]. 
Researchers at Sangamo BioSciences have also developed a platform for engineering ZFNs; 
although some details of this method have been published [8], implementation requires 
access to a proprietary archive of engineered zinc-finger units [9]. Researchers may purchase 
customized ZFNs made by the Sangamo approach through the Sigma-Aldrich CompoZr 
service, but the cost of these proteins [9] limits the scale and scope of projects that can be 
performed. 
Here we describe context-dependent assembly (CoDA), a publicly available platform 
of reagents and software that is simple to practice and has a success rate for generating active 
zinc-finger arrays comparable to that of selection-based methods such as OPEN. With the 
CoDA approach, three-finger arrays are assembled using N- and C-terminal fingers that have 
been previously identified in other arrays containing a common middle finger (F2 units) (Fig. 
1). CoDA can be implemented by using a large archive consisting of 319 N-terminal-end 
fingers (F1 units) and 344 C-terminal-end fingers (F3 units) (Supplementary Tables 1 and 2) 
engineered to function well when positioned adjacent to one of 18 fixed F2 units (Online 
Methods). Thus, in contrast to modular assembly, CoDA does not treat fingers as independent 
modules but instead explicitly accounts for context-dependent effects between adjacent 
fingers [10, 11], thereby increasing the probability that a multifinger array will function well. 
CoDA is rapid and requires neither specialized expertise nor labor-intensive selections; 
dozens of multifinger arrays can be constructed in 1–2 weeks or less using standard cloning 
techniques or commercial DNA synthesis.  
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Figure. A. 1: Schematic overview of Context-Dependent Assembly (CoDA). Zinc fingers 
(units F1–F3) and their respective 3-bp DNA 'subsites' are shown. Two different three-zinc-finger 
arrays, each engineered to bind different 9-bp target sites and that have in common a middle F2 unit, 
can be used to create a three-finger array with a new specificity by joining together the F1 unit from 
the first array, the F2 unit, and the F3 unit from the second array. 
 
To test the CoDA approach, we assembled 181 three-finger arrays and evaluated each 
for its ability to bind its cognate DNA target site using an established bacterial two-hybrid 
(B2H) reporter assay [5, 7]. Previous work has shown that three-finger arrays that do not 
activate transcription by more than 1.57-fold in the B2H reporter assay are likely to be 
inactive as ZFNs in mammalian cells [5] and those that activate by threefold or more have a 
high probability of functioning efficiently as ZFNs in zebrafish, plant and human cells [7, 12-
15]. Of the 181 CoDA-generated arrays we tested using the B2H reporter assay, <8% (14 
arrays) activated transcription by <1.57-fold and >76% (139 arrays) activated transcription 
by greater than threefold (Supplementary Fig. 1 and Supplementary Table 3). These 'failure' 
and 'success' rates for DNA-binding activity (as predicted by the B2H reporter assay) are 
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comparable to what we have previously observed with three-finger arrays made by OPEN 
[7]. Because so few (<25%) of the CoDA-generated arrays we tested gave less than threefold 
activation in the B2H reporter assay, our results suggest that one could skip the B2H reporter 
assay step and instead directly test the arrays in the cell type of interest.  
We compared the efficacy of CoDA with that of modular assembly by using both 
approaches to construct three-finger arrays for 26 different 9–base-pair (bp) sites and by 
testing these proteins for DNA-binding activity in the B2H reporter assay (Supplementary 
Table 4). For these sites that we could target by both methods, CoDA-generated zinc-finger 
arrays performed better than those generated by modular assembly as judged by multiple 
comparisons of their DNA-binding activities (Supplementary Fig. 2 and Supplementary 
Discussion). The most likely explanation for the relatively higher rates of generating active 
arrays by CoDA is its explicit consideration of context-dependent activities between fingers 
[10, 11]. This difference will be more pronounced when one targets a ZFN site because two 
functional arrays must be engineered to create a ZFN dimer. 
We used CoDA to engineer ZFNs for endogenous gene targets in zebrafish and plants. 
Using CoDA-generated zinc-finger arrays that activated transcription at least threefold in the 
B2H reporter assay, we constructed ZFN pairs for 24 gene targets in zebrafish, 13 gene 
targets in Arabidopsis thaliana and one target present in two duplicated genes in soybean 
(Table 1). CoDA-generated ZFNs induced targeted insertion or deletion mutations with high 
efficiencies in 12 of 24 zebrafish target sites (mutation frequencies, ≤1% to 16.7%), in 6 of 
13Arabidopsis gene targets (mutation frequencies, ≤1% to 8.4%) and in a target site present 
in two duplicated soybean genes in transformed root tissue (mutation frequencies, 18.8% and 
10.7%) (Table 1 and Supplementary Figs. 3 and 4). 
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Table A.1: Endogenous zebrafish and plant genes targeted by CoDA-generated ZFNs 
Gene 
symbol 
Organism ZFN target site Mutant 
alleles/total 
alleles 
Mutation 
frequency 
(%) 
aTarget sites in each gene are written 5′ to 3′ with the two half-sites targeted by the zinc-
finger arrays (uppercase letters) and the intervening spacer sequence (lowercase letters). 
Dcl4a Soybean TGCTTCATCacaatGGAGATGAT 6/32 18.8 
Dcl4b Soybean TGCTTCATCacaatGGAGATGAT 3/28 10.7 
MPK8 Thale 
cress 
CTCCACAACatcagGATGACGAA 7/83 8.4 
MPK11 Thale 
cress 
CTCTTCGTCctatcgGCAGAGGCG 3/90 3.3 
MKK9 Thale 
cress 
GCCAGCGACggtggtGGTGGTGGC 3/95 3.2 
MPK15 Thale 
cress 
TTCTTCATCcagatGTTGTTGAG 2/73 2.7 
MAPKKK18 Thale 
cress 
CCCTTCCACaacaacGGAGAAGCT 2/75 2.7 
GA3OX2 Thale 
cress 
AGCTACGCCgtagccGGAGACGCC 1/94 ≤1 
MAPKKK1 Thale 
cress 
GGCACCTCCgatttcGTGGAGGAA 0/190 0 
MAPKKK12 Thale 
cress 
TCCTCCACCgaatcGACGGCGCT 0/187 0 
MAPKKK12 Thale 
cress 
TTCCTCCACcgaatcGACGGCGCT 0/186 0 
MAPKKK4 Thale 
cress 
GTCTCCGCCtaggaGATGCAGAC 0/190 0 
MPK15 Thale 
cress 
TGCTTCTTCatccaGATGTTGTT 0/94 0 
MPK4 Thale 
cress 
CTCTTCGTCctatcgGTAGAGGCG 0/190 0 
TZP Thale TTCGTCTTCgagtcGTCGTTGTT 0/141 0 
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Gene 
symbol 
Organism ZFN target site Mutant 
alleles/total 
alleles 
Mutation 
frequency 
(%) 
cress 
actn1 Zebrafish GCCTTCTCCggggcGCAGAAGGT 10/60 16.7 
rag2 Zebrafish ATCTTCTGCtccaggGGTGAAGGT 4/52 7.7 
gad2 Zebrafish AGCCGCAGCtctcgGCTGTAGAC 3/43 7 
lmna Zebrafish CTCTTCTCCcccagaGCTGTGGAG 2/41 4.9 
apoeb Zebrafish CCCCTCAGCccagaTGGGAGGAG 3/64 4.7 
trpm7 Zebrafish CACACCTGCacacaGATGCTGCT 2/55 3.6 
grip1 Zebrafish GGCCACCTCcaccaGCAGCGGGC 3/90 3.3 
pclo Zebrafish CCCCTCTCCtcaaaGCAGATGCA 3/96 3.1 
jak3 Zebrafish GGCCCCACCaagcctGCTGGAGGA 1/71 ≤1 
ago1 Zebrafish CTCTGCCGCcacctaGAGGATGGT 1/96 ≤1 
slitrk1 Zebrafish GCCCACAGCaatggcGGAGCCGCC 1/96 ≤1 
bmpr2a Zebrafish GACTTCCTCtctgtGCAGTCGGC 1/117 ≤1 
bmpr2a Zebrafish ACCTCCTGCagtgtGAGGTTGTC 0/156 0 
cnot1 Zebrafish GGCGTCCACgtacgaGCGGAGGAG 0/93 0 
ctcf Zebrafish TTCCTCCTCctgatGCGGAGGCT 0/96 0 
dicer1 Zebrafish TTCTGCAGCtcaatGGAGATGGT 0/96 0 
dicer1 Zebrafish AGCTTCCTCcgccgGAAGTTGAG 0/96 0 
drosha Zebrafish GTCCTCCTCatggcgGTCGATGGT 0/96 0 
g6pcb Zebrafish TCCCACTGCtgattGTAGGTGGA 0/134 0 
nedd4l Zebrafish AACCGCACCacacaGTGGAAGAG 0/86 0 
nod2 Zebrafish AACTACAACattaggGCTGGAGGA 0/103 0 
rag1 Zebrafish GTCCTCCCCttcaaGTCGAATAG 0/91 0 
th2 Zebrafish CTCCTCCTCaaacacGAAGCTGTC 0/142 0 
tp53 Zebrafish AGCAGCTGCatgggGGGGATGAA 0/107 0 
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Our overall per-target success rate for obtaining mutations with CoDA-generated 
ZFNs is 50% (19 of 38 target sites) in zebrafish and plants, a frequency comparable to our 
success rates of ~67% (16 of 24 target sites) with OPEN-generated ZFNs in zebrafish, plants 
and human cells (refs. [7, 12-15] and unpublished data). For CoDA, success rates for 
obtaining mutations as calculated per ZFN pair and per ZFN target site are the same because 
only a single CoDA-generated ZFN pair is tested per ZFN target site. Although we do not 
know why some CoDA- and OPEN-generated ZFNs do not induce mutations, we 
hypothesize that chromatin state or DNA methylation of the site, or protein stability or 
folding might be responsible. Regardless of the precise mechanism, we recommend that users 
of CoDA plan to make ZFNs for at least two target sites per gene of interest to increase the 
likelihood that at least one pair will introduce mutations. 
CoDA still has some limitations compared to existing methods. Although modular 
assembly was less efficient than CoDA in our direct comparisons, modular assembly can 
potentially be used to target sites that CoDA currently cannot target [4, 6], and one recent 
report demonstrated a comparable success rate of 23% for modular assembly using a more 
limited subset of modules [6]. In addition, although CoDA accounts for context-dependence 
between adjacent fingers, it also has some limitations relative to selection-based methods 
such as OPEN. For example, CoDA constrains the identity of the F2 unit and does not 
'balance' the effects of all three fingers on affinity and specificity of the final array. In 
addition, CoDA in its current form guides assembly of arrays to 9-bp target sites, ignoring the 
identities of the adjacent upstream and downstream bases. Thus, for highly demanding 
therapeutic applications (for example, introduction of alterations into human pluripotent stem 
cells [15]), ZFNs made by OPEN may still be preferable to those made by CoDA, and it may 
be necessary to engineer zinc-finger arrays with greater specificities. Nonetheless, our overall 
results demonstrate that CoDA is a method for assembling zinc-finger arrays that accounts 
for context-dependent effects, is easier to perform than OPEN selections and yields ZFNs 
that efficiently modify genes. 
With the current archive of CoDA units, a potential ZFN target site can be found 
approximately once in every 500 bp of random sequence (Supplementary Discussion). 
However, actual targeting range can be higher, depending on genomic sequences. For 
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example, ~81% of 27,305 unique protein-coding transcripts in the zebrafish genome 
(Ensembl Zv8.57 database) contain one or more potentially targetable ZFN sites (mean, 4.37 
sites), a frequency equivalent to one potential site every ~400 bp of transcript-coding 
sequence. By contrast, ~63% of 33,200 unique protein coding transcripts in 
the Arabidopsis genome (The Arabidopsis Information Resource 9 release) contain one or 
more potential ZFN target sites (mean, 2.45 sites), a frequency equal to one potential site 
every ~790 bp of transcript-coding sequence. We updated our publicly available web-based 
zinc finger targeter (ZiFiT) program (http://bindr.gdcb.iastate.edu/ZiFiT/ or 
http://www.zincfingers.org/software-tools.htm) to enable users to identify potential CoDA 
ZFN target sites in any given gene sequence (Supplementary Fig. 5 and Supplementary 
Discussion). 
In summary, CoDA is an effective alternative method for using publicly available 
reagents to engineer ZFNs. The rapidity and high success rate of CoDA enabled us to mutate 
20 endogenous genes in three different organisms. CoDA will foster broader adoption of 
ZFN technology and also enable large-scale ZFN projects focused on multigene pathways or 
genome-wide alterations that are difficult to implement using existing methodologies. 
METHODS 
Identification of finger units for practicing CoDA 
To identify 'fixed' F2 fingers for various 3-bp target subsites, we analyzed the amino 
acid sequences of F2 units from a collection of three-finger arrays previously identified from 
OPEN selections performed for over 130 different 9-bp sites (refs. [7, 12-15] and M. 
Maeder et al., unpublished data). From this analysis, we identified F2 units for 18 different 3-
bp subsites that occurred in at least two or more different contexts. The F1 and F3 units 
found adjacent to these F2 units were also chosen as CoDA units because they had been 
selected to work well together. To obtain additional F1 and F3 CoDA units for other 3-bp 
subsites, we performed OPEN selections in which we interrogated combinatorial three-finger 
array libraries composed of a fixed F2 unit and randomized F1 and F3 units for binding to 
specific 9-bp target sequences. From these selections, we analyzed the amino acid sequences 
of three-finger arrays that activated transcription threefold or more in the B2H reporter assay 
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to identify additional F1 and F3 finger units that worked well when positioned next to a 
specific fixed F2 CoDA unit. For selections that yielded multiple three-finger array clones, 
we chose F1 and F3 units that occurred the most frequently in multiple distinct arrays and/or 
that were found in three-finger arrays that gave the highest-fold activation in the B2H 
reporter assay. OPEN selections were performed essentially as described previously [7, 
16] but with the modification that a beta-lactamase antibiotic resistance gene was used for 
selection instead of the HIS3 gene. This modified version of OPEN enabled selections to be 
performed with higher throughput (M.J.G. et al., unpublished data). Each of the three-finger 
arrays from which the F1, F2 and F3 units were derived was determined to be active in a 
B2H reporter assay. 
Construction of zinc-finger arrays by modular assembly 
Construction of plasmids encoding the modularly assembled zinc-finger arrays used 
in this study has been described previously [5].  
Construction of zinc-finger arrays by CoDA 
To assemble CoDA zinc-finger arrays, DNA fragments encoding an F1–F2 cassette or 
an F3 cassette were amplified by PCR from plasmids using primer pairs OK1424 and 
OK1427 or OK1428 and OK1429, respectively. (Sequences of all primers are listed in 
Supplementary Table 5). The resulting PCR products were digested with DpnI (New England 
Biolabs) to degrade template plasmid DNA and purified using a Qiagen PCR purification kit. 
The cassettes were then fused together and amplified in a single PCR step using primers 
OK1430 and OK1432. PCR products encoding a three-finger array were then purified using a 
Qiagen PCR purification kit, treated with Pfu polymerase (Stratagene) in the presence of 
dTTP nucleotide to create overhangs, phosphorylated with T4 polynucleotide kinase (New 
England Biolabs) and ligated to a B2H expression plasmid (pMG414) in which the zinc-
finger array is expressed as a fusion to a fragment of the yeast Gal11P protein [16]. All 
plasmids were sequenced using primer OK61. 
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B2H reporter assay 
Zinc-finger arrays made by modular assembly or CoDA were each tested for binding 
to its cognate target site by measuring its ability to activate transcription in the B2H reporter 
assay as described previously [16, 17]. All assays were performed in triplicate. 
Zebrafish gene mutation analysis 
Injection of zebrafish embryos, isolation of genomic DNA, limited-cycle PCR 
amplification of the locus of interest, cloning of PCR fragments using the TOPO TA Cloning 
kit (Invitrogen) and transformation of Escherichia coli were performed as described 
previously [12, 18]. Resulting colonies were assessed for gene mutations by one of two 
methods: (i) direct sequencing of individual clones or (ii) screening of three pooled clones for 
alterations in PCR fragment size using fluorescence-based analysis as described previously 
[18], followed by identification of specific mutations by direct sequencing. 
Arabidopsis gene mutation analysis 
ZFN transgene expression constructs, Arabidopsis transformation methods, induction 
of ZFN expression in Arabidopsis seedlings by β-estradiol and isolation 
of Arabidopsis genomic DNA were done as described previously [14]. ZFN recognition sites 
in the Arabidopsis genomic DNA were amplified by PCR, the resulting fragments were 
cloned using the TOPO TA Cloning kit, and DNA from individual colonies was sequenced to 
identify mutations at the ZFN recognition site. 
Soybean gene mutation analysis 
Cotyledons of the soybean variety Bert were transformed using a previously 
described hairy root transformation protocol [19]. The ZFN transgene was induced by 
application of 10 µM of β-estradiol (Sigma) on tissue culture medium. Hairy root DNA was 
isolated using the Qiagen DNeasy kit. Transformed roots were screened for the ZFN 
transgene using primers (forward primer, 5′-TGGATATGTATATGGTGGTAATGC-3′ and 
reverse primer, 5′-TTGAGCTTGTGGCGCAGCTCG-3′). Roots containing the transgene 
were then screened for mutations by a cleaved amplified polymorphic sequence (CAPS) 
analysis (forward primer, 5′-GTAAAAGATGTTGAAAGAAAGTTGG-3′ and reverse 
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primer, 5′-GCTTTTGACTTGAGCATGATGG-3′) using restriction enzyme MslI, which 
digests the nucleotide sequence targeted for mutagenesis. A single root was identified as 
carrying putative mutations in the Dcl4a and Dcl4b genes. The targeted regions 
of Dcl4a andDcl4b were amplified by PCR from this root using the CAPS primers. PCR 
fragments were cloned in pGem T-easy (Promega) and colony PCR products for 60 clones 
were subsequently sequenced. Mutations were identified via sequence alignments using 
MEGA 4.1 (ref. [20]). 
Identification of potential CoDA ZFN sites in D. rerio and Arabidopsis 
Potential ZFN target sites in D. rerio and Arabidopsis were identified from the 
Ensembl (Zv8.57) and The Arabidopsis information resource (TAIR9) chromosomal 
assemblies and gene table files. Potential ZFN target sites were defined as those that could be 
targeted using the CoDA reagents described here and that had a spacer sequence of 5, 6 or 7 
nucleotides that was entirely within an exon. 
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SUPPLEMENTARY DISCUSSION  
Direct comparisons of CoDA and modular assembly zinc finger arrays for 26 
target DNA sites  
The DNA sites used for this experiment were chosen from among 104 sites we had 
previously tested to assess the efficacy of modular assembly 6 (Supplementary Table 4) and 
represent all of these sites for which finger arrays can currently be made using CoDA.  
Nearly all of these sites (24 out of 26) matched the consensus sequence 5’GNNGNNGNN3’, 
a category of target sites for which modular assembly showed the highest success rates in our 
earlier report 6. In addition, it is important to note that although we made and tested only one 
CoDA finger array for each of the 26 target sites, multiple modularly assembled arrays (two 
to six arrays) were made and tested for nearly all (25 of the 26) sites (Supplementary Table 
4), using three previously published module archives.2-6  
Our results demonstrate that CoDA yielded the zinc finger array with the highest B2H 
assay activity for 20 of the 26 target sites (Supplementary Table 4).  Furthermore, the mean 
B2H fold activation of all CoDA proteins tested (5.59-fold) is higher than those made using 
the three different modular assembly sets (1.43-, 2.11-, and 2.53-fold; Supplementary Table 
4).  To further compare CoDA and modular assembly, we examined fold-activation values in 
the B2H reporter assay of the most active protein made by each of the two methods for the 26 
target DNA sites. Of these proteins, ~38% of the modular assembled arrays activated 
transcription by 1.57 fold or less in the B2H compared with 0% of the CoDA arrays 
(Supplementary Figure 2).  Furthermore, ~23% of the modularly assembled arrays activated 
transcription by three-fold or more in the B2H assay compared with ~69% of the CoDA 
arrays (Supplementary Figure 2).  
Comparison of mutation frequencies induced by ZFNs made using CoDA and 
other engineering platforms 
The range of CoDA ZFN-induced mutation frequencies we observed in zebrafish 
somatic cell experiments (≤1% to 16.7%) are similar but somewhat lower than those from 
previously published experiments.  Somatic mutation rates were reported to be 3% to 20% 
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for ZFNs made by OPEN or B1H selection 7, 8 and 3% to 32% for ZFNs made by the 
proprietary Sangamo  
platform.9 Nonetheless, our previous experience suggests that the frequencies of 
somatic mutations we observed are high enough to make it likely that germline founders 
could be readily identified using these ZFNs (ref. 7 and unpublished data).  For Arabidopsis, 
the frequencies of mutagenesis (as measured by number of mutated alleles) induced by 
CoDA ZFNs are comparable to those previously observed with ZFNs made by OPEN.10 No 
comparisons to prior experiments could be made for the soybean experiments because, to our 
knowledge, these are the first examples of ZFN- targeted mutations in endogenous soybean 
genes.  
Predicted Targeting Range of CoDA ZFNs in Random DNA Sequence  
The number of 9 bp sequences that can be targeted for each F2 triplet can be 
calculated as the product of F1 and F3 domains selected to function well in the context of the 
fixed F2 anchor finger for that triplet (i.e. CoDA targets where F2 target is GGG = 23 F1s x 
20 F3s ). Therefore, total number of 9 bp sequences that can be targeted with our current 
CoDA finger units is the sum of the 9bp targets for each of the 18 different F2 triplets which 
equals 6680 9bp sequences or approximately 2.55% of all possible 9bp DNA sequences. 
Because each ZFN requires two 9bp arrays and can be designed with three spacer sizes (5, 6 
or 7 bp), 11, 12 CoDA targets are expected to occur about every 500bp of random sequence (1/ 
(3*%55.2*%55.2)). We note that the theoretical targeting range in random DNA sequence for 
ZFNs made using the proprietary Sangamo platform has been reported to be 1 in ~31 bp of 
random sequence, 13 a capability currently superior to that of CoDA.  Therefore, an important 
priority for future experiments will be to identify additional context-sensitive finger units for 
CoDA to further expand the range of potentially targetable genes and sequences. 
Modified ZiFiT software for identifying potential CoDA ZFN target sites  
Our new ZiFiT V3.3 program can be accessed at: http://bindr.gdcb.iastate.edu/ZiFiT/ 
or at http://www.zincfingers.org/software-tools.htm.  Output from the ZiFiT program 
(Supplementary Figure 5) provides the sequence of potential CoDA target sites and unique 
identification numbers for requesting plasmids encoding the finger units required to assemble 
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arrays (individual CoDA zinc finger units can be requested from the Joung lab by any 
interested academic researcher). Alternatively, ZiFiT can also generate DNA sequences 
encoding CoDA zinc finger arrays required to target a given site; these <290 bp DNA 
fragments can be synthesized through a commercial provider and then seamlessly cloned into 
existing Zinc Finger Consortium ZFN expression vectors. 1, 7, 14, 15 
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APPENDIX B. ZIFIT (ZINC FINGER TARGETER):  AN 
UPDATED ZINC FINGER ENGINEERING TOOL 
Jeffry D. Sander, Morgan L. Maeder,  Deepak Reyon, Daniel F. Voytas, J. Keith Joung & Drena 
Dobbs. Nucleic Acids Research. 2010 April 30. 
ABSTRACT 
ZiFiT (Zinc Finger Targeter) is a simple and intuitive web-based tool that provides an 
interface to identify potential binding sites for engineered zinc finger proteins (ZFPs) in user-
supplied DNA sequences.  In this updated version, ZiFiT identifies potential sites for ZFPs 
made by both the modular assembly and OPEN engineering methods.  In addition, ZiFiT 
now integrates additional tools and resources including scoring schemes for modular 
assembly, an interface with the Zinc Finger Database (ZiFDB) of engineered ZFPs, and 
direct querying of NCBI BLAST servers for identifying potential off-target sites within a 
host genome. Taken together, these features facilitate design of ZFPs using reagents made 
available to the academic research community by the Zinc Finger Consortium.  ZiFiT is 
freely available on the web without registration at http://bindr.gdcb.iastate.edu/ZiFiT/. 
INTRODUCTION 
Engineered zinc finger proteins (ZFPs) are important tools for gene regulation and 
genome modification because they can be used to target functional domains to virtually any 
desired location in a complex genome[1, 2]. Zinc Finger Nucleases (ZFNs) consist of an 
engineered ZFP fused to a non-specific nuclease domain and can be used to create double-
stranded breaks (DSBs) in specific endogenous genes [3]. These DSBs can be exploited to 
induce highly efficient insertion or alteration of DNA sequences via homologous 
recombination at the targeted locus [4-11]. Alternatively, imperfect repair of a ZFN-induced 
DSB by non-homologous end joining can lead to highly efficient generation of gene-specific 
knockouts [7, 12-17]. 
Engineered C2H2 zinc finger proteins comprise multiple (usually 3 to 6) ZF domains 
joined together by a fixed amino acid linker sequence(s), typically TGEKP.  Each individual 
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domain conforms to the zinc finger motif X2-C-X2-4-C-X12-H3-5-H which, when chelated with 
a zinc ion, forms a ββα fold. This structure presents a stabilized α-helix (the  
recognition helix) capable of making base specific contacts with approximately 3 bases in the 
major groove of double-stranded DNA. Adjacent ZF domains in a ZFP typically specify 
adjacent DNA triplets, establishing specificity for an extended target site [18]. 
ZFPs can be engineered to recognize new DNA sequences by altering as many as six 
important residues in the recognition helix. Because ZFP libraries covering this sequence 
space (2018 variants for a three finger protein) cannot be built or adequately sampled using 
existing molecular biology techniques, much effort has been placed on developing alternative 
methods for engineering multi-finger proteins [7, 19-29]. These methods typically involve 
identifying individual zinc finger domains that recognize specific DNA triplet “subsites” and 
then joining these domains together to create multi-finger proteins. The two most common 
ZFP engineering methods, modular assembly and oligomerized pool engineering (OPEN), 
both use variations on this general approach (Reviewed in Cathomen and Joung, 2008, 
Molecular Therapy). Modular assembly usually assumes that a single domain (module) can 
recognize a specific DNA triplet regardless of the position of the triplet within the target site 
or the identities of adjacent neighboring fingers (i.e., it assumes binding of the ZF module is 
context-independent). Appropriate modules are simply joined together to create a ZFP that 
should recognize the target sequence.  Modular assembly is relatively simple to accomplish; 
however, ZFPs generated using this method have been shown to have a high failure rate in 
vivo [30-32]. In contrast, OPEN uses customized “pools” of ZF modules selected to 
recognize triplets in a specific sequence context. These pools can be assembled to create 
combinatorial libraries (with up to one million unique solutions for a three-finger protein) 
from which the ZFPs best able to bind the chosen target DNA site are identified. Although 
OPEN is somewhat more labor intensive, it is more robust, with a higher success rate than 
modular assembly [7]. 
ZiFiT provides a simple interface for scanning a DNA sequence to identify potential 
ZFP and ZFN binding sites. The updated version (3.2) identifies target sites for proteins 
engineered using either OPEN or modular assembly. ZiFiT 3.2 also provides several new 
tools to help researchers evaluate ZFP targets, including validated scoring schemes for 
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ranking potential target sites, a tool for querying NCBI BLAST servers for potential off-
target sites, and a seamless interface with the Zinc Finger Database (ZiFDB, a database of 
engineered ZFPs [33]). 
MATERIALS & METHODS 
Modular Assembly 
The modular assembly engineering approach employs individual zinc finger domains 
(modules) that have been pre-characterized (in the middle position of a three-finger array) to 
bind  a specific DNA triplet sub site. Several (three to six) of these modules can be arranged 
and linked together to generate a ZFP that recognizes an extended DNA sequence 
corresponding to the desired target site. ZiFiT provides support for the three most commonly 
used module sets developed by three independent research groups [21, 23, 27]. 
Oligomerized Pool ENgineering 
Oligomerized Pool ENgineering (OPEN) utilizes pools of zinc finger domains pre-
characterized to bind a specific DNA triplet sub site in the first, second or third position of 
the target site for a three-finger ZFP[7]. Appropriate pools are combined to generate 
hundreds of thousands of distinct solutions for a given 9 bp target DNA sequence.  The best 
solutions are subsequently identified using a bacterial two-hybrid (B2H) assay [34].  
Although this method requires considerable effort, it reliably generates ZFPs that bind with 
high affinity and specificity to their intended target site [7, 9, 11, 16]. 
GNN Scoring  
The GNN score is an empirical estimate of the probability that a modularly assembled 
three-finger ZFP will provide > 1.6-fold activation in the B2H assay (proteins that fail to 
meet this cutoff have been shown to fail to function in mammalian cells [30]). Using 
probabilities based on evaluation of a set of 168 three-finger ZFPs generated by modular 
assembly, ZFPs designed to bind target sites containing 3, 2, 1, and 0 triplets of the form 
GNN (where N is any nucleotide) are predicted to have success rates of 59%, 29%, 12%, and 
0%, respectively[30].  
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Affinity Scoring  
The affinity score is an energy-based parameter that predicts which modularly 
assembled three-finger ZFPs are most likely to function by inferring the contributions of the 
individual modules. Scores are calculated by estimating the relative free energy contributions 
of individual modules from dissociation constants reported for modules in the middle (F2) 
position of a three-finger ZFP[27]. These affinity scores have been calibrated to B2H fold-
activation values for modularly assembled ZFPs tested in vivo.  ZFPs with affinity scores less 
than 5 are expected to have adequate affinity to function in the B2H assay [35]. These scores 
do not directly address specificity and are available only for ZFPs composed exclusively of 
Barbas GNN and TGG modules. 
Program Input 
The ZiFiT 3.2 interface enables customizable searches for potential ZFP and ZFN 
binding sites that can be targeted using either the modular assembly or OPEN engineering 
methods.  After selecting ZiFiT from the menu bar, users select their preferred engineering 
method (modular assembly or OPEN) and target type (ZFP or ZFN), e.g., OPEN - Zinc 
Finger Nuclease.  In all interfaces, users enter their DNA query sequence into the Sequence 
input box near the top of the page (Figure B.1). Sequences can be submitted either in FASTA 
format or raw text. Ideally, sequences should be entered using uppercase characters to denote 
exons and lowercase characters to denote introns. Entering information in this format can 
facilitate target selection for certain experimental applications, such as generation of 
knockout mutations via ZFN-induced DSBs within a protein-encoding region. This function 
can be disabled by de-selecting the Exon/Intron Case Sensitivity check box immediately 
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below the Sequence input box.
 
Figure B.1. ZiFiT Input Window. In this example the user has chosen to scan for ZFN sites using 
OPEN. The sequence has been entered in FASTA format, with exon sequences in uppercase and 
intron sequences in lowercase. Published sets of OPEN finger pools available through the Zinc Finger 
Consortium are checked by default. 
 
The engineering method chosen by the user determines which sequences can be 
targeted.  For modular assembly, users can choose one or more of the three available module 
sets by selecting the Barbas, ToolGen, and Sangamo check boxes at the top of the page[21, 
23, 26, 27, 36].  Several studies have generated functional zinc fingers by combining 
modules from different sets [21]. For OPEN, users indicate which pools they wish to use by 
choosing the corresponding target DNA triplet for each finger position in a three-finger array. 
All published OPEN pools currently available from the Zinc Finger Consortium are checked 
by default [7]. 
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Users can specify the number of ZF modules to include in the Left Array and Right 
Array using drop-down menus below the Sequence input box. ZiFiT restricts the number of 
modules in concordance with the available reagents. OPEN reagents and Sangamo modules 
are specific to three-finger ZFPs or ZFNs, whereas practitioners of modular assembly 
implementing only Barbas and Toolgen modules may scan for individual target sites for ZFPs 
consisting of 3 to 8 fingers, or for dimeric target sites for ZFNs consisting of 3 or 4 fingers 
for each target “half-site.” Users should note that although increasing the number of modules 
might be expected to confer enhanced specificity, this is not always the case because 
deformation of the DNA upon ZFP binding may limit the number of ZF domains that bind 
concurrently [37].  In addition, because three domains are often sufficient to bind DNA with 
high affinity, longer ZFP arrays may require disrupted linkers between domains to prevent 
binding at unintended sub-sequences within the target site [24]. 
For ZFN targets, users must also specify the length of the spacer region between the 
binding sites for the left and right ZF arrays using the Spacer drop-down menu immediately 
below the Sequence input box. An active dimeric ZFN cleaves within the spacer region and 
its preferred length is dependent on the sequence and length of the amino acid linker between 
the ZF and nuclease domains.  Zinc Finger Consortium vectors harbor a linker that works 
with spacers of 5 or 6 bp of DNA [38-40].  An additional linker permitting spacers with 6 or 
7 bp of DNA has also been identified[40].  By default, ZiFiT scans for ZFN targets with 
spacers of 5, 6, or 7 bp.  Users can choose to limit the scan to only one or two spacer lengths. 
Advanced search options are accessible by selecting the Advanced link in the lower 
right hand corner (this link then toggles to Basic, which hides the Advanced options).  
Advanced options allow users to customize their scan by adjusting additional constraints. For 
example, users can restrict the minimum and maximum number of GNN, ANN, CNN and 
TNN triplets for reported targets.  This feature can help users identify the best sites by 
restricting searches to more successful GNN-rich sites [12, 30].  Additional Advanced 
options available for a subset of the input interfaces include:  (i) Ignore Asp overlap: This 
option is available to users of modular assembly; it refers to “target site overlap” in which an 
Asp in position +2 of the recognition helix specifies a 4th base[41]. This option is useful for 
troubleshooting why ZiFiT fails to return an expected target site; its use during design should 
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be restricted to advanced users. (ii) Search both strands: Because ZFPs bind directionally in 
a 5’ - 3’ manner, they can be engineered to bind either strand of DNA.  ZiFiT searches both 
strands by default.  Additional guidance for using Advanced options is provided on the ZiFiT 
Instructions and FAQ pages. 
Program Output 
ZiFiT scans the user-supplied input DNA sequence for potential ZFP binding or ZFN 
cleavage sites based on the selected engineering method and any additional user-defined 
restrictions.  For each user submission, ZiFiT displays a graphic map of the submitted 
sequence with each target site (‘hit’) indicated above the sequence (Figure B.2a). (Users may 
need to “enable pop-ups” in their browser for this feature to function properly.)  The 
submitted sequence is displayed as a red bar at the bottom of the map. When an Exon/Intron 
Case-Sensitive search is performed (see Program Input), exons are represented by thick red 
bars and introns by thin red lines. Hits are represented as short colored bars above the 
sequence track, with overlapping hits overflowing vertically into auxiliary tracks. Each bar is 
a clickable link to detailed target information on the main output page.  For ZFN scans, hits 
are color-coded according to the length of the spacer. 
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Figure B.2. ZiFiT Output Windows. (A) The Graphic Summary window (top) displays 
potential ZFN-binding sites (‘hits’) identified in the input sequence. Exons (denoted by uppercase 
characters in the input sequence) are displayed as thick red bars and introns as thin red lines. Hits are 
represented by short colored bars above the input sequence track; these serve as bookmarks that are 
linked to individual target sites in the Detailed Target List. ZFN hits are color-coded based on spacer 
size (5 bp = Blue; 6 bp = Green; 7 bp = Gold). (B) The Detailed Target List window (bottom) 
provides in-depth information about each hit. Hits are presented as double-stranded DNA sequences 
and labeled according to the FASTA description, spacer size, and index. Each hit can be expanded to 
reveal a reagent list for generating the corresponding ZFP. Hits can be sorted according to various 
criteria as detailed in the text. 
 
The main output page opens with a summary of the search parameters, followed by a 
drop-down Sort By menu that can be used to sort individual hits based on position or score 
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when available (see Materials & Methods). Because ZFN targets consist of two ZFP target 
sites, both of which must be targeted successfully, score-based sorting considers the score of 
the inferior scoring array site before the better scoring array target. When users implement an 
‘Exon/intron case-sensitive’ scan for ZFN targets, a Filter intronic splice sites checkbox is 
present immediately to the right of the Sort By menu. Selecting this box will hide ZFN 
targets whose spacers occur within (or overlap) an intron (Figure 2b). In addition to its web-
based output, ZiFiT also provides a text version of the output which can be downloaded as a 
.csv file from the top of the output page. 
Each hit is named using the description/comment line of the submitted FASTA 
sequence and an index number. If no sequence name is supplied by the user, this parameter is 
set to ‘Unknown’. Names for ZFN targets also include the spacer length.  For example, for a 
submission with the FASTA description ‘>ZFN-SAMPLE,” the third ZFN target site with a 
spacer of 7 bps would be labeled ‘ZFN-SAMPLE-SP-7-3’. Immediately beneath each hit 
name, the double-stranded DNA target sequence is displayed, along with its position within 
the submitted sequence. Individual triplets within this sequence are highlighted with distinct 
colors denoting the targets of individual ZF domains.  Each highlighted ZFP is linked to 
ZiFDB, a database of engineered ZFPs. Clicking these links automatically queries ZiFDB for 
available information regarding ZFPs tested against the same or similar target DNA 
sequences [33]. If an expected functional activity score is available for a given ZFP, the score 
is presented on the same line as the target.  ZiFiT currently provides two validated functional 
scoring schemes for modular assembly targets [30, 35]. Scoring schemes for OPEN targets 
are under development. 
Individual ZF targets can be expanded using the ‘+’ to the left of the target name.  
Expanding a target reveals three types of information. (i) A table describing reagents that can 
be used to generate corresponding ZFPs. Each row in the table describes a reagent (pool or 
module) corresponding to a Triplet DNA sequence, which is color-coded according to its 
position in the double-stranded sequence above the table. Entries in the Reference Number 
column of the table signify the names of reagents (either modules or pools) that are currently 
available to the academic research community through the Zinc Finger Consortium.  
Modules (and other reagents for performing modular assembly) are available from the non-
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profit plasmid distribution service Addgene (http://www.addgene.org/zfc) [42].  OPEN 
pools are available by request from the Joung lab (jjoung@partners.org) and other reagents 
for practicing OPEN are also available from Addgene (http://www.addgene.org/zfc). (ii) 
Sequences of oligonucleotides that must be synthesized to create bacterial two-hybrid 
selection and/or reporter strains needed to screen or select ZFPs for DNA-binding activity 
[34, 42]. (iii) An Organism drop-down menu for selecting a host genome and BLAST button 
that can be used to scan the selected host organism genome for exact & similar target 
matches. The BLAST button submits search parameters to NCBI and via a popup directs 
users to NCBI website where they can initiate the query by selecting the "view report" 
button. This is useful because it is generally desirable to avoid targeting sites that occur 
frequently in a genome (e.g., sites that fall within repeat regions). When using BLAST to 
search for genomic ZFN targets, the spacer is replaced with N’s to prevent it from positively 
influencing a scan.  Due to the nature of the algorithm (and a fixed spacer size in the case of 
a nuclease), this query is not guaranteed to identify all similar sites. ZiFiT output may need to 
complete loading before BLAST queries are accessible. ZiFiT is freely available on the web 
without registration at http://bindr.gdcb.iastate.edu/ZiFiT/. 
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APPENDIX C. SUPPLEMENTARY MATERIALS  
Construction of TALE repeat arrays and TALE nuclease expression vectors  
We assembled DNA encoding TALE repeat arrays that possess the same sequence 
architecture described by Miller et al. [1] in which four TALE repeat backbones that differ in 
their DNA and amino acid sequences (and which we designate types I, II, III, and IV; see 
Supplementary Figure 6) occur in a consistent repeating pattern (e.g.—I-II-III-IV-III-III-IV-I-
II-III-IV).  To do this, we initially commercially synthesized (Genscript) a large series of 
plasmids encoding the various individual TALE repeats required to construct the arrays 
shown in Figure 1 and Supplementary Figures 3, 4, and 5).  These individual TALE repeats 
harbored the following repeat variable di-residues (RVDs):  NN (for binding to G), NG (for 
binding to T), NI (for binding to A), or HD (for binding to C) (Supplementary Table 1 and 
Supplementary Figure 7).  In all of these plasmids, the DNA sequence encoding the 
individual TALE repeat is flanked by unique XbaI and BbsI restriction sites on the 5’ end and 
unique BsaI and BamHI restriction sites on the 3’ end (Supplementary Table 1).  In addition, 
for all of these plasmids, the 4 bp overhang generated upon digestion with BsaI can be 
ligated to the 4 bp overhang generated upon digestion with BbsI (Supplementary Table 1).  
Note that in order to enable cloning of the final DNA fragment encoding the full-length 
TALE repeat array, slightly different 5’ and 3’ ends were required for Type I TALE repeats 
present on the N-terminal end of an array and for Type III TALE repeats on the C-terminal 
end of an array, respectively (Supplementary Table 1).  The full DNA and amino acid 
sequences of these commercially synthesized plasmids are given in Supplementary Table 1 
and Supplementary Figure 7.  
To join together sequences encoding individual TALE repeats, we used the restriction 
enzyme-based strategy outlined in Supplementary Figure 8, an approach similar to one we 
and others have used previously to fuse individual zinc fingers into arrays [2, 3]. Briefly, 
DNA fragments encoding first and second TALE repeats can be joined together by ligating 
compatible overhangs generated by digestion of the first TALE repeat-encoding DNA with 
BsaI and by digestion of the second TALE repeat-encoding DNA with BbsI (Supplementary 
Figure 8).  In the resulting fusion, the TALE repeats are joined together in the order first-
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then-second (amino-terminal to carboxy-terminal).  In addition, the DNA encoding two 
TALE repeats remains flanked by a BbsI site on the 5’ end and a BsaI site on the 3’ end 
(Supplementary Figure 8).  Thus, this process can continue to be repeated in an iterative 
fashion to join together both single and multiple TALE repeats into longer arrays.  To 
generate the variable length TALE repeat arrays required for our studies, we joined together 
subsets of TALE repeats into shorter arrays and then joined these together to create the final 
desired full-length arrays.  An example of how we utilized this strategy is illustrated for 
creation of the TALE repeat array for TALE nuclease clone #1257 (targeted to the hey2 gene) 
in Supplementary Figure 9.    
We also constructed TALE nuclease expression vectors into which our assembled 
TALE repeat arrays could be cloned.  These vectors each harbor the following elements:  a 
T7 promoter, a nuclear localization signal, a FLAG tag, amino acids 153 to 288 from the 
TALE13 protein (numbering as defined by Miller et al. [1]), two adjacent BsmBI restriction 
sites into which a DNA fragment encoding a TALE repeat array can be cloned, a 0.5 TALE 
repeat, amino acids 715 to 777 from the C-terminal end of the TALE13 protein (numbering 
as defined by Miller et al [1]), and the wild-type FokI cleavage domain.  Plasmid pJDS70 
encodes a 0.5 TALE repeat with a NI RVD (for recognition of an A nucleotide), plasmid 
pJDS71 encodes a 0.5 TALE repeat with a HD RVD (for recognition of a C nucleotide), and 
plasmid pJDS78 encodes a 0.5 TALE repeat with a NG RVD (for recognition of a T 
nucleotide).  The full DNA sequences of these plasmids are provided in Supplementary 
Figure 10.  BbsI/BsaI-digested DNA fragments encoding arrays of TALE repeats were cloned 
into BsmBI-digested TALE nuclease expression vector backbone (the overhangs generated 
by digestion of the TALE repeat array-encoding fragment with BbsI and BsaI are 
complementary to the first and second BsmBI overhangs, respectively, generated by 
digestion of the TALE nuclease expression vector).  In the resulting plasmids, the TALE 
repeat arrays are expressed from the T7 promoter on RNA as in-frame fusions with the NLS, 
the FLAG tag, and the wild-type FokI nuclease domain.  The full DNA and amino acid 
sequences of the TALE nucleases used in this study can be found in Supplementary Figures 4 
and 5.   All of the plasmids described above are available upon request from the Joung lab 
(http://www.jounglab.org).  
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Preparation of ZFN- and TALE nuclease-encoding mRNAs   
ZFN and TALE nuclease expression vectors were linearized with PmeI and 
transcribed in vitro using the mMESSAGE mMACHINE£ T7 ULTRA kit (Ambion). The 
transcribed RNAs were then polyadenylated using the reagents in the same kit. 
Microinjection and analysis of somatic mutations Approximately 2 nl of the TALE nuclease 
mRNAs (300 pg/nl) or ZFN mRNAs (200-250 pg/nl) were injected into one-cell stage 
zebrafish embryos. On the next day, the surviving injected embryos were grouped into either 
“normal” or “deformed” phenotypes.  Genomic DNA was extracted from pools of 8-10 
embryos from each “normal” group. Target genomic loci were amplified using primers 
designed to anneal approximately 150 to 200 base pairs upstream and downstream from the 
expected cut site.  The resulting PCR product was cloned into pGEM-5Zf(+) using a pGEM-
T Easy kit (Promega) or into pCR4 TOPO-TA using a TOPO-TA kit (Invitrogen). After 
transformation of the ligated vectors, single colonies were reinoculated for plasmid DNA 
isolation and sequencing. The sequence of each clone represents one amplified allele.  
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Supplementary Figure 4  
Common Sequence: 
GACGGATCGGGAGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCA
GTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACC
GACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATT
GATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTT
ACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGC
CAATAGGGACTTTCCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATAT
GCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTT
CCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATA
127 
 
 
 
GCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGAC
TTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAG
CTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGXXXX
XXCAACTAGTCAAAAGTGAACTGGAGGAGAAGAAATCTGAACTTCGTCATAAATTGAAATATGTGCCTCATGAATATATTG
AATTAATTGAAATTGCCAGAAATTCCACTCAGGATAGAATTCTTGAAATGAAGGTAATGGAATTTTTTATGAAAGTTTATGG
ATATAGAGGTAAACATTTGGGTGGATCAAGGAAACCGGACGGAGCAATTTATACTGTCGGATCTCCTATTGATTACGGTGTG
ATCGTGGATACTAAAGCTTATAGCGGAGGTTATAATCTGCCAATTGGCCAAGCAGATGAAATGCAACGATATGTCGAAGAA
AATCAAACACGAAACAAACATATCAACCCTAATGAATGGTGGAAAGTCTATCCATCTTCTGTAACGGAATTTAAGTTTTTAT
TTGTGAGTGGTCACTTTAAAGGAAACTACAAAGCTCAGCTTACACGATTAAATCATATCACTAATTGTAATGGAGCTGTTCTT
AGTGTAGAAGAGCTTTTAATTGGTGGAGAAATGATTAAAGCCGGCACATTAACCTTAGAGGAAGTGAGACGGAAATTTAAT
AACGGCGAGATAAACTTTTAAGGGCCCTTCGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGCGTACCG
GTCATCATCACCATCACCATTGAGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGC
CCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTG
TCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCA
TGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGT
AGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTT
TCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGCATCCCTTTAGGGTTCCGAT
TTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGT
TTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGG
TCTATTCTTTTGATTTATAAGGGATTTTGGGGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCG
AATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGGCAGGCAGAAGTATGCAAAGCATGC
ATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTA
GTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCT
GACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGA
GGCCTAGGCTTTTGCAAAAAGCTCCCGGGAGCTTGTATATCCATTTTCGGATCTGATCAGCACGTGTTGACAATTAATCATCG
GCATAGTATATCGGCATAGTATAATACGACAAGGTGAGGAACTAAACCATGGCCAAGCCTTTGTCTCAAGAAGAATCCACC
CTCATTGAAAGAGCAACGGCTACAATCAACAGCATCCCCATCTCTGAAGACTACAGCGTCGCCAGCGCAGCTCTCTCTAGCG
ACGGCCGCATCTTCACTGGTGTCAATGTATATCATTTTACTGGGGGACCTTGTGCAGAACTCGTGGTGCTGGGCACTGCTGCT
GCTGCGGCAGCTGGCAACCTGACTTGTATCGTCGCGATCGGAAATGAGAACAGGGGCATCTTGAGCCCCTGCGGACGGTGTC
GACAGGTGCTTCTCGATCTGCATCCTGGGATCAAAGCGATAGTGAAGGACAGTGATGGACAGCCGACGGCAGTTGGGATTC
GTGAATTGCTGCCCTCTGGTTATGTGTGGGAGGGCTAAGCACTTCGTGGCCGAGGAGCAGGACTGACACGTGCTACGAGATT
TCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGG
GGATCTCATGCTGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAA
ATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTATAC
CGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACAC
AACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCAC
TGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTAT
TGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGG
CGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAAC
CGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGA
GGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCT
GCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTT
CGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTAT
CGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTAT
GTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGC
TGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGT
TTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGG
AACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAA
GTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCG
ATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCC
CAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGA
GCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCA
GTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTC
CGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTT
GTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAG
ATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGT
CAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTC
AAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCA
GCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTC
ATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAA
AATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTC 
 
Specific sequence for clone #1257:  
GCTAGCACCATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATGAC
AAGATGGCCCCCAAGAAGAAGAGGAAGGTGGGCATTCACCGCGGGGTACCTATGGTGGACTTGAGGACACTCGGTTATTCG
CAACAGCAACAGGAGAAAATCAAGCCTAAGGTCAGGAGCACCGTCGCGCAACACCACGAGGCGCTTGTGGGGCATGGCTTC
ACTCATGCGCATATTGTCGCGCTTTCACAGCACCCTGCGGCGCTTGGGACGGTGGCTGTCAAATACCAAGATATGATTGCGG
CCCTGCCCGAAGCCACGCACGAGGCAATTGTAGGGGTCGGTAAACAGTGGTCGGGAGCGCGAGCACTTGAGGCGCTGCTGA
128 
 
 
 
CTGTGGCGGGTGAGCTTAGGGGGCCTCCGCTCCAGCTCGACACCGGGCAGCTGCTGAAGATCGCGAAGAGAGGGGGAGTAA
CAGCGGTAGAGGCAGTGCACGCCTGGCGCAATGCGCTCACCGGGGCCCCCTTGAACCTGACCCCAGACCAGGTAGTCGCAA
TCGCGTCAAACGGAGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTA
CACCGGAGCAAGTCGTGGCCATTGCAAGCAATGGGGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCT
CTGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCGAACATTGGAGGGAAACAAGCATTGGAGACTGTC
CAACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCAGCCATGATGGCGGTA
AGCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAA
TCGCGTCAAACGGAGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTA
CACCGGAGCAAGTCGTGGCCATTGCAAATAATAACGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCT
CTGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCGCATGACGGAGGGAAACAAGCATTGGAGACTGT
CCAACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCTCGAATGGCGGCGGT
AAGCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCA
ATCGCGAACAATAATGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTT
ACACCGGAGCAAGTCGTGGCCATTGCATCCCACGACGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTC
TCTGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCCAACGGTGGAGGGAAACAAGCATTGGAGACTGT
CCAACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCAGCCATGATGGCGGT
AAGCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCA
ATCGCGTCACATGACGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTA
CACCGGAGCAAGTCGTGGCCATTGCATCCCACGACGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCT
CTGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGAATAACAATGGAGGGAAACAAGCATTGGAGACTGT
CCAACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCAGCCATGATGGCGGT
AAGCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACACCCGAACAGGTGGTCGCC
ATTGCTTCTAATGGGGGAGGACGGCCAGCCTTGGAGTCCATCGTAGCCCAATTGTCCAGGCCCGATCCCGCGTTGGCTGCGT
TAACGAATGACCATCTGGTGGCGTTGGCATGTCTTGGTGGACGACCCGCGCTCGATGCAGTCAAAAAGGGTCTGCCTCATGC
TCCCGCATTGATCAAAAGAACCAACCGGCGGATTCCCGAGAGAACTTCCCATCGAGTCGCGGGATCC 
 
Specific sequence for clone #1258:  
GCTAGCACCATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATGAC
AAGATGGCCCCCAAGAAGAAGAGGAAGGTGGGCATTCACCGCGGGGTACCTATGGTGGACTTGAGGACACTCGGTTATTCG
CAACAGCAACAGGAGAAAATCAAGCCTAAGGTCAGGAGCACCGTCGCGCAACACCACGAGGCGCTTGTGGGGCATGGCTTC
ACTCATGCGCATATTGTCGCGCTTTCACAGCACCCTGCGGCGCTTGGGACGGTGGCTGTCAAATACCAAGATATGATTGCGG
CCCTGCCCGAAGCCACGCACGAGGCAATTGTAGGGGTCGGTAAACAGTGGTCGGGAGCGCGAGCACTTGAGGCGCTGCTGA
CTGTGGCGGGTGAGCTTAGGGGGCCTCCGCTCCAGCTCGACACCGGGCAGCTGCTGAAGATCGCGAAGAGAGGGGGAGTAA
CAGCGGTAGAGGCAGTGCACGCCTGGCGCAATGCGCTCACCGGGGCCCCCTTGAACCTGACCCCAGACCAGGTAGTCGCAA
TCGCGTCACATGACGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTAC
ACCGGAGCAAGTCGTGGCCATTGCAAATAATAACGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTC
TGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCCAACGGTGGAGGGAAACAAGCATTGGAGACTGTC
CAACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCAGCCATGATGGCGGTA
AGCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAA
TCGCGTCACATGACGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTAC
ACCGGAGCAAGTCGTGGCCATTGCAAGCAACATCGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTC
TGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCGAACATTGGAGGGAAACAAGCATTGGAGACTGTCC
AACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCTCGAATGGCGGCGGTAA
GCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAAT
CGCGTCGAACATTGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTACA
CCGGAGCAAGTCGTGGCCATTGCAAATAATAACGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTCT
GTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCGCATGACGGAGGGAAACAAGCATTGGAGACTGTCC
AACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCTCGAATGGCGGCGGTAA
GCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAAT
CGCGTCAAACGGAGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTAC
ACCGGAGCAAGTCGTGGCCATTGCATCCCACGACGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTC
TGTCAAGCCCACGGGCTGACACCCGAACAGGTGGTCGCCATTGCTTCTAATGGGGGAGGACGGCCAGCCTTGGAGTCCATCG
TAGCCCAATTGTCCAGGCCCGATCCCGCGTTGGCTGCGTTAACGAATGACCATCTGGTGGCGTTGGCATGTCTTGGTGGACG
ACCCGCGCTCGATGCAGTCAAAAAGGGTCTGCCTCATGCTCCCGCATTGATCAAAAGAACCAACCGGCGGATTCCCGAGAG
AACTTCCCATCGAGTCGCGGGATCC  
 
Specific sequence for clone #1259:  
GCTAGCACCATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATGAC
AAGATGGCCCCCAAGAAGAAGAGGAAGGTGGGCATTCACCGCGGGGTACCTATGGTGGACTTGAGGACACTCGGTTATTCG
CAACAGCAACAGGAGAAAATCAAGCCTAAGGTCAGGAGCACCGTCGCGCAACACCACGAGGCGCTTGTGGGGCATGGCTTC
ACTCATGCGCATATTGTCGCGCTTTCACAGCACCCTGCGGCGCTTGGGACGGTGGCTGTCAAATACCAAGATATGATTGCGG
CCCTGCCCGAAGCCACGCACGAGGCAATTGTAGGGGTCGGTAAACAGTGGTCGGGAGCGCGAGCACTTGAGGCGCTGCTGA
CTGTGGCGGGTGAGCTTAGGGGGCCTCCGCTCCAGCTCGACACCGGGCAGCTGCTGAAGATCGCGAAGAGAGGGGGAGTAA
CAGCGGTAGAGGCAGTGCACGCCTGGCGCAATGCGCTCACCGGGGCCCCCTTGAACCTGACCCCAGACCAGGTAGTCGCAA
TCGCGTCGAACATTGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTAC
ACCGGAGCAAGTCGTGGCCATTGCAAGCAACATCGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTC
TGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCGAACATTGGAGGGAAACAAGCATTGGAGACTGTCC
AACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCAACAACAACGGCGGTAA
129 
 
 
 
GCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAAT
CGCGTCGAACATTGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTACA
CCGGAGCAAGTCGTGGCCATTGCAAATAATAACGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTCT
GTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCGCATGACGGAGGGAAACAAGCATTGGAGACTGTCC
AACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCTCCAATATTGGCGGTAA
GCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAAT
CGCGAACAATAATGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTAC
ACCGGAGCAAGTCGTGGCCATTGCAAGCAACATCGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTC
TGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCGAACATTGGAGGGAAACAAGCATTGGAGACTGTCC
AACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCTCCAATATTGGCGGTAA
GCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAAT
CGCGTCACATGACGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTAC
ACCGGAGCAAGTCGTGGCCATTGCAAGCAATGGGGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTC
TGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCGCATGACGGAGGGAAACAAGCATTGGAGACTGTC
CAACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTCTGACACCCGAACAGGTGGTCGCCATTGCTTCTAACATCGGAGGAC
GGCCAGCCTTGGAGTCCATCGTAGCCCAATTGTCCAGGCCCGATCCCGCGTTGGCTGCGTTAACGAATGACCATCTGGTGGC
GTTGGCATGTCTTGGTGGACGACCCGCGCTCGATGCAGTCAAAAAGGGTCTGCCTCATGCTCCCGCATTGATCAAAAGAACC
AACCGGCGGATTCCCGAGAGAACTTCCCATCGAGTCGCGGGATCC  
 
Specific sequence for clone #1260:  
GCTAGCACCATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATGAC
AAGATGGCCCCCAAGAAGAAGAGGAAGGTGGGCATTCACCGCGGGGTACCTATGGTGGACTTGAGGACACTCGGTTATTCG
CAACAGCAACAGGAGAAAATCAAGCCTAAGGTCAGGAGCACCGTCGCGCAACACCACGAGGCGCTTGTGGGGCATGGCTTC
ACTCATGCGCATATTGTCGCGCTTTCACAGCACCCTGCGGCGCTTGGGACGGTGGCTGTCAAATACCAAGATATGATTGCGG
CCCTGCCCGAAGCCACGCACGAGGCAATTGTAGGGGTCGGTAAACAGTGGTCGGGAGCGCGAGCACTTGAGGCGCTGCTGA
CTGTGGCGGGTGAGCTTAGGGGGCCTCCGCTCCAGCTCGACACCGGGCAGCTGCTGAAGATCGCGAAGAGAGGGGGAGTAA
CAGCGGTAGAGGCAGTGCACGCCTGGCGCAATGCGCTCACCGGGGCCCCCTTGAACCTGACCCCAGACCAGGTAGTCGCAA
TCGCGTCGAACATTGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTAC
ACCGGAGCAAGTCGTGGCCATTGCAAGCAACATCGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTC
TGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCGAACATTGGAGGGAAACAAGCATTGGAGACTGTCC
AACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCAACAACAACGGCGGTAA
GCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAAT
CGCGTCGAACATTGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTACA
CCGGAGCAAGTCGTGGCCATTGCAAATAATAACGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTCT
GTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCGCATGACGGAGGGAAACAAGCATTGGAGACTGTCC
AACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCTCCAATATTGGCGGTAA
GCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAAT
CGCGAACAATAATGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTAC
ACCGGAGCAAGTCGTGGCCATTGCAAGCAACATCGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTC
TGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCGAACATTGGAGGGAAACAAGCATTGGAGACTGTCC
AACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCTCCAATATTGGCGGTAA
GCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAAT
CGCGTCACATGACGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTAC
ACCGGAGCAAGTCGTGGCCATTGCAAGCAATGGGGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTC
TGTCAAGCCCACGGGCTGACACCCGAACAGGTGGTCGCCATTGCTTCCCACGACGGAGGACGGCCAGCCTTGGAGTCCATCG
TAGCCCAATTGTCCAGGCCCGATCCCGCGTTGGCTGCGTTAACGAATGACCATCTGGTGGCGTTGGCATGTCTTGGTGGACG
ACCCGCGCTCGATGCAGTCAAAAAGGGTCTGCCTCATGCTCCCGCATTGATCAAAAGAACCAACCGGCGGATTCCCGAGAG
AACTTCCCATCGAGTCGCGGGATCC  
 
Specific sequence for clone #1295:  
GCTAGCACCATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATGAC
AAGATGGCCCCCAAGAAGAAGAGGAAGGTGGGCATTCACCGCGGGGTACCTATGGTGGACTTGAGGACACTCGGTTATTCG
CAACAGCAACAGGAGAAAATCAAGCCTAAGGTCAGGAGCACCGTCGCGCAACACCACGAGGCGCTTGTGGGGCATGGCTTC
ACTCATGCGCATATTGTCGCGCTTTCACAGCACCCTGCGGCGCTTGGGACGGTGGCTGTCAAATACCAAGATATGATTGCGG
CCCTGCCCGAAGCCACGCACGAGGCAATTGTAGGGGTCGGTAAACAGTGGTCGGGAGCGCGAGCACTTGAGGCGCTGCTGA
CTGTGGCGGGTGAGCTTAGGGGGCCTCCGCTCCAGCTCGACACCGGGCAGCTGCTGAAGATCGCGAAGAGAGGGGGAGTAA
CAGCGGTAGAGGCAGTGCACGCCTGGCGCAATGCGCTCACCGGGGCCCCCTTGAACCTGACCCCAGACCAGGTAGTCGCAA
TCGCGTCACATGACGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTAC
ACCGGAGCAAGTCGTGGCCATTGCAAATAATAACGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTC
TGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCCAACGGTGGAGGGAAACAAGCATTGGAGACTGTC
CAACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCAGCCATGATGGCGGTA
AGCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAA
TCGCGTCACATGACGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTAC
ACCGGAGCAAGTCGTGGCCATTGCAAGCAACATCGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTC
TGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCGAACATTGGAGGGAAACAAGCATTGGAGACTGTCC
AACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCTCGAATGGCGGCGGTAA
GCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAAT
CGCGTCGAACATTGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTACA
130 
 
 
 
CCGGAGCAAGTCGTGGCCATTGCAAATAATAACGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTCT
GTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCGCATGACGGAGGGAAACAAGCATTGGAGACTGTCC
AACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCTCGAATGGCGGCGGTAA
GCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAAT
CGCGTCAAACGGAGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTAC
ACCGGAGCAAGTCGTGGCCATTGCATCCCACGACGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTC
TGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCCAACGGTGGAGGGAAACAAGCATTGGAGACTGTC
CAACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTCTGACACCCGAACAGGTGGTCGCCATTGCTTCCCACGACGGAGGAC
GGCCAGCCTTGGAGTCCATCGTAGCCCAATTGTCCAGGCCCGATCCCGCGTTGGCTGCGTTAACGAATGACCATCTGGTGGC
GTTGGCATGTCTTGGTGGACGACCCGCGCTCGATGCAGTCAAAAAGGGTCTGCCTCATGCTCCCGCATTGATCAAAAGAACC
AACCGGCGGATTCCCGAGAGAACTTCCCATCGAGTCGCGGGATCC  
 
Specific sequence for clone #1297:  
GCTAGCATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATGACAA
GATGGCCCCCAAGAAGAAGAGGAAGGTGGGCATTCACCGCGGGGTACCTATGGTGGACTTGAGGACACTCGGTTATTCGCA
ACAGCAACAGGAGAAAATCAAGCCTAAGGTCAGGAGCACCGTCGCGCAACACCACGAGGCGCTTGTGGGGCATGGCTTCAC
TCATGCGCATATTGTCGCGCTTTCACAGCACCCTGCGGCGCTTGGGACGGTGGCTGTCAAATACCAAGATATGATTGCGGCC
CTGCCCGAAGCCACGCACGAGGCAATTGTAGGGGTCGGTAAACAGTGGTCGGGAGCGCGAGCACTTGAGGCGCTGCTGACT
GTGGCGGGTGAGCTTAGGGGGCCTCCGCTCCAGCTCGACACCGGGCAGCTGCTGAAGATCGCGAAGAGAGGGGGAGTAACA
GCGGTAGAGGCAGTGCACGCCTGGCGCAATGCGCTCACCGGGGCCCCCTTGAACCTGACCCCAGACCAGGTAGTCGCAATC
GCGTCACATGACGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTACA
CCGGAGCAAGTCGTGGCCATTGCAAGCAATGGGGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTCT
GTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCCAACGGTGGAGGGAAACAAGCATTGGAGACTGTCC
AACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCAGCCATGATGGCGGTAA
GCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAAT
CGCGTCACATGACGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTAC
ACCGGAGCAAGTCGTGGCCATTGCAAATAATAACGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTC
TGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCCAACGGTGGAGGGAAACAAGCATTGGAGACTGTC
CAACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCTCGAATGGCGGCGGTA
AGCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAA
TCGCGTCAAACGGAGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTA
CACCGGAGCAAGTCGTGGCCATTGCATCCCACGACGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCT
CTGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCGCATGACGGAGGGAAACAAGCATTGGAGACTGT
CCAACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCTCCAATATTGGCGGTA
AGCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACCCCAGACCAGGTAGTCGCAA
TCGCGTCACATGACGGGGGAAAGCAAGCCCTGGAAACCGTGCAAAGGTTGTTGCCGGTCCTTTGTCAAGACCACGGCCTTAC
ACCGGAGCAAGTCGTGGCCATTGCAAGCAACATCGGTGGCAAACAGGCTCTTGAGACGGTTCAGAGACTTCTCCCAGTTCTC
TGTCAAGCCCACGGGCTGACTCCCGATCAAGTTGTAGCGATTGCGTCCAACGGTGGAGGGAAACAAGCATTGGAGACTGTC
CAACGGCTCCTTCCCGTGTTGTGTCAAGCCCACGGTTTGACGCCTGCACAAGTGGTCGCCATCGCCAGCCATGATGGCGGTA
AGCAGGCGCTGGAAACAGTACAGCGCCTGCTGCCTGTACTGTGCCAGGATCATGGACTGACACCCGAACAGGTGGTCGCCA
TTGCTTCTAATGGGGGAGGACGGCCAGCCTTGGAGTCCATCGTAGCCCAATTGTCCAGGCCCGATCCCGCGTTGGCTGCGTT
AACGAATGACCATCTGGTGGCGTTGGCATGTCTTGGTGGACGACCCGCGCTCGATGCAGTCAAAAAGGGTCTGCCTCATGCT
CCCGCATTGATCAAAAGAACCAACCGGCGGATTCCCGAGAGAACTTCCCATCGAGTCGCGGGATCC  
 
DNA sequences of plasmids expressing TALE nucleases used in this study 
 
The DNA sequences of all six TALE nuclease expression plasmids we constructed 
are identical except for the region indicated by six Xs in the common sequence listed above.  
The specific sequences for each of the six plasmids in this variable region are given below 
with their associated clone names.  The full expression plasmid sequence for each TALE 
nuclease clone can be created by substituting the specific variable sequence in place of the 
six Xs in the common sequence. 
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Clone #1257:  
MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRKVGIHRGVPMVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHG
FTHAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTA
VEAVHAWRNALTGAPLNLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPEQVVAIASNGGGKQALETVQRLLPVLCQA
HGLTPDQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPAQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGG
GKQALETVQRLLPVLCQDHGLTPEQVVAIANNNGGKQALETVQRLLPVLCQAHGLTPDQVVAIASHDGGKQALETVQRLLPVLC
131 
 
 
 
QAHGLTPAQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIANNNGGKQALETVQRLLPVLCQDHGLTPEQVVAIASH
DGGKQALETVQRLLPVLCQAHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPAQVVAIASHDGGKQALETVQRLLPV
LCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPDQVVAIA
NNNGGKQALETVQRLLPVLCQAHGLTPAQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPEQVVAIASNGGGRPALESIVAQLS
RPDPALAALTNDHLVALACLGGRPALDAVKKGLPHAPALIKRTNRRIPERTSHRVAGSQLVKSELEEKKSELRHKLKYVPHEYIEL
IEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRN
KHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINF  
 
Clone #1258:  
MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRKVGIHRGVPMVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHG
FTHAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTA
VEAVHAWRNALTGAPLNLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPEQVVAIANNNGGKQALETVQRLLPVLCQA
HGLTPDQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPAQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDG
GKQALETVQRLLPVLCQDHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQ
AHGLTPAQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPEQVVAIANNN
GGKQALETVQRLLPVLCQAHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNGGGKQALETVQRLLPVL
CQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQVVAIAS
NGGGRPALESIVAQLSRPDPALAALTNDHLVALACLGGRPALDAVKKGLPHAPALIKRTNRRIPERTSHRVAGSQLVKSELEEKKS
ELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQ
ADEMQRYVEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLE
EVRRKFNNGEINF  
 
Clone #1259:  
MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRKVGIHRGVPMVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHG
FTHAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTA
VEAVHAWRNALTGAPLNLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAH
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPAQVVAIANNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGK
QALETVQRLLPVLCQDHGLTPEQVVAIANNNGGKQALETVQRLLPVLCQAHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQA
HGLTPAQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIANNNGGKQALETVQRLLPVLCQDHGLTPEQVVAIASNIGG
KQALETVQRLLPVLCQAHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNIGGKQALETVQRLLPVLCQD
HGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPEQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPDQVVAIASHDG
GKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGRPALESIVAQLSRPDPALAALTNDHLVALACLGGRPALDAVKKGLPHAPA
LIKRTNRRIPERTSHRVAGSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKP
DGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLT
RLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINF 
 
Clone #1260:  
MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRKVGIHRGVPMVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHG
FTHAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTA
VEAVHAWRNALTGAPLNLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAH
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPAQVVAIANNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGK
QALETVQRLLPVLCQDHGLTPEQVVAIANNNGGKQALETVQRLLPVLCQAHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQA
HGLTPAQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIANNNGGKQALETVQRLLPVLCQDHGLTPEQVVAIASNIGG
KQALETVQRLLPVLCQAHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNIGGKQALETVQRLLPVLCQD
HGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPEQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDG
GRPALESIVAQLSRPDPALAALTNDHLVALACLGGRPALDAVKKGLPHAPALIKRTNRRIPERTSHRVAGSQLVKSELEEKKSELR
HKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADE
MQRYVEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEEVR
RKFNNGEINF  
 
Clone #1295:  
MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRKVGIHRGVPMVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHG
FTHAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTA
VEAVHAWRNALTGAPLNLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPEQVVAIANNNGGKQALETVQRLLPVLCQA
HGLTPDQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPAQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDG
GKQALETVQRLLPVLCQDHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQ
AHGLTPAQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPEQVVAIANNN
GGKQALETVQRLLPVLCQAHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNGGGKQALETVQRLLPVL
CQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPDQVVAIAS
NGGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGRPALESIVAQLSRPDPALAALTNDHLVALACLGGRPALDAVKKGLP
HAPALIKRTNRRIPERTSHRVAGSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGG
SRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKA
QLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINF  
 
Clone #1297:  
MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRKVGIHRGVPMVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHG
FTHAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTA
VEAVHAWRNALTGAPLNLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPEQVVAIASNGGGKQALETVQRLLPVLCQA
132 
 
 
 
HGLTPDQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPAQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDG
GKQALETVQRLLPVLCQDHGLTPEQVVAIANNNGGKQALETVQRLLPVLCQAHGLTPDQVVAIASNGGGKQALETVQRLLPVLC
QAHGLTPAQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPEQVVAIASH
DGGKQALETVQRLLPVLCQAHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPAQVVAIASNIGGKQALETVQRLLPV
LCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPEQVVAIASNIGGKQALETVQRLLPVLCQAHGLTPDQVVAIAS
NGGGKQALETVQRLLPVLCQAHGLTPAQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPEQVVAIASNGGGRPALESIVAQLSR
PDPALAALTNDHLVALACLGGRPALDAVKKGLPHAPALIKRTNRRIPERTSHRVAGSQLVKSELEEKKSELRHKLKYVPHEYIELI
EIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRN
KHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINF  
 
Full amino acid sequences of the six TALE nucleases used in this study FokI nuclease 
domains are underlined in each sequence. 
 
 
 
133 
 
 
 
 
 
134 
 
 
 
 
 
135 
 
 
 
 
 
Supplementary Figure 10    
Common Sequence: 
GACGGATCGGGAGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCA
GTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACC
GACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATT
GATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTT
ACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGC
CAATAGGGACTTTCCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATAT
GCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTT
CCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATA
136 
 
 
 
GCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGAC
TTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAG
CTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTA
GCaccATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATGACAAGATGGCCCC
CAAGAAGAAGAGGAAGGTGGGCATTCACCGCGGGGTACCTATGGTGGACTTGAGGACACTCGGTTATTCGCAACAGCAACA
GGAGAAAATCAAGCCTAAGGTCAGGAGCACCGTCGCGCAACACCACGAGGCGCTTGTGGGGCATGGCTTCACTCATGCGCA
TATTGTCGCGCTTTCACAGCACCCTGCGGCGCTTGGGACGGTGGCTGTCAAATACCAAGATATGATTGCGGCCCTGCCCGAA
GCCACGCACGAGGCAATTGTAGGGGTCGGTAAACAGTGGTCGGGAGCGCGAGCACTTGAGGCGCTGCTGACTGTGGCGGGT
GAGCTTAGGGGGCCTCCGCTCCAGCTCGACACCGGGCAGCTGCTGAAGATCGCGAAGAGAGGGGGAGTAACAGCGGTAGA
GGCAGTGCACGCCTGGCGCAATGCGCTCACCGGGGCCCCCTTGAACAGAGACGATTAATGCGTCTCGCTGACACCCGAACA
GGTGGTCGCCATTGCTXXXXXXXXXGGAGGACGGCCAGCCTTGGAGTCCATCGTAGCCCAATTGTCCAGGCCCGATCCCGC
GTTGGCTGCGTTAACGAATGACCATCTGGTGGCGTTGGCATGTCTTGGTGGACGACCCGCGCTCGATGCAGTCAAAAAGGGT
CTGCCTCATGCTCCCGCATTGATCAAAAGAACCAACCGGCGGATTCCCGAGAGAACTTCCCATCGAGTCGCGGGATCCCAAC
TAGTCAAAAGTGAACTGGAGGAGAAGAAATCTGAACTTCGTCATAAATTGAAATATGTGCCTCATGAATATATTGAATTAAT
TGAAATTGCCAGAAATTCCACTCAGGATAGAATTCTTGAAATGAAGGTAATGGAATTTTTTATGAAAGTTTATGGATATAGA
GGTAAACATTTGGGTGGATCAAGGAAACCGGACGGAGCAATTTATACTGTCGGATCTCCTATTGATTACGGTGTGATCGTGG
ATACTAAAGCTTATAGCGGAGGTTATAATCTGCCAATTGGCCAAGCAGATGAAATGCAACGATATGTCGAAGAAAATCAAA
CACGAAACAAACATATCAACCCTAATGAATGGTGGAAAGTCTATCCATCTTCTGTAACGGAATTTAAGTTTTTATTTGTGAGT
GGTCACTTTAAAGGAAACTACAAAGCTCAGCTTACACGATTAAATCATATCACTAATTGTAATGGAGCTGTTCTTAGTGTAG
AAGAGCTTTTAATTGGTGGAGAAATGATTAAAGCCGGCACATTAACCTTAGAGGAAGTCAGACGGAAATTTAATAACGGCG
AGATAAACTTTTAAGGGCCCTTCGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGCGTACCGGTCATCAT
CACCATCACCATTGAGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCC
GTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAG
GTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGG
ATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCG
CATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTC
TTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGCATCCCTTTAGGGTTCCGATTTAGTGCT
TTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCC
CTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTT
TTGATTTATAAGGGATTTTGGGGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTAATTC
TGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGGCAGGCAGAAGTATGCAAAGCATGCATCTCAATT
AGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAA
CCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATT
TTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGG
CTTTTGCAAAAAGCTCCCGGGAGCTTGTATATCCATTTTCGGATCTGATCAGCACGTGTTGACAATTAATCATCGGCATAGTA
TATCGGCATAGTATAATACGACAAGGTGAGGAACTAAACCATGGCCAAGCCTTTGTCTCAAGAAGAATCCACCCTCATTGAA
AGAGCAACGGCTACAATCAACAGCATCCCCATCTCTGAAGACTACAGCGTCGCCAGCGCAGCTCTCTCTAGCGACGGCCGCA
TCTTCACTGGTGTCAATGTATATCATTTTACTGGGGGACCTTGTGCAGAACTCGTGGTGCTGGGCACTGCTGCTGCTGCGGCA
GCTGGCAACCTGACTTGTATCGTCGCGATCGGAAATGAGAACAGGGGCATCTTGAGCCCCTGCGGACGGTGTCGACAGGTG
CTTCTCGATCTGCATCCTGGGATCAAAGCGATAGTGAAGGACAGTGATGGACAGCCGACGGCAGTTGGGATTCGTGAATTGC
TGCCCTCTGGTTATGTGTGGGAGGGCTAAGCACTTCGTGGCCGAGGAGCAGGACTGACACGTGCTACGAGATTTCGATTCCA
CCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCAT
GCTGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAA
ATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTCGACCT
CTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGA
GCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTT
TCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTC
TTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATAC
GGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAG
GCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAA
ACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACC
GGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGT
CGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGT
CCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTG
CTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGT
TACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAG
CAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACT
CACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCA
ATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATT
TCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAA
TGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTG
GTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTG
CGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACG
ATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAG
TTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTG
ACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATA
ATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACC
GCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGT
137 
 
 
 
GAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTT
TTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATA
GGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTC 
 
DNA sequences of plasmids for expressing TALE nucleases 
As described in Supplementary Methods, we constructed three different plasmids into 
which DNA fragments encoding assembled TALE arrays can be cloned to generate TALE 
nuclease expression vectors.  The three plasmids differ in the identity of the C-terminal 0.5 
TALE repeat.   
All plasmids share the common sequence above and differ at just nine nucleotide 
positions marked as XXXXXXXXX (underlined and bold).  The sequence of these 9 bps and 
plasmid names are also shown below for vectors that have the NI, HD, and NG RVDs as the 
C-terminal  
0.5 TALE repeat.    
 
Plasmid name   Sequence of variable 9 bps   RVD of C-terminal 0.5 TALE 
repeat  
pJDS70     TCTAACATC     NI (for binding to an A 
nucleotide)  
pJDS71     TCCCACGAC     HD (for binding to a C 
nucleotide)  
pJDS78     TCTAATGGG     NG (for binding to a T 
nucleotide) 
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Supplementary Discussion 
Criteria used by ZiFiT Targeter to pick potential TALEN cleavage sites 
Users input DNA sequences of interest into ZiFiT Targeter with a single target 
nucleotide bracketed.  The software then attempts to identify potential TALEN target sites 
where the bracketed nucleotide falls within the “spacer” sequence between the half-sites 
bound by TALEN monomers. As the range of sequences that can be targeted using TALENs 
is very large, ZiFiT Targeter uses the iterative approach described below to identify as many 
as five potential target sites.  
ZiFiT Targeter first truncates the query sequence to 101 base pairs (50 base pairs 
flanking the bracketed nucleotide). This sequence is then scanned for all potential TALEN 
target sites in which the bracketed nucleotide falls within the spacer sequence between the 
half sites and in which half-sites are 16 to 18 base pairs in length (including the conserved 5’ 
T and the 3’-most nucleotide bound by the 0.5 TALE repeat array) and spacer sequences are 
16 to 18 base pairs in length. Full target sites chosen are also filtered to ensure that they differ 
from each other by at least six base pairs (three base pairs in each half-site). This list is then 
rank-ordered based on the total length of the target site (i.e.—the sum of the lengths of the 
target half-sites) and the top five sites are reported as “First Tier” sites.   
If ZiFiT Targeter fails to find five “First Tier” sites, it will identify “Second Tier” sites 
by performing the same search but loosening constraints to allow spacer sequences 13 to 23 
base pairs in length.  As with First Tier sites, these sites are filtered to ensure that they differ 
from each other by at least six base pairs and then rank-ordered based on the total length of 
the full site.  If there are multiple target sites of the same length, these subsets of sites are 
secondarily ranked according to the degree of similarity between the spacer length and an 
ideal spacer length of 17 base pairs.  For example, a spacer length of 15 base pairs (difference 
of two relative to 17) is more highly ranked than a spacer length of 20 base pairs (difference 
of three relative to 17).  A total of five First Tier and Second Tier target sites are then 
displayed.   
The criteria used above for selecting target sites are based on published data from 
Miller et al. and some of our own unpublished experience. 
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If ZiFiT Targeter fails to identify a total of five First Tier and Second Tier sites, the 
program provides users with the option to relax search criteria further to allow identification 
of potential TALEN target sites with half-sites 12 to 22 base pairs in length (including the 
conserved 5’ T) and spacer sequences 13 to 23 base pairs in length.  This can be done by 
clicking the box for “Relax Search Criteria” underneath the sequence input box and clicking 
the Search button again.  This relaxed search will still filter sites to ensure that they differ 
from each other by at least six base pairs.  Users can expand the list of potential sites even 
further by eliminating the filter for similar sites.  This can be accomplished by unclicking the 
box for “Mask Redundant Sites” and then clicking the Search button again. 
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